{"meta":{"query_hash":"5f0ee675a940","filters":{"venue":"Clinical Drug Investigation"},"cohort_total":101,"direct_labels_cover":0,"predictions_cover":101,"exported":101,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/5f0ee675a940","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Drug+Investigation"},"results":[{"id":"W1070976522","doi":"10.2165/0044011-200828120-00002","title":"Metabolism, Distribution and Elimination of Lisdexamfetamine Dimesylate","year":2008,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Center for Diagnosis and Research on Alzheimer's Disease","funders":"","keywords":"Tolerability; Pharmacokinetics; Urine; Medicine; Pharmacology; Adverse effect; Volume of distribution; Whole blood; Internal medicine","score_opus":0.09007126275613525,"score_gpt":0.36019622267936857,"score_spread":0.2701249599232333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1070976522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947229,0.00025665926,0.0011373806,0.0031827716,0.00014657773,0.00027731355,0.000016110269,0.000052842595,0.0002074339],"genre_scores_gemma":[0.99750143,0.0004022825,0.0007464053,0.00026182516,0.00011075394,0.000009475362,0.00037333884,0.0000131169045,0.00058139715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986137,0.00015451167,0.0006117869,0.0002505506,0.00025654933,0.000112905596],"domain_scores_gemma":[0.9988259,0.00029412212,0.00026583418,0.00020023008,0.0002633059,0.00015058949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053045753,0.00010837421,0.00034457818,0.000060090886,0.00007589055,0.000005161139,0.000035431778,0.00011430523,0.000028950872],"category_scores_gemma":[0.001953448,0.00009939117,0.00009987487,0.00023267452,0.0005085832,0.00022181924,0.000032647287,0.00021673102,0.000023052293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024925402,0.0007606977,0.9594856,0.00021610346,0.00013885509,0.000015426107,0.0007595941,0.00004145876,0.009011418,0.005984854,0.0025404468,0.020796305],"study_design_scores_gemma":[0.001366402,0.00008501141,0.9918142,0.00005014211,0.00014449956,0.00003368659,0.00011978493,0.0024743972,0.0019444845,0.0003708681,0.0015035274,0.0000929819],"about_ca_topic_score_codex":0.000022825607,"about_ca_topic_score_gemma":0.0000026924106,"teacher_disagreement_score":0.032328628,"about_ca_system_score_codex":0.000018004657,"about_ca_system_score_gemma":0.00007781055,"threshold_uncertainty_score":0.40530542},"labels":[],"label_agreement":null},{"id":"W1151626562","doi":"10.1007/s40261-015-0313-7","title":"Effect of Inhaled Corticosteroids on Salival Composition: A Cross-Sectional Study in Patients with Bronchial Asthma","year":2015,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Salivary Gland Disorders and Functions","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine and Dentistry, University of Alberta; Ministerio de Ciencia e Innovación; Novartis","keywords":"Medicine; Asthma; Inhaled corticosteroids; Saliva; Cross-sectional study; Internal medicine; Corticosteroid; Pathology","score_opus":0.041395273605322684,"score_gpt":0.35589457898629273,"score_spread":0.31449930538097004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1151626562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979828,0.0000066107327,0.00001882037,0.00009488818,0.00045720264,0.0009936433,0.000009804792,0.00003354416,0.00040270196],"genre_scores_gemma":[0.9991451,3.9996743e-7,0.00007379437,0.0002620677,0.00018121769,0.000035598994,0.00024518167,0.000013889126,0.000042747317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980101,0.0004149028,0.0006887178,0.00028877278,0.00047201963,0.00012547833],"domain_scores_gemma":[0.9987711,0.00041804815,0.00017400298,0.00021197842,0.000200036,0.00022486823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009635945,0.00013442086,0.0003467915,0.00010629625,0.00004585288,0.000018189708,0.00005003934,0.00009243869,0.00002117058],"category_scores_gemma":[0.0005231617,0.000097221826,0.000072139985,0.00023649742,0.00023711083,0.00010115843,0.000023624365,0.00027897808,0.00002720005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006731794,0.0015960499,0.9906899,0.000023961788,0.000036924805,0.0000082601955,0.00016752124,0.00012852978,0.000004200797,0.000027904916,0.00020374847,0.00038122],"study_design_scores_gemma":[0.022063589,0.016453968,0.9608481,0.000067466295,0.00004660835,0.000004334369,0.000033891774,0.00026179163,0.00004025639,0.00008094747,0.000010616678,0.00008842687],"about_ca_topic_score_codex":0.00007110242,"about_ca_topic_score_gemma":0.000024571824,"teacher_disagreement_score":0.02984178,"about_ca_system_score_codex":0.00006037711,"about_ca_system_score_gemma":0.00012836963,"threshold_uncertainty_score":0.3964591},"labels":[],"label_agreement":null},{"id":"W127233696","doi":"10.2165/00044011-200020050-00005","title":"Efficacy and Safety of Inhaled Zanamivir for the Treatment of Influenza in Patients with Asthma or Chronic Obstructive Pulmonary Disease","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Saint Jerome","funders":"","keywords":"Medicine; Zanamivir; Asthma; Placebo; COPD; Exacerbation; Internal medicine; Disease","score_opus":0.03052877370913406,"score_gpt":0.3122925710824548,"score_spread":0.28176379737332075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W127233696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99792063,0.0002605191,0.000008162076,0.00024017625,0.00004141655,0.0014308082,0.000031473788,0.000009374303,0.00005744515],"genre_scores_gemma":[0.9990609,0.00014457147,0.00013356388,0.0002503255,0.00007222577,0.000040116087,0.00005604504,0.0000119264805,0.00023030625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988022,0.00011410798,0.00062138366,0.00020278545,0.00015801477,0.00010150835],"domain_scores_gemma":[0.9986443,0.00070701,0.00019178863,0.00020764148,0.0001205779,0.00012867762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019564823,0.000111977744,0.00029025596,0.000053318345,0.00004866856,0.0000031390628,0.000039867115,0.00006239365,0.00004961855],"category_scores_gemma":[0.0002183247,0.000060519033,0.00006713433,0.00016219808,0.0004988523,0.00007050637,0.000006822834,0.00007956433,0.0000021925416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01806388,0.0013042932,0.763302,0.00019560405,0.00010995037,0.000008922493,0.0007184367,0.00086742785,0.00001935433,0.00009929219,0.000023429942,0.21528739],"study_design_scores_gemma":[0.009289803,0.0011924456,0.98497504,0.00018829362,0.00011466559,7.366449e-7,0.000040879604,0.0024312914,0.00013073579,0.000042740765,0.0015248939,0.000068468726],"about_ca_topic_score_codex":0.000013323726,"about_ca_topic_score_gemma":0.000015610585,"teacher_disagreement_score":0.22167301,"about_ca_system_score_codex":0.00007162483,"about_ca_system_score_gemma":0.00024424947,"threshold_uncertainty_score":0.24678946},"labels":[],"label_agreement":null},{"id":"W1677866495","doi":"10.1007/s40261-015-0327-1","title":"Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study","year":2015,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; NIH Clinical Center; Ajou University; Clinical Trial Center, China Medical University Hospital","keywords":"Medicine; Epoetin alfa; Pharmacokinetics; Crossover study; Pharmacodynamics; Bioequivalence; Erythropoietin; Confidence interval; Internal medicine; Pharmacology; Adverse effect; Area under the curve; Gastroenterology; Placebo","score_opus":0.1443688003860833,"score_gpt":0.4558119339915855,"score_spread":0.3114431336055022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1677866495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915646,0.0011012246,0.00003215734,0.0032060547,0.00039879745,0.0031695133,0.00000712169,0.000058882433,0.00046165628],"genre_scores_gemma":[0.9969964,0.00014864549,0.001764678,0.00034875833,0.00015396313,0.0001232187,0.00011762784,0.000040719115,0.0003060133],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958484,0.0007307095,0.0019843595,0.00065052125,0.00044118013,0.0003448294],"domain_scores_gemma":[0.9978093,0.0005339084,0.00055585476,0.00032788588,0.00022881781,0.0005442634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002688112,0.00033716904,0.0013548402,0.00022491669,0.00014815335,0.000052458796,0.00010062729,0.00011824315,0.000063987165],"category_scores_gemma":[0.00038068581,0.0002856271,0.00014453178,0.00032456862,0.0012023264,0.00020830474,0.00011987836,0.0005537056,0.000007756571],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05490413,0.004743274,0.92482615,0.00024856054,0.00019572965,0.000033632776,0.0076146913,0.00014550911,0.0008837602,0.00039707508,0.00070525735,0.0053022164],"study_design_scores_gemma":[0.9199651,0.0031134787,0.031784374,0.0005622177,0.00089371286,0.00007512058,0.0039019182,0.035835836,0.000882888,0.0023701063,0.00016010129,0.00045514593],"about_ca_topic_score_codex":0.0014503438,"about_ca_topic_score_gemma":0.000670083,"teacher_disagreement_score":0.8930418,"about_ca_system_score_codex":0.00017082614,"about_ca_system_score_gemma":0.00018724821,"threshold_uncertainty_score":0.9999596},"labels":[],"label_agreement":null},{"id":"W1898364441","doi":"10.2165/00044011-200727100-00001","title":"The Concept of Complete Remission of Gastro-Oesophageal Reflux Disease","year":2007,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Gastroesophageal reflux and treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Esomeprazole; Pantoprazole; Medicine; Reflux; Disease; Internal medicine; Gastro-; Proton-pump inhibitor; Gastroenterology; Symptom relief; Omeprazole","score_opus":0.20328624441495483,"score_gpt":0.4660601266133393,"score_spread":0.2627738821983845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1898364441","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036982473,0.99365693,0.00002973216,0.00010869565,0.00046842956,0.0014517008,0.00018799133,0.000039119746,0.00035916196],"genre_scores_gemma":[0.016702164,0.9782849,0.0013079972,0.00013397538,0.0004858939,0.000037150345,0.00135098,0.000068646696,0.0016282958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953689,0.00059096434,0.002596559,0.0004877933,0.0006330361,0.00032272827],"domain_scores_gemma":[0.9944645,0.0019878664,0.0016761873,0.00085541216,0.00027962218,0.0007363814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001443065,0.0003900799,0.001993573,0.000113210226,0.000108920496,0.000010681736,0.0002818731,0.0002789629,0.000033708908],"category_scores_gemma":[0.0023545695,0.00022691149,0.0010363874,0.0003265028,0.0013145717,0.000050829596,0.000107791,0.00068423426,0.000041308736],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013559307,0.00032217332,0.011623022,0.007411397,0.000411177,0.00016949911,0.000048386595,7.1800696e-7,0.0000017372909,0.000722107,0.0019958846,0.9771583],"study_design_scores_gemma":[0.0039775646,0.0015731188,0.0546499,0.044827845,0.008946421,0.000044737237,0.00003384841,0.000076588505,0.000112353846,0.0019234988,0.88345236,0.00038176318],"about_ca_topic_score_codex":0.000006922992,"about_ca_topic_score_gemma":6.307448e-7,"teacher_disagreement_score":0.97677654,"about_ca_system_score_codex":0.000090575246,"about_ca_system_score_gemma":0.00077325705,"threshold_uncertainty_score":0.92531824},"labels":[],"label_agreement":null},{"id":"W1963571177","doi":"10.2165/00044011-200424090-00005","title":"Efficacy and Safety Assessment of a Novel Once-Daily Tablet Formulation of Tramadol","year":2004,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Veterinary Pharmacology and Anesthesia","field":"Veterinary","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeshore General Hospital; Université de Montréal","funders":"","keywords":"Tramadol; Medicine; Anesthesia; Dosing; Osteoarthritis; Analgesic; Adverse effect; Nausea; Internal medicine","score_opus":0.14750340375279625,"score_gpt":0.4335215681560633,"score_spread":0.28601816440326705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963571177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959019,0.000025830053,0.0022445056,0.00088177295,0.00012425634,0.00037810963,0.000015151928,0.000034177985,0.00039431953],"genre_scores_gemma":[0.98859644,0.000032602522,0.010877807,0.00031368143,0.00007726884,0.000011924888,0.00004648942,0.000013129093,0.000030656447],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983556,0.00017551267,0.00091007666,0.00025910823,0.00016069038,0.00013900385],"domain_scores_gemma":[0.99873525,0.00047558974,0.0004176313,0.00018443703,0.00007667932,0.00011039945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009673219,0.0001280079,0.00033924033,0.00005909769,0.00007004274,0.000006531808,0.0001139052,0.00014972354,0.000030342482],"category_scores_gemma":[0.00017120007,0.00012116803,0.000084309504,0.000134215,0.00036146448,0.00023276274,0.00004833151,0.0002340619,0.000003729254],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00617923,0.005399031,0.24651605,0.0012491717,0.000438776,0.00009066167,0.004294282,0.008960868,0.61483026,0.09373888,0.0004763675,0.017826399],"study_design_scores_gemma":[0.0076135886,0.0017746203,0.97783214,0.00023827289,0.00009815192,0.000061787614,0.000061229344,0.006409238,0.0020351473,0.003226615,0.0004677943,0.00018141113],"about_ca_topic_score_codex":0.000034237277,"about_ca_topic_score_gemma":0.0000020716323,"teacher_disagreement_score":0.7313161,"about_ca_system_score_codex":0.000033579145,"about_ca_system_score_gemma":0.0001396369,"threshold_uncertainty_score":0.4941089},"labels":[],"label_agreement":null},{"id":"W1971473849","doi":"10.1007/s40261-013-0085-x","title":"Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin® Tablets Compared with Original OxyContin® Tablets in Healthy Adults","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"Purdue Pharma; Purdue University","keywords":"Tolerability; Medicine; Pharmacokinetics; Crossover study; Adverse effect; Dosing; Nasal administration; Anesthesia; Area under the curve; Pharmacology","score_opus":0.026866076236207424,"score_gpt":0.3231715285779246,"score_spread":0.2963054523417172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971473849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937805,0.000080383885,0.00014003982,0.0040573105,0.00010677125,0.0014235477,0.000009831087,0.000034114204,0.00036748723],"genre_scores_gemma":[0.9957991,0.00019058617,0.0030067868,0.0006081469,0.00008870366,0.000026486996,0.0001802821,0.000015713715,0.00008415414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972837,0.00023588153,0.0015381103,0.0003818967,0.00031273556,0.00024770474],"domain_scores_gemma":[0.998242,0.00033820356,0.0005397475,0.000285881,0.00034107297,0.00025308615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011804779,0.00018374526,0.0006750258,0.00013828662,0.000036552185,0.000015543888,0.00010203941,0.00011978833,0.00008470248],"category_scores_gemma":[0.0004113812,0.0001509717,0.00005429571,0.0003518607,0.00046481518,0.00023978758,0.000039645536,0.0003246003,0.0000049745154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073945057,0.00053789205,0.9825737,0.0010340109,0.00007490897,0.000007315224,0.0006151949,0.00007858089,0.0017259548,0.00039853406,0.0009177017,0.004641733],"study_design_scores_gemma":[0.009360789,0.0014313828,0.9604173,0.0007634462,0.00009785921,0.0000020458212,0.00017232569,0.02425757,0.002172382,0.00057886617,0.00058026245,0.00016577805],"about_ca_topic_score_codex":0.0006593065,"about_ca_topic_score_gemma":0.00031865918,"teacher_disagreement_score":0.024178991,"about_ca_system_score_codex":0.000046880763,"about_ca_system_score_gemma":0.00020351574,"threshold_uncertainty_score":0.6156447},"labels":[],"label_agreement":null},{"id":"W1976361964","doi":"10.2165/00044011-200828110-00001","title":"Perindopril for Control of Blood Pressure in Patients with Hypertension and Other Cardiovascular Risk Factors","year":2008,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Integre de Sante et de Services Sociaux de Laval; Dr. Georges-L.-Dumont University Hospital Centre; Toronto Western Hospital; University of Toronto","funders":"","keywords":"Perindopril; Tolerability; Medicine; Blood pressure; Internal medicine; Adverse effect; Risk factor; Pharmacotherapy; Cardiology","score_opus":0.04654721880806912,"score_gpt":0.25812353976106234,"score_spread":0.21157632095299322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976361964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948764,0.0040268325,0.000042299893,0.00014890602,0.00006095515,0.0007588323,0.000037804133,0.000019115934,0.000028889377],"genre_scores_gemma":[0.99842167,0.00015545789,0.0005774858,0.0006879698,0.000069062466,0.00001958581,0.000012812533,0.000018450997,0.000037515958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987839,0.00013136001,0.0004325845,0.0002843472,0.00024323414,0.00012460291],"domain_scores_gemma":[0.99878144,0.0004448803,0.00014793163,0.00024329656,0.000274171,0.00010826755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039758356,0.00012794242,0.0007570257,0.000054513253,0.00007476924,0.0000027653532,0.00003336207,0.00011334663,0.0000028270495],"category_scores_gemma":[0.0006674552,0.00008437412,0.00015721036,0.0000796235,0.0003474914,0.000051891628,0.000019273117,0.00017516868,6.199227e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034638433,0.0002168911,0.996844,0.000073305695,0.0014735331,0.0000027892813,0.0002892217,0.000041894324,0.000025522208,0.000010706846,0.00031217764,0.00036356135],"study_design_scores_gemma":[0.01205988,0.0005017412,0.97703576,0.00010735149,0.0050963843,0.0000036377598,0.000051631447,0.00029477914,0.00035762455,0.00004510972,0.004344494,0.00010159594],"about_ca_topic_score_codex":0.00015989425,"about_ca_topic_score_gemma":0.000008946186,"teacher_disagreement_score":0.019808242,"about_ca_system_score_codex":0.0000012643892,"about_ca_system_score_gemma":0.00004104368,"threshold_uncertainty_score":0.3440677},"labels":[],"label_agreement":null},{"id":"W1983647616","doi":"10.2165/11315290-000000000-00000","title":"Shortness of Breath, a ‘Wearing-Off’ Symptom in Parkinsonʼs Disease","year":2009,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Parkinson's Clinic of Eastern Toronto & Movement Disorders Centre","funders":"","keywords":"Medicine; Pharmacotherapy; Disease; Parkinson's disease; Intensive care medicine; Physical therapy; Psychiatry; Internal medicine","score_opus":0.0409931398489421,"score_gpt":0.34352859934577046,"score_spread":0.30253545949682836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983647616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99655426,0.00041536847,0.000040398238,0.0017645874,0.00013870644,0.0004429769,0.000019045961,0.000058866503,0.000565789],"genre_scores_gemma":[0.99736005,0.00017529608,0.0006144147,0.0013235327,0.00012450186,0.000025213369,0.00013775012,0.000015055916,0.0002241923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981812,0.00014148158,0.0007187702,0.0004242381,0.00030847645,0.00022581685],"domain_scores_gemma":[0.9986171,0.00014119442,0.0001746776,0.00038569458,0.00008261193,0.0005987021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046156152,0.00017332233,0.00044120496,0.00012905661,0.000035656576,0.000012044056,0.00009401999,0.000104793304,0.000044962282],"category_scores_gemma":[0.00053707795,0.00015291614,0.00018771594,0.00028906192,0.00014577662,0.0001127388,0.000026623238,0.00019662466,0.00003647693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039835655,0.0011213573,0.956914,0.00006103774,0.00004326027,0.00015340807,0.00013946297,0.000022199356,0.0001777003,0.0015124374,0.00033906027,0.03911773],"study_design_scores_gemma":[0.002407742,0.00021384232,0.98159724,0.00039216608,0.00017357657,0.0000028933039,0.00002153535,0.0022314268,0.0005511893,0.0108618885,0.0014175425,0.00012897946],"about_ca_topic_score_codex":0.00004797026,"about_ca_topic_score_gemma":0.000014520734,"teacher_disagreement_score":0.03898875,"about_ca_system_score_codex":0.00006282049,"about_ca_system_score_gemma":0.00025800016,"threshold_uncertainty_score":0.62357396},"labels":[],"label_agreement":null},{"id":"W1984348569","doi":"10.2165/11319610-000000000-00000","title":"Perioperative Use of Nonsteroidal Anti-Inflammatory Drugs","year":2009,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Ketorolac; Ketoprofen; Diclofenac; Perioperative; Ibuprofen; Nonsteroidal; Analgesic; Anesthesia; Pharmacology","score_opus":0.04449040060894345,"score_gpt":0.3261087660218128,"score_spread":0.2816183654128694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984348569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969447,0.000049724815,0.00004198806,0.0013903902,0.00043738747,0.0005244241,0.0000052139712,0.000080444406,0.0005257021],"genre_scores_gemma":[0.9947219,0.00004367134,0.0017008964,0.002513104,0.00049264147,0.000008087763,0.00003244684,0.00001709406,0.00047016048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791306,0.00029449628,0.0009211314,0.0003166662,0.0003350172,0.00021965214],"domain_scores_gemma":[0.99821335,0.0005516688,0.0002757631,0.00036437076,0.00024156347,0.00035328872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009543483,0.00018439033,0.0005269067,0.000104375926,0.000072880364,0.000022812521,0.00007937654,0.00018743766,0.000042574273],"category_scores_gemma":[0.0016454943,0.00015447642,0.00020447969,0.00017813791,0.00045270027,0.00029081095,0.00002318257,0.00038486684,0.00008225179],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044166783,0.0004005246,0.91229993,0.00025493593,0.00010620843,0.00008757555,0.0042404407,0.00006603058,0.046422303,0.0030989815,0.008074866,0.024506528],"study_design_scores_gemma":[0.0023885341,0.0005550361,0.9426093,0.00038796468,0.00011632765,0.000012072767,0.00013452228,0.002522202,0.047819592,0.00032590854,0.002892234,0.0002363191],"about_ca_topic_score_codex":0.000009931942,"about_ca_topic_score_gemma":0.0000025848447,"teacher_disagreement_score":0.030309347,"about_ca_system_score_codex":0.000030573803,"about_ca_system_score_gemma":0.0002808792,"threshold_uncertainty_score":0.6299366},"labels":[],"label_agreement":null},{"id":"W1989110922","doi":"10.2165/11319800-000000000-00000","title":"Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination","year":2009,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada)","funders":"","keywords":"Rosuvastatin; Medicine; Simvastatin; Atorvastatin; Combination therapy; Statin; Internal medicine; Pharmacology; Pharmacotherapy; Rosuvastatin Calcium; Fenofibrate; Gastroenterology; Population","score_opus":0.04619729645364628,"score_gpt":0.3819313796049937,"score_spread":0.3357340831513474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989110922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939228,0.00015895172,0.0014252891,0.0029064997,0.00008653057,0.00047441144,0.0000034100942,0.00003388391,0.0009881947],"genre_scores_gemma":[0.987886,0.00014285551,0.010644815,0.0010290578,0.00013250833,0.000007491424,0.000065118154,0.000008763824,0.00008338536],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985553,0.00023498693,0.00053156586,0.00022488451,0.00033656252,0.00011670171],"domain_scores_gemma":[0.9991569,0.00007417823,0.00016464852,0.0002544885,0.00015328405,0.00019648693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015192216,0.000087699205,0.0003494577,0.000054648946,0.000048032696,0.00001431925,0.000033571807,0.000068262794,0.000009853901],"category_scores_gemma":[0.00027646282,0.000076515964,0.000098942706,0.00014634801,0.00011739662,0.00009707012,0.000015225022,0.00019438432,0.0000046504315],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004875079,0.0014809084,0.36804435,0.00082793174,0.00033807705,0.00002820016,0.0012650554,0.00023204152,0.016104337,0.07586209,0.0031406544,0.53218883],"study_design_scores_gemma":[0.004092711,0.00066904,0.963661,0.00013445593,0.000099695724,0.000006334614,0.00007441845,0.0130971465,0.0035804457,0.014334185,0.00015091032,0.00009961861],"about_ca_topic_score_codex":0.000051974763,"about_ca_topic_score_gemma":0.0000038780704,"teacher_disagreement_score":0.5956167,"about_ca_system_score_codex":0.000037626036,"about_ca_system_score_gemma":0.00022026066,"threshold_uncertainty_score":0.31202304},"labels":[],"label_agreement":null},{"id":"W1992770459","doi":"10.1007/s40261-014-0187-0","title":"Availability of Data on Adverse Reactions to Antiretroviral Drugs in Medical Charts According to the Naranjo Algorithm: An Example of a Brazilian Historical Cohort","year":2014,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Adverse effect; Medical record; Cohort; Medical prescription; Dyslipidemia; Lipodystrophy; Referral; Pharmacy; Human immunodeficiency virus (HIV); Antiretroviral therapy; Family medicine; Internal medicine; Viral load; Disease; Pharmacology","score_opus":0.2423668398692314,"score_gpt":0.48011020635694857,"score_spread":0.23774336648771716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992770459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911298,0.000012073259,0.00039954387,0.0053799516,0.0016637006,0.00071903813,0.000118977005,0.00005540339,0.00052147935],"genre_scores_gemma":[0.9928637,0.000057696212,0.0007897111,0.0052155,0.00060969195,0.00005517102,0.00017210022,0.000020532108,0.00021586425],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99533254,0.0016771448,0.0013783176,0.00075069425,0.0005076886,0.0003536005],"domain_scores_gemma":[0.99524873,0.0024996754,0.00036140453,0.0010065818,0.00014766288,0.0007359395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008507133,0.00021092495,0.00053544756,0.00019756606,0.00018515681,0.000007274809,0.00092802785,0.00029255587,0.00019490012],"category_scores_gemma":[0.0029957518,0.00018062559,0.00012154659,0.0006878754,0.00039491116,0.00041207892,0.00025264907,0.0012241213,0.00013027826],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000770028,0.002401649,0.7495747,0.00012499565,0.00015759777,0.000009180351,0.0037910803,0.0016870267,0.0072398502,0.001040371,0.026435994,0.2067675],"study_design_scores_gemma":[0.004698247,0.001538333,0.33481675,0.00035066588,0.00039630343,0.000011312029,0.0014148041,0.14385979,0.01078192,0.0011033854,0.5001771,0.00085143646],"about_ca_topic_score_codex":0.0019807073,"about_ca_topic_score_gemma":0.00022879806,"teacher_disagreement_score":0.47374105,"about_ca_system_score_codex":0.00020718318,"about_ca_system_score_gemma":0.0002822465,"threshold_uncertainty_score":0.73656976},"labels":[],"label_agreement":null},{"id":"W1995273109","doi":"10.2165/00044011-200020050-00001","title":"Randomised, Multicentre Phase III Study of Saquinavir plus Zidovudine plus Zalcitabine in Previously Untreated or Minimally Pretreated HIV-Infected Patients","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary General Hospital; Foothills Medical Centre","funders":"","keywords":"Zalcitabine; Zidovudine; Medicine; Saquinavir; Context (archaeology); Didanosine; Regimen; Internal medicine; Clinical endpoint; Clinical trial; Phases of clinical research; Human immunodeficiency virus (HIV); Viral load; Antiretroviral therapy; Virology; Viral disease","score_opus":0.03442539373868219,"score_gpt":0.3394667003142452,"score_spread":0.305041306575563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995273109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914482,0.00006738643,0.0000028049228,0.0005185601,0.00011424274,0.007082294,0.000029977811,0.0001626409,0.0005738708],"genre_scores_gemma":[0.98466307,0.00014253923,0.0005480005,0.00015072965,0.00007700863,0.0002600307,0.0014964773,0.000055407378,0.012606756],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948793,0.0006892274,0.0025538604,0.0007980071,0.0005841185,0.00049549906],"domain_scores_gemma":[0.99717426,0.0008725488,0.0005460329,0.00052944064,0.00036715917,0.0005105804],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007779538,0.0004927342,0.0015067637,0.0002954177,0.00009446681,0.000022984736,0.00017000413,0.00023493131,0.00079166173],"category_scores_gemma":[0.0015770658,0.0003644598,0.0002006327,0.0010820878,0.00025157447,0.00021255016,0.000055612036,0.000387797,0.00016445901],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06942828,0.014796377,0.8829904,0.00018381789,0.0006884988,0.0002506054,0.011665385,0.00017168708,0.00010908951,0.0000023919547,0.0022814265,0.017432002],"study_design_scores_gemma":[0.6133344,0.003568116,0.369968,0.0009602517,0.0012236531,0.000005829231,0.0006518327,0.008688154,0.0008207885,0.00001636244,0.00029595615,0.00046660408],"about_ca_topic_score_codex":0.0002123187,"about_ca_topic_score_gemma":0.000456785,"teacher_disagreement_score":0.54390615,"about_ca_system_score_codex":0.0004285802,"about_ca_system_score_gemma":0.0005799569,"threshold_uncertainty_score":0.99988073},"labels":[],"label_agreement":null},{"id":"W2003069609","doi":"10.2165/11533440-000000000-00000","title":"Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee","year":2010,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Tapentadol; Medicine; Oxycodone; Placebo; Anesthesia; Osteoarthritis; Discontinuation; Analgesic; Tramadol; Chronic pain; Opioid; Internal medicine; Physical therapy","score_opus":0.01585256211730917,"score_gpt":0.29155836713003985,"score_spread":0.2757058050127307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003069609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985087,0.00020909273,0.0003343899,0.0068978295,0.00012196736,0.007212207,0.000042952724,0.000019997415,0.000074564174],"genre_scores_gemma":[0.9958641,0.0000716146,0.0028621065,0.00054432504,0.000025358828,0.00028930386,0.000046465844,0.000025602241,0.00027111967],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978399,0.00029108126,0.00106345,0.00032768134,0.00030391105,0.00017392357],"domain_scores_gemma":[0.9971886,0.0012683114,0.0004276643,0.0006544381,0.0002434189,0.00021756568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012244651,0.00017763763,0.0006500198,0.000050231723,0.00009046106,0.00000760765,0.0001384736,0.00008428997,0.000018757977],"category_scores_gemma":[0.0009000384,0.000102930164,0.00014922947,0.0002716835,0.00036671944,0.000038261504,0.00008016872,0.00021206468,0.0000023746964],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25267014,0.008655268,0.09181137,0.0070335134,0.008477314,0.00004373423,0.016901638,0.027435848,0.045135096,0.0215167,0.00489685,0.5154225],"study_design_scores_gemma":[0.15300006,0.006589833,0.79166746,0.0040246868,0.002756523,0.000010262161,0.0015938351,0.028652111,0.008482239,0.0022663656,0.0005491384,0.0004074708],"about_ca_topic_score_codex":0.0000440287,"about_ca_topic_score_gemma":0.000109518885,"teacher_disagreement_score":0.6998561,"about_ca_system_score_codex":0.000037734226,"about_ca_system_score_gemma":0.00018650392,"threshold_uncertainty_score":0.41973704},"labels":[],"label_agreement":null},{"id":"W2004371282","doi":"10.2165/00044011-200121090-00005","title":"Comparison of Salmeterol/Fluticasone Propionate Combination with Budesonide in Patients with Mild-to-Moderate Asthma","year":2001,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Salmeterol; Fluticasone propionate; Budesonide; Tolerability; Morning; Evening; Fluticasone; Asthma; Combination therapy; Anesthesia; Spirometry; Internal medicine; Adverse effect","score_opus":0.04419868005731209,"score_gpt":0.3507770570434884,"score_spread":0.3065783769861763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004371282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976332,0.000032753323,0.00032304417,0.0008825403,0.00005810791,0.00091244,0.0000055310297,0.000040883777,0.000111464324],"genre_scores_gemma":[0.9965289,0.0000041968688,0.0022991442,0.00087693485,0.000043637152,0.000033837987,0.000105243256,0.000025222596,0.00008288663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799055,0.00020593093,0.00075789064,0.00035335895,0.00048323933,0.00020900383],"domain_scores_gemma":[0.9986154,0.00015465559,0.0002743268,0.00025852665,0.00036412108,0.00033301194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035206063,0.00017048526,0.000504938,0.0001644926,0.00005378704,0.000014649429,0.00007834922,0.00009560168,0.000015550908],"category_scores_gemma":[0.00031309246,0.00011789634,0.00005290647,0.0004811162,0.00030361727,0.00014209146,0.000026622001,0.0002527987,0.000022623477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022194888,0.0012450853,0.98811907,0.00006458074,0.000024751016,0.0000070625606,0.000202589,0.0003163881,0.00006472285,0.00006987707,0.00018370821,0.007482667],"study_design_scores_gemma":[0.0056456076,0.0026541078,0.98658395,0.0005399392,0.0000557003,0.0000010535211,0.00008215448,0.0031054332,0.00074439327,0.00011184957,0.00032941825,0.00014638527],"about_ca_topic_score_codex":0.000022494407,"about_ca_topic_score_gemma":0.00006231955,"teacher_disagreement_score":0.0073362817,"about_ca_system_score_codex":0.000055215372,"about_ca_system_score_gemma":0.00017197525,"threshold_uncertainty_score":0.48076734},"labels":[],"label_agreement":null},{"id":"W2005805496","doi":"10.1007/s40261-013-0053-5","title":"Effect of Implantation of Augment® Bone Graft on Serum Concentrations of Platelet-Derived Growth Factors: A Pharmacokinetic Study","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Periodontal Regeneration and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"BioMimetic Therapeutics","keywords":"Augment; Medicine; Pharmacokinetics; Pharmacology; Platelet; Pharmacotherapy; Internal medicine","score_opus":0.03752778564131822,"score_gpt":0.3616140800555922,"score_spread":0.324086294414274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005805496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782556,0.000027027834,0.000016789498,0.00020729912,0.00014342839,0.0016187159,0.000035230194,0.000022451728,0.00010349183],"genre_scores_gemma":[0.9993922,0.000027684073,0.00009982392,0.00009363855,0.000036064415,0.000056395864,0.00021761753,0.000012246911,0.000064327774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998071,0.0003734267,0.00092168717,0.00021148691,0.00030911397,0.00011327186],"domain_scores_gemma":[0.9984863,0.0005127641,0.00046158466,0.00017573196,0.00020316616,0.00016046666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003268521,0.00015075103,0.00050035806,0.000091396214,0.00003541377,0.0000065679637,0.000051198826,0.00007089726,0.0001014663],"category_scores_gemma":[0.00047762407,0.00011160411,0.00012723361,0.00017603784,0.00020837945,0.000116491094,0.000015892025,0.00012071016,0.000016182204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003131518,0.001064996,0.81646436,0.00020236739,0.0002397242,0.0000036267616,0.0010891218,0.00002096777,0.1772317,0.00008952527,0.00017163136,0.0031088179],"study_design_scores_gemma":[0.004291684,0.002619527,0.5050555,0.000092429786,0.00017924476,0.0000014372788,0.000116806994,0.00035920244,0.48718867,0.000043924872,0.0000021303488,0.00004949916],"about_ca_topic_score_codex":0.00023117122,"about_ca_topic_score_gemma":0.000016332835,"teacher_disagreement_score":0.3114089,"about_ca_system_score_codex":0.000033093133,"about_ca_system_score_gemma":0.00007610647,"threshold_uncertainty_score":0.45510834},"labels":[],"label_agreement":null},{"id":"W2006812895","doi":"10.1007/s40261-014-0192-3","title":"Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users","year":2014,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"Purdue Pharma; Regeneron Pharmaceuticals; Purdue University","keywords":"Oxycodone; Medicine; (+)-Naloxone; Placebo; Anesthesia; Opioid; Tolerability; Narcotic antagonist; Crossover study; Opioid antagonist; Pharmacology; Adverse effect; Internal medicine","score_opus":0.026012143143953177,"score_gpt":0.3055863440596846,"score_spread":0.27957420091573143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006812895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940865,0.00009517599,0.0014023883,0.0028659762,0.0004231774,0.0006575044,0.000009345913,0.00005662667,0.00040328735],"genre_scores_gemma":[0.9925529,0.00020547964,0.0055809407,0.00056548405,0.0002537644,0.00004030092,0.00044028976,0.000028063469,0.00033278912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727273,0.0003785479,0.0011583134,0.00043793576,0.0005000786,0.00025236988],"domain_scores_gemma":[0.99849993,0.0003351723,0.00034940982,0.00037968621,0.00018861901,0.00024716023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012933007,0.00019024067,0.00048664125,0.00020023948,0.000054232045,0.000013161726,0.000113047405,0.00016795915,0.000067322944],"category_scores_gemma":[0.0007066852,0.00018255482,0.00017484944,0.00026634667,0.00030123544,0.00014245346,0.00003420315,0.0003587256,0.00008780306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011882175,0.0041605253,0.938635,0.0004478832,0.00031221443,0.000036918485,0.008088411,0.0014125068,0.013788666,0.0043465327,0.002851041,0.024732113],"study_design_scores_gemma":[0.005538564,0.00038915375,0.96803045,0.00042795553,0.00022514892,0.000011402867,0.00036324805,0.014668155,0.004852005,0.0049397955,0.00033004416,0.00022409459],"about_ca_topic_score_codex":0.00049224804,"about_ca_topic_score_gemma":0.00022863026,"teacher_disagreement_score":0.02939546,"about_ca_system_score_codex":0.00016376402,"about_ca_system_score_gemma":0.00026745207,"threshold_uncertainty_score":0.744437},"labels":[],"label_agreement":null},{"id":"W2007223681","doi":"10.2165/00044011-200020030-00003","title":"A Retrospective, Naturalistic Review Comparing Clinical Outcomes of In-Hospital Treatment with Risperidone and Olanzapine","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Hospital Edmonton","funders":"Janssen Pharmaceuticals","keywords":"Risperidone; Olanzapine; Medicine; Schizoaffective disorder; Schizophrenia (object-oriented programming); Antipsychotic; Atypical antipsychotic; Clozapine; Pharmacotherapy; Retrospective cohort study; Dopamine antagonist; Psychiatry; Pediatrics; Internal medicine; Anesthesia; Psychosis; Haloperidol","score_opus":0.05771796142956127,"score_gpt":0.3873884926423954,"score_spread":0.32967053121283413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007223681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893668,0.0036801568,0.0000013259654,0.0057038832,0.00005632271,0.0009065433,0.000007920236,0.00002940519,0.00024761754],"genre_scores_gemma":[0.9781746,0.018540608,0.0023756975,0.00042124474,0.00007975549,0.000046082692,0.00006798484,0.000014615256,0.00027939212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791276,0.0002287061,0.0009563535,0.00041459015,0.00029065684,0.00019691203],"domain_scores_gemma":[0.99866855,0.00040707245,0.00016473822,0.00032178353,0.000100541016,0.0003373394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006358323,0.00018239277,0.0010198918,0.000057613903,0.000034367862,0.000009745524,0.000056982743,0.000079974525,0.00009805061],"category_scores_gemma":[0.00075175485,0.00011326045,0.00015329433,0.00023242462,0.00054006284,0.0000776639,0.000020840562,0.00032743238,0.00002621335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012397595,0.00071026414,0.9792218,0.0001504525,0.000176824,0.00004909708,0.000049552942,6.077989e-7,0.0000013958376,0.00018013304,0.00017657466,0.018043494],"study_design_scores_gemma":[0.008754841,0.002828202,0.98576283,0.0013427491,0.00022523571,0.000011972503,0.00001062541,0.00031259801,0.00001839954,0.00043283092,0.00019353066,0.000106165215],"about_ca_topic_score_codex":0.0002470245,"about_ca_topic_score_gemma":0.0002861116,"teacher_disagreement_score":0.017937329,"about_ca_system_score_codex":0.00010839437,"about_ca_system_score_gemma":0.00017535967,"threshold_uncertainty_score":0.4618627},"labels":[],"label_agreement":null},{"id":"W2009098521","doi":"10.2165/00044011-200019030-00007","title":"LIPI-WATCH, a Belgian/Luxembourg Survey on Achievement of European Atherosclerosis Society Lipid Goals","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"European Atherosclerosis Society","keywords":"Medicine; Body mass index; Internal medicine; Diabetes mellitus; Coronary heart disease; Lipid profile; Risk factor; Cholesterol; Endocrinology","score_opus":0.07260013807781045,"score_gpt":0.3247633831257585,"score_spread":0.252163245047948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009098521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930681,0.000085620944,0.00003971117,0.0039781844,0.00022943597,0.00067778764,0.000042309086,0.00008421774,0.001794606],"genre_scores_gemma":[0.9879802,0.0011602333,0.00104762,0.0063614124,0.0011234893,0.000018830928,0.00023571111,0.0000584665,0.0020140547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99603057,0.0013565188,0.0011366932,0.0005066014,0.00066658214,0.00030301345],"domain_scores_gemma":[0.99798495,0.00032225632,0.0002525043,0.00082939886,0.00017856275,0.000432316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0070804553,0.00021473563,0.0006522722,0.000026980235,0.000118595024,0.00001989751,0.00015862013,0.00015328257,0.00020942815],"category_scores_gemma":[0.000600879,0.00017846933,0.0006765706,0.0003154994,0.00033501445,0.0000712565,0.000044536562,0.00048344786,0.0002959515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005014716,0.0017208594,0.69009614,0.0004875055,0.0008347196,0.0000053876674,0.0017971678,0.00013831124,0.0020108104,0.00022851842,0.062557526,0.2396216],"study_design_scores_gemma":[0.0021564164,0.00059301953,0.98277736,0.00040897544,0.00011896228,0.000001297686,0.000037538863,0.00014687289,0.0018801825,0.00007943282,0.011628896,0.00017107656],"about_ca_topic_score_codex":0.0006688391,"about_ca_topic_score_gemma":0.000041558404,"teacher_disagreement_score":0.2926812,"about_ca_system_score_codex":0.0000739705,"about_ca_system_score_gemma":0.000186976,"threshold_uncertainty_score":0.72777677},"labels":[],"label_agreement":null},{"id":"W2021841808","doi":"10.2165/11537460-000000000-00000","title":"Mycophenolate Mofetil in the Treatment of Adults with Advanced Rheumatoid Arthritis","year":2010,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Mycophenolate; Rheumatoid arthritis; Internal medicine; Ciclosporin; Placebo; Adverse effect; Rheumatism; Mycophenolic acid; Gastroenterology; Refractory (planetary science); Transplantation; Pathology","score_opus":0.01971433525382949,"score_gpt":0.31069815578278737,"score_spread":0.2909838205289579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021841808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947809,0.0016129911,0.0000057568723,0.0022343735,0.000120733195,0.0007084193,0.000006991967,0.000028616625,0.00050123857],"genre_scores_gemma":[0.95756847,0.04038909,0.0016117734,0.00019196594,0.00005371269,0.00009929602,0.00004157377,0.000015022527,0.00002911377],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99845755,0.00017509119,0.0005833569,0.00024726868,0.0003238219,0.00021290443],"domain_scores_gemma":[0.998659,0.0005218424,0.00014234174,0.00039164355,0.00011929252,0.00016587238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005645874,0.00013002788,0.0003489846,0.00007112181,0.00005914335,0.000016828415,0.0001047752,0.00006674514,0.00006530171],"category_scores_gemma":[0.00037686242,0.00007679347,0.0000890699,0.00022574367,0.00060666923,0.0001139958,0.000008484722,0.00031847923,0.000028689004],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025352642,0.001622123,0.3148961,0.00005826542,0.00008671359,0.00006884075,0.014903709,0.000011021623,0.0031503006,0.0027491853,0.00033670102,0.6595818],"study_design_scores_gemma":[0.056530114,0.01265569,0.85977924,0.0034315607,0.0000124033795,0.00020574112,0.006034533,0.001813949,0.017435048,0.011797087,0.029767321,0.0005373151],"about_ca_topic_score_codex":0.0001903153,"about_ca_topic_score_gemma":0.0008235285,"teacher_disagreement_score":0.65904444,"about_ca_system_score_codex":0.000014401645,"about_ca_system_score_gemma":0.00015502899,"threshold_uncertainty_score":0.3131547},"labels":[],"label_agreement":null},{"id":"W2030320412","doi":"10.2165/11633550-000000000-00000","title":"Pharmacokinetics of a New Immediate-Release Methadone Tablet Formulation with Decreased In vitro Solubility","year":2012,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Paladin Labs (Canada)","funders":"","keywords":"Cmax; Pharmacokinetics; Bioavailability; Crossover study; Methadone; Pharmacology; Medicine; Solubility; Elimination rate constant; Bioequivalence; Chromatography; Chemistry; Volume of distribution","score_opus":0.06093009706750442,"score_gpt":0.3502869022208261,"score_spread":0.2893568051533217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030320412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557203,0.00016102055,0.0018440031,0.0013541745,0.0001470413,0.00064594444,0.0000037966101,0.00003949491,0.00023247754],"genre_scores_gemma":[0.98602515,0.00005046118,0.0119317155,0.0011874068,0.00034169367,0.000015421056,0.00020335162,0.000016992557,0.00022782163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827415,0.00020632957,0.000736416,0.00021700753,0.00030164808,0.000264455],"domain_scores_gemma":[0.9984193,0.00047496377,0.00026490082,0.00027544177,0.00008941296,0.0004759738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018467191,0.00013661492,0.00036361985,0.00012449904,0.00002228747,0.0000063856824,0.000072337476,0.00009282488,0.0000389644],"category_scores_gemma":[0.0014764305,0.00011231978,0.00008099284,0.00039430018,0.00013909604,0.00023795532,0.000033983953,0.0002556241,0.000016157162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012077995,0.00044408077,0.9776861,0.00017535608,0.00004709524,0.0000024978074,0.00045052837,0.00006754324,0.009417417,0.00014144738,0.0017055336,0.0086545935],"study_design_scores_gemma":[0.0056580435,0.000121718746,0.92495644,0.00011930324,0.0002609809,4.224558e-7,0.0000744348,0.017509637,0.049250945,0.0010405583,0.00086302275,0.00014450873],"about_ca_topic_score_codex":0.00028173337,"about_ca_topic_score_gemma":0.000019301558,"teacher_disagreement_score":0.052729685,"about_ca_system_score_codex":0.000051967418,"about_ca_system_score_gemma":0.00017339796,"threshold_uncertainty_score":0.45802677},"labels":[],"label_agreement":null},{"id":"W2037415449","doi":"10.1007/s40261-013-0092-y","title":"Effectiveness and Tolerability of a Trandolapril-Based Antihypertensive Treatment Regimen over 12 months in Actual Clinical Care Across Canada","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Abbott (Canada); Hamilton Health Sciences","funders":"","keywords":"Medicine; Trandolapril; Tolerability; Regimen; Renal function; Internal medicine; Diabetes mellitus; Blood pressure; Adverse effect; ACE inhibitor; Angiotensin-converting enzyme; Endocrinology","score_opus":0.05152526555235366,"score_gpt":0.3504815952297871,"score_spread":0.29895632967743346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037415449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952256,0.0013556107,0.0000034030381,0.0018473397,0.00022365786,0.0012473452,0.000031024007,0.00001962587,0.0000463916],"genre_scores_gemma":[0.9973498,0.00012745362,0.00019840088,0.002086253,0.00009956882,0.000073094576,0.000031450967,0.000014567238,0.000019440931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735874,0.00066933734,0.0010067064,0.0004893793,0.0002465358,0.00022931742],"domain_scores_gemma":[0.995775,0.0029994268,0.00020403494,0.00034632336,0.00040757563,0.00026763082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080744637,0.00020262646,0.0012747577,0.000024088964,0.0000702157,0.0000115619505,0.000054023392,0.00019021462,0.000012436082],"category_scores_gemma":[0.0012032719,0.00014622294,0.00015927956,0.00010571038,0.0005825772,0.000086634886,0.00003878346,0.00027333805,0.0000019435959],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006584991,0.00029181023,0.9780758,0.00024312893,0.00020707988,0.00002147046,0.0011441483,0.000010838562,0.00027342688,0.000003621327,0.0010973366,0.01797283],"study_design_scores_gemma":[0.009516169,0.000638943,0.9845903,0.00028390117,0.00032434554,0.000002495677,0.0010871318,0.00054585317,0.002138939,0.00006140305,0.00067281706,0.0001376837],"about_ca_topic_score_codex":0.19316065,"about_ca_topic_score_gemma":0.12904069,"teacher_disagreement_score":0.06411998,"about_ca_system_score_codex":0.00006197685,"about_ca_system_score_gemma":0.00056997204,"threshold_uncertainty_score":0.886852},"labels":[],"label_agreement":null},{"id":"W2040543869","doi":"10.2165/00044011-200121040-00007","title":"Bioequivalence Study of Two Formulations (Sachet and Tablet) of Cefixime after Single Oral Doses of 200mg in Healthy Male Volunteers","year":2001,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Bioequivalence; Cmax; Cefixime; Medicine; Bioavailability; Pharmacokinetics; Pharmacology; Crossover study; Confidence interval; Tolerability; Dosage form; Internal medicine; Adverse effect; Chemistry; Antibiotics; Cephalosporin; Placebo","score_opus":0.09374060141338489,"score_gpt":0.40408994518102703,"score_spread":0.3103493437676421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040543869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985486,0.00017093903,0.00011216721,0.00050355477,0.000071191294,0.00046191268,0.000010695329,0.0000073791202,0.00011352452],"genre_scores_gemma":[0.99744844,0.0001312311,0.0020731783,0.00019168886,0.000039068123,0.0000029355479,0.00001520745,0.000010706612,0.000087532906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983525,0.00011168401,0.000985082,0.00020587734,0.000202264,0.00014254279],"domain_scores_gemma":[0.9989873,0.00024818248,0.00027020037,0.00019670778,0.00016413724,0.00013344127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063411257,0.00009591326,0.00039657237,0.00013506727,0.000017411143,0.0000036764677,0.00005913196,0.000059470793,0.000043793796],"category_scores_gemma":[0.0003896502,0.00008752507,0.00005097796,0.00034515758,0.00037273671,0.00008357515,0.00004809441,0.0001587397,0.000001768053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046463808,0.0014594973,0.9917189,0.00014415865,0.000024732286,0.0000043300406,0.00061848114,0.00017771802,0.0043630833,0.00013368338,0.00008505557,0.0008057337],"study_design_scores_gemma":[0.0049496833,0.0018372018,0.98156524,0.00023770952,0.00014804125,0.0000046135087,0.00023220132,0.007867886,0.002598563,0.00039794476,0.00006935222,0.00009157451],"about_ca_topic_score_codex":0.0005506171,"about_ca_topic_score_gemma":0.00018983826,"teacher_disagreement_score":0.01015366,"about_ca_system_score_codex":0.000017392087,"about_ca_system_score_gemma":0.000085388754,"threshold_uncertainty_score":0.35691687},"labels":[],"label_agreement":null},{"id":"W2059248961","doi":"10.2165/11599870-000000000-00000","title":"Randomized Open-Label Drug-Drug Interaction Trial of Dextromethorphan/Quinidine and Paroxetine in Healthy Volunteers","year":2012,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Respiratory and Cough-Related Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Public Health","funders":"","keywords":"Dextromethorphan; Paroxetine; CYP2D6; Medicine; Pharmacokinetics; Pharmacology; Quinidine; Drug interaction; Randomized controlled trial; Crossover study; Anesthesia; Internal medicine; Placebo; Cytochrome P450; Serotonin","score_opus":0.1980616557976609,"score_gpt":0.4780799159940573,"score_spread":0.2800182601963964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059248961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888032,0.0009130643,0.00004818866,0.0059516383,0.00093062484,0.002610319,0.0000035055311,0.000029846155,0.0007095887],"genre_scores_gemma":[0.99496806,0.0008083896,0.001309501,0.0012507362,0.0005746563,0.00018486347,0.00005140142,0.000026844962,0.0008255513],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99383265,0.003034809,0.0019082892,0.0004063063,0.00043575524,0.0003821894],"domain_scores_gemma":[0.9948643,0.0034803832,0.0004982301,0.0003582077,0.0002034948,0.0005954219],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016266853,0.00019965455,0.0011586386,0.0002741438,0.00008099146,0.000033462886,0.00018028395,0.00020122698,0.00009054337],"category_scores_gemma":[0.009132238,0.00016048393,0.00013105613,0.00052927283,0.00070621335,0.00053984846,0.00015757905,0.0009969503,0.00003949122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9478872,0.0020400546,0.030210633,0.00028950372,0.00015324814,0.000006946804,0.0014195828,0.000008364243,0.0013243725,0.0010708459,0.0033665767,0.01222266],"study_design_scores_gemma":[0.9812476,0.0011151296,0.0063578244,0.0005774555,0.00020919551,0.0000093517765,0.000499717,0.0034905565,0.002236073,0.0012724182,0.0027527143,0.00023198154],"about_ca_topic_score_codex":0.0003119551,"about_ca_topic_score_gemma":0.000037028633,"teacher_disagreement_score":0.03336037,"about_ca_system_score_codex":0.000077588345,"about_ca_system_score_gemma":0.00029425116,"threshold_uncertainty_score":0.99921423},"labels":[],"label_agreement":null},{"id":"W2059623829","doi":"10.1007/bf03261913","title":"Effect of Ketoconazole on the Pharmacokinetic Profile of Buprenorphine following Administration of a Once-Weekly Buprenorphine Transdermal System","year":2012,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Ketoconazole; Medicine; Buprenorphine; Cmax; Pharmacokinetics; Placebo; Crossover study; Pharmacology; Confidence interval; Transdermal; Area under the curve; Anesthesia; Internal medicine; Opioid","score_opus":0.10642077970965888,"score_gpt":0.43825656655936307,"score_spread":0.33183578684970416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059623829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931711,0.0006927102,0.00005487024,0.00069946324,0.0019337712,0.0015327645,0.00016107116,0.000046128414,0.0017081293],"genre_scores_gemma":[0.99851435,0.000090219466,0.00013986608,0.00032962984,0.0005474792,0.00015645668,0.00007561308,0.000033408778,0.00011296939],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99446785,0.002684447,0.0016978213,0.00030844746,0.00043737763,0.0004040307],"domain_scores_gemma":[0.99468136,0.0034886925,0.0009809522,0.00034231757,0.00015988917,0.0003467915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060417904,0.00032005258,0.0007887338,0.00012074849,0.00012227506,0.0000066578373,0.00042172283,0.00028438104,0.00024549416],"category_scores_gemma":[0.00055933674,0.00023331793,0.0004580106,0.0003883893,0.0006057911,0.00015373729,0.00006436494,0.00073839154,0.000030162628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040308335,0.0018061061,0.08532561,0.0022429868,0.0010829545,0.000010820478,0.002644867,0.0014501556,0.8517414,0.0059861876,0.0024160529,0.04126202],"study_design_scores_gemma":[0.003880614,0.0007929891,0.013706112,0.00018179338,0.0010656478,0.0000054833135,0.00008814583,0.010997089,0.9673689,0.00008702775,0.0016093914,0.00021683217],"about_ca_topic_score_codex":0.000017992095,"about_ca_topic_score_gemma":0.00000140866,"teacher_disagreement_score":0.115627475,"about_ca_system_score_codex":0.000028878769,"about_ca_system_score_gemma":0.00014676606,"threshold_uncertainty_score":0.9514429},"labels":[],"label_agreement":null},{"id":"W2059944626","doi":"10.1007/s40261-013-0079-8","title":"Pharmacokinetics and Dose Proportionality of Fentanyl Sublingual Spray: a Single-Dose 5-Way Crossover Study","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AXYS Technologies (Canada)","funders":"","keywords":"Fentanyl; Medicine; Crossover study; Sublingual administration; Pharmacokinetics; Anesthesia; Adverse effect; Bioavailability; Pharmacology; Placebo","score_opus":0.08705137726059048,"score_gpt":0.3785797956719751,"score_spread":0.2915284184113846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059944626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514836,0.00006504364,0.00002135842,0.0025454885,0.00025184147,0.0015192674,0.0000043733394,0.00005916029,0.00038510095],"genre_scores_gemma":[0.9959468,0.000024991814,0.0010904814,0.0013003882,0.00039410254,0.000035001256,0.000049747978,0.000017372862,0.0011410926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978875,0.0002246366,0.0009324578,0.0003616784,0.00041298312,0.00018074473],"domain_scores_gemma":[0.99852467,0.00030532214,0.00033677524,0.00028726383,0.0002826114,0.00026338422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001342865,0.00015215766,0.00034588037,0.00008073858,0.00006359299,0.000046895755,0.00008705184,0.00007869609,0.00015453988],"category_scores_gemma":[0.001479812,0.0001282517,0.0000860199,0.00022317834,0.0005209344,0.00019507564,0.000102231075,0.00025725242,0.00004061582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014829075,0.0012589515,0.9850799,0.00013231416,0.000089669506,0.000009048579,0.0006371552,0.0000032167245,0.0038080593,0.00016730532,0.00500139,0.0036646903],"study_design_scores_gemma":[0.004454176,0.00044019998,0.9880911,0.00006643244,0.0002025681,9.108315e-7,0.00038367778,0.0016221598,0.0016301048,0.0019204384,0.001055315,0.00013292754],"about_ca_topic_score_codex":0.00011206535,"about_ca_topic_score_gemma":0.000013520879,"teacher_disagreement_score":0.004305885,"about_ca_system_score_codex":0.00002975313,"about_ca_system_score_gemma":0.0000796638,"threshold_uncertainty_score":0.5229953},"labels":[],"label_agreement":null},{"id":"W2062703060","doi":"10.2165/00044011-200222030-00008","title":"Stevens-Johnson Syndrome Associated with Codeine in a Child","year":2002,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Codeine; Medicine; Pharmacotherapy; Pediatrics; Psychiatry; Pharmacology; Morphine","score_opus":0.07096297443176268,"score_gpt":0.3095869458347072,"score_spread":0.2386239714029445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062703060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97724265,0.000051548308,0.00002144454,0.0067913574,0.00019293014,0.00050707295,0.0000075665785,0.00016005464,0.0150253475],"genre_scores_gemma":[0.9961582,0.00005525104,0.0003648923,0.0010197753,0.00011395511,0.000020848014,0.00009931671,0.00003626545,0.0021314889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803054,0.00018027253,0.00074768835,0.00039634173,0.00034032107,0.00030484147],"domain_scores_gemma":[0.99839044,0.000559926,0.00025572616,0.0003322634,0.000105775485,0.0003558578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096209475,0.00017565995,0.00044960217,0.00017954377,0.00007357839,0.000014670624,0.00007685348,0.00020115936,0.000036208254],"category_scores_gemma":[0.002456247,0.00015188107,0.00010065585,0.00070450426,0.00025286106,0.00019172039,0.000023709032,0.0007984862,0.000229784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013056582,0.0054219696,0.93960047,0.00021603784,0.0007291836,0.0028843218,0.0021612768,0.0003894275,0.0013666867,0.0018696802,0.0052247625,0.04000564],"study_design_scores_gemma":[0.0033583469,0.00014840376,0.9894612,0.00093070505,0.000126087,0.00022792492,0.00010615084,0.0030898678,0.00015736221,0.0002805837,0.0019105951,0.00020281473],"about_ca_topic_score_codex":0.00006184255,"about_ca_topic_score_gemma":0.00029220837,"teacher_disagreement_score":0.04986071,"about_ca_system_score_codex":0.00022710254,"about_ca_system_score_gemma":0.00007045489,"threshold_uncertainty_score":0.61935306},"labels":[],"label_agreement":null},{"id":"W2063846810","doi":"10.2165/00044011-200019040-00003","title":"Theoretical Basis for Loxapine Augmentation in Risperidone Partial Responders","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Riverview Hospital; University of British Columbia","funders":"","keywords":"Risperidone; Medicine; Pharmacology; Antipsychotic; Pharmacodynamics; Dopamine receptor D2; Atypical antipsychotic; Pharmacokinetics; Schizophrenia (object-oriented programming); Internal medicine; Dopamine; Psychiatry","score_opus":0.06441166863861404,"score_gpt":0.400540279129865,"score_spread":0.336128610491251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063846810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799749,0.00006516756,0.000094150746,0.018359775,0.00009134097,0.0008932086,0.00001312671,0.00006341782,0.00044489192],"genre_scores_gemma":[0.9894609,0.0001389674,0.008006534,0.0012170841,0.00030793608,0.00018823952,0.0002089799,0.00001828094,0.00045307117],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998272,0.00026392454,0.00058238115,0.00034691274,0.00027346832,0.00026129567],"domain_scores_gemma":[0.9984589,0.0008650274,0.000051085655,0.00022272351,0.000063351144,0.00033886946],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011009645,0.00011780933,0.00026493595,0.00009337389,0.000058628426,0.000020478485,0.000058645004,0.00010820704,0.0017808786],"category_scores_gemma":[0.0016214943,0.00009742527,0.0001359367,0.00022913424,0.00049488666,0.00009468209,0.000011262615,0.00022096206,0.0001761917],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.124423884,0.0026653574,0.218401,0.00024519782,0.0003541798,0.0001504486,0.0014832708,0.00018447677,0.0016110687,0.16344798,0.014929117,0.472104],"study_design_scores_gemma":[0.033262275,0.002426406,0.77416134,0.00037599966,0.00024535757,0.000015784379,0.0002588306,0.052792948,0.012548074,0.12144096,0.0020973738,0.00037463568],"about_ca_topic_score_codex":0.000033014694,"about_ca_topic_score_gemma":0.000048808877,"teacher_disagreement_score":0.5557603,"about_ca_system_score_codex":0.00011002167,"about_ca_system_score_gemma":0.00025223126,"threshold_uncertainty_score":0.9991316},"labels":[],"label_agreement":null},{"id":"W2069015817","doi":"10.2165/00044011-200424020-00003","title":"Oxybutynin Extended Release and Tolterodine Immediate Release","year":2004,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Radiation Oncology; McGill University; Royal Victoria Hospital","funders":"","keywords":"Oxybutynin; Tolterodine; Overactive bladder; Medicine; Urology; Extended release; Pharmacology","score_opus":0.060921529881403896,"score_gpt":0.3717230359503727,"score_spread":0.31080150606896884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069015817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97792536,0.0005844112,0.000086921515,0.01983957,0.0001602727,0.00047230633,0.000011382617,0.000098645556,0.00082110596],"genre_scores_gemma":[0.9929513,0.0011297617,0.0018299916,0.002247722,0.0004225778,0.000027265256,0.00015278901,0.00002742482,0.0012111736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980764,0.00019863165,0.0006182301,0.0004578419,0.00033879667,0.0003101208],"domain_scores_gemma":[0.9982895,0.00029957623,0.00010111203,0.000323649,0.00013926256,0.00084689475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010522923,0.00016084567,0.0003235773,0.000102073056,0.0001093535,0.00003230392,0.000076909564,0.00013474768,0.000068843285],"category_scores_gemma":[0.0017599199,0.00013705221,0.00009696518,0.00023284568,0.00055451685,0.00017694873,0.00007939871,0.00058326183,0.00019042843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008420072,0.0046152743,0.56293327,0.0023738143,0.0006401641,0.0032308365,0.0062222653,0.00016552665,0.042487197,0.0133862775,0.041850995,0.31367433],"study_design_scores_gemma":[0.014174383,0.002479432,0.9032882,0.00055311545,0.00022522875,0.00021853735,0.00026075527,0.0014138867,0.018371018,0.05298413,0.005522609,0.00050873327],"about_ca_topic_score_codex":0.00011742128,"about_ca_topic_score_gemma":0.00001319038,"teacher_disagreement_score":0.34035492,"about_ca_system_score_codex":0.00005160114,"about_ca_system_score_gemma":0.0003365772,"threshold_uncertainty_score":0.55888265},"labels":[],"label_agreement":null},{"id":"W2073529780","doi":"10.1007/s40261-013-0088-7","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Tolerability; Pharmacodynamics; Pharmacokinetics; Crossover study; Dosing; Adverse effect; Ipratropium bromide; Placebo; Anesthesia; COPD; Tiotropium bromide; Pharmacology; Bronchodilator; Internal medicine; Asthma; Lung","score_opus":0.0649579216921815,"score_gpt":0.4054841485212134,"score_spread":0.3405262268290319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073529780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988607,0.004610338,0.0000141786295,0.0042424924,0.00017285103,0.0020999038,0.0000217383,0.000023430359,0.00020809703],"genre_scores_gemma":[0.99282306,0.0055369553,0.00096994545,0.0003840344,0.00010414187,0.00006884129,0.0000355197,0.0000213732,0.00005614634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995992,0.001124172,0.0017928233,0.00046739043,0.00036985925,0.00025374806],"domain_scores_gemma":[0.9943764,0.003996702,0.0004572334,0.0002798128,0.0005411198,0.0003487299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026845462,0.00019921089,0.0013251427,0.00018841194,0.0000432861,0.000011073958,0.00008771337,0.00008811489,0.000038885093],"category_scores_gemma":[0.0048777154,0.00016881808,0.00012953774,0.0003285871,0.0027045647,0.00018472898,0.00021252298,0.00037534133,0.000002100296],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066081956,0.0018981431,0.85115397,0.008061522,0.00064176996,0.000037797567,0.0032726277,0.000100045196,0.0278388,0.0007756621,0.00041023426,0.039727475],"study_design_scores_gemma":[0.3877544,0.0010771769,0.49949336,0.001686137,0.00089075475,0.000049006867,0.0021417388,0.06333219,0.014450615,0.028519537,0.00007156587,0.0005334978],"about_ca_topic_score_codex":0.00034550726,"about_ca_topic_score_gemma":0.000053212327,"teacher_disagreement_score":0.3516606,"about_ca_system_score_codex":0.00014529443,"about_ca_system_score_gemma":0.00025047897,"threshold_uncertainty_score":0.9965081},"labels":[],"label_agreement":null},{"id":"W2073707487","doi":"10.2165/00044011-200020020-00007","title":"Pharmacokinetics of Estradiol Valerate 2mg + Dienogest 2mg (Climodien?? 2/2) after Single and Repeated Oral Administration in Healthy Postmenopausal Women","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Dienogest; Estrone; Estradiol valerate; Pharmacokinetics; Tolerability; Medicine; Endocrinology; Estrogen; Internal medicine; Valerate; Sex hormone-binding globulin; Hormone; Oral administration; Area under the curve; Pharmacology; Adverse effect; Androgen; Chemistry; Endometriosis","score_opus":0.07500335401889527,"score_gpt":0.3791222907515989,"score_spread":0.3041189367327036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073707487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556243,0.00029965412,0.0000019882357,0.0026124185,0.00014984646,0.0008918376,0.000041787614,0.00004630984,0.00039373178],"genre_scores_gemma":[0.99520385,0.0005253523,0.0009619535,0.002649478,0.00013569825,0.00006857447,0.00016462378,0.000029885758,0.00026056406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713326,0.00034164774,0.0013456754,0.00046920154,0.0002657496,0.00044448418],"domain_scores_gemma":[0.9983126,0.00023230775,0.00028039725,0.0002821046,0.000099609104,0.0007930024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009290257,0.00023181425,0.0005638423,0.00013435111,0.00006134595,0.00002420711,0.000054996137,0.00016798776,0.00022951695],"category_scores_gemma":[0.0002884826,0.00020262571,0.000017968307,0.00032665455,0.00032412168,0.00018611716,0.000016686792,0.0003338372,0.000025463258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029538527,0.0062279007,0.8263846,0.0017593486,0.0003143109,0.0005754288,0.005648177,0.0000714675,0.021328487,0.00013147297,0.0006615655,0.10735871],"study_design_scores_gemma":[0.011793264,0.021839032,0.96050745,0.00039096948,0.00017028446,0.000058122085,0.00006131419,0.0010898486,0.0023061798,0.0007248812,0.00080354395,0.00025511306],"about_ca_topic_score_codex":0.00013219449,"about_ca_topic_score_gemma":0.00006523081,"teacher_disagreement_score":0.13412283,"about_ca_system_score_codex":0.000172918,"about_ca_system_score_gemma":0.00033931405,"threshold_uncertainty_score":0.8262837},"labels":[],"label_agreement":null},{"id":"W2074097337","doi":"10.1007/s40261-013-0110-0","title":"Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Allergic Rhinitis and Sensitization","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Medicine; Pharmacokinetics; Renal function; Antihistamine; Urology; Internal medicine; Pharmacology","score_opus":0.08899851646535378,"score_gpt":0.329584416136197,"score_spread":0.2405858996708432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074097337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770397,0.00008630714,0.00021393922,0.00054942566,0.00010123034,0.00066784443,0.0000024610938,0.000007409959,0.0006674073],"genre_scores_gemma":[0.9984375,0.000027438056,0.001345995,0.00008073624,0.000046505873,0.000008652519,0.000016201046,0.000009767979,0.000027159691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768233,0.0004210004,0.00091565767,0.00016181766,0.00072706555,0.0000921355],"domain_scores_gemma":[0.9975804,0.0003188266,0.00059938245,0.00021593767,0.0012244623,0.000060976752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015700004,0.00008782389,0.00028587782,0.000090587375,0.00001770736,0.000003407701,0.000075227515,0.00007409372,0.00004269841],"category_scores_gemma":[0.002404065,0.00005593986,0.000056302964,0.00048706002,0.0004677436,0.00007429251,0.000026209262,0.00015709033,0.000001624761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004806224,0.003725939,0.6159947,0.000425497,0.00017304275,0.0000038525563,0.004814918,0.054748345,0.25489533,0.0011169043,0.00067581784,0.06294506],"study_design_scores_gemma":[0.0028477546,0.00060154696,0.7931803,0.00047732732,0.00019272036,0.0000048804463,0.00011549312,0.170204,0.031681467,0.0006271154,0.000006955202,0.00006043642],"about_ca_topic_score_codex":0.000203574,"about_ca_topic_score_gemma":0.00011927665,"teacher_disagreement_score":0.22321385,"about_ca_system_score_codex":0.00004179548,"about_ca_system_score_gemma":0.0004071505,"threshold_uncertainty_score":0.2878064},"labels":[],"label_agreement":null},{"id":"W2077423491","doi":"10.2165/11598940-000000000-00000","title":"Cost-Effectiveness and Cost-Utility of Beclomethasone/Formoterol versus Fluticasone Propionate/Salmeterol in Patients with Moderate to Severe Asthma","year":2012,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institute for Theoretical Astrophysics; Chiesi Farmaceutici","keywords":"Salmeterol; Fluticasone propionate; Medicine; Formoterol; Asthma; Exacerbation; Fluticasone; Quality-adjusted life year; Quality of life (healthcare); Pediatrics; Cost effectiveness; Emergency medicine; Budesonide; Internal medicine","score_opus":0.08262178632127089,"score_gpt":0.3634312461936802,"score_spread":0.28080945987240935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077423491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968282,0.00007609506,0.00027158295,0.00016768367,0.00018527135,0.0023553083,0.000039351675,0.000027688615,0.00004884591],"genre_scores_gemma":[0.998367,0.0000044064336,0.0009309673,0.00041184915,0.0000713177,0.000116655654,0.00006572002,0.0000209292,0.000011162818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980938,0.00043335027,0.00053120335,0.00032978176,0.0003236246,0.00028826692],"domain_scores_gemma":[0.9982296,0.0005373631,0.00015717522,0.00025880887,0.00021827202,0.0005987502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009381258,0.0001835527,0.0004688546,0.0001075702,0.000050256218,0.000010811399,0.0000611224,0.00013509131,0.000016986753],"category_scores_gemma":[0.0009833309,0.00013641022,0.000060604558,0.00026082664,0.00033082964,0.00025610835,0.00006335626,0.0002572908,0.000012293247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070022866,0.0005523148,0.94450545,0.00017323527,0.00003628827,0.0000015405333,0.00021048344,0.000030069046,0.00005169659,0.000018717814,0.000057261565,0.047360666],"study_design_scores_gemma":[0.00898603,0.001053042,0.98722833,0.0002664767,0.000063767824,0.0000010110313,0.000061879866,0.0010825687,0.0008148675,0.000048897087,0.00024718756,0.00014592512],"about_ca_topic_score_codex":0.000024828749,"about_ca_topic_score_gemma":0.000011145543,"teacher_disagreement_score":0.047214743,"about_ca_system_score_codex":0.000057520196,"about_ca_system_score_gemma":0.00012254264,"threshold_uncertainty_score":0.5562647},"labels":[],"label_agreement":null},{"id":"W2078098902","doi":"10.2165/00044011-200020020-00005","title":"Mammographic Density in Postmenopausal Women Treated with Tibolone, Estriol or Conventional Hormone Replacement Therapy","year":2000,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Digital Radiography and Breast Imaging","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Trois-Rivieres; Cegep de Thetford","funders":"","keywords":"Tibolone; Medicine; Estriol; Medroxyprogesterone acetate; Hormone replacement therapy (female-to-male); Menopause; Estrogen; Medroxyprogesterone; Internal medicine; Gynecology; Urology; Testosterone (patch)","score_opus":0.027944960573764242,"score_gpt":0.2974984960247114,"score_spread":0.2695535354509472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078098902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966715,0.00012789693,0.0000066215466,0.0013763945,0.000034238532,0.0006069727,0.000011270623,0.000099601406,0.0010655152],"genre_scores_gemma":[0.9956697,0.00035628836,0.0004946245,0.0017300971,0.00009492932,0.00009922653,0.00021069394,0.000020999782,0.0013234471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814594,0.00015645038,0.00063610094,0.00043086987,0.00031693987,0.0003137211],"domain_scores_gemma":[0.99900573,0.00018495048,0.00012612906,0.00026519035,0.0000856996,0.00033228437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007097976,0.00019518578,0.0003796031,0.00019867432,0.0000625257,0.000038307273,0.00007743265,0.000097057615,0.00029371356],"category_scores_gemma":[0.000082827064,0.00013756043,0.000090722744,0.0008035944,0.0004927802,0.00023135683,0.000010932782,0.0003102906,0.00004085701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00984894,0.00079503696,0.9419928,0.000018263949,0.00014119492,0.00011063976,0.00015429023,0.0000059459917,0.00019914945,0.00009738601,0.00072227046,0.045914065],"study_design_scores_gemma":[0.008821465,0.0031031945,0.98426807,0.00016935897,0.00003993861,0.000113969494,0.00008483116,0.00017201497,0.00031769884,0.000947654,0.001766804,0.00019498453],"about_ca_topic_score_codex":0.0000906577,"about_ca_topic_score_gemma":0.000019607036,"teacher_disagreement_score":0.04571908,"about_ca_system_score_codex":0.00006605902,"about_ca_system_score_gemma":0.00018467137,"threshold_uncertainty_score":0.56095517},"labels":[],"label_agreement":null},{"id":"W2080870880","doi":"10.1007/s40261-014-0195-0","title":"Clinical Pharmacokinetics of the Nicotinic Channel Modulator Dexmecamylamine (TC-5214) in Subjects with Various Degrees of Renal Impairment","year":2014,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Nicotinic Acetylcholine Receptors Study","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Pharmacokinetics; Nicotinic agonist; Pharmacotherapy; Pharmacology; Internal medicine; Receptor","score_opus":0.02027199749577582,"score_gpt":0.3037944552337191,"score_spread":0.2835224577379433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080870880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977113,0.00013786984,0.00059404824,0.000388671,0.00045338704,0.0005787359,0.000012205226,0.000011933552,0.000111873596],"genre_scores_gemma":[0.9971897,0.00017671846,0.0016149931,0.00033070394,0.00044624164,0.000023003257,0.000045004796,0.000035857545,0.0001377886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616677,0.0009931482,0.0016692283,0.00056628464,0.00031368513,0.00029087023],"domain_scores_gemma":[0.99761975,0.00037582568,0.00087802124,0.00072370906,0.00022967065,0.00017300484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026958485,0.0002456816,0.0005510561,0.0000527837,0.00004414199,0.000007125656,0.0004957591,0.00027536624,0.000008343398],"category_scores_gemma":[0.0017371516,0.00017419194,0.00025572538,0.0002976153,0.0008253812,0.000007944628,0.00029608072,0.00044726016,0.0000036293195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053194957,0.001409369,0.9452709,0.000121705176,0.0002236923,3.09403e-7,0.00027069025,0.0059211818,0.04040896,0.0001640177,0.0018386071,0.003838607],"study_design_scores_gemma":[0.009431161,0.0034520782,0.67120767,0.00039944518,0.00025147962,0.000010017749,0.00011970146,0.02260668,0.28977317,0.00045460006,0.0017003394,0.0005936793],"about_ca_topic_score_codex":0.00007081561,"about_ca_topic_score_gemma":0.00027972748,"teacher_disagreement_score":0.27406326,"about_ca_system_score_codex":0.000019098665,"about_ca_system_score_gemma":0.00027796382,"threshold_uncertainty_score":0.7103341},"labels":[],"label_agreement":null},{"id":"W2082548041","doi":"10.2165/00044011-200525010-00004","title":"Dose Conversion and Cost???Effectiveness of Erythropoietic???Therapies in Chemotherapy-Related Anaemia","year":2005,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Medicine; Darbepoetin alfa; Epoetin alfa; Dosing; Confidence interval; Internal medicine; Chemotherapy; Oncology","score_opus":0.033923485562995154,"score_gpt":0.34490357357782436,"score_spread":0.31098008801482924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082548041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99124736,0.00062914024,0.000009584369,0.0068836533,0.00010390414,0.00066656206,0.0000025314037,0.000040232273,0.00041701697],"genre_scores_gemma":[0.9962746,0.001245213,0.0015323897,0.0005982853,0.00006125412,0.00001700382,0.000046356512,0.000018494928,0.0002064199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844193,0.00032556968,0.00060721044,0.00030590707,0.0001681155,0.00015125198],"domain_scores_gemma":[0.99877536,0.00062207715,0.00016243632,0.00020051177,0.00007835648,0.00016125254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001112135,0.00014837108,0.00043530052,0.00008895471,0.000036396425,0.0000068776167,0.000044518103,0.00018432466,0.00009078932],"category_scores_gemma":[0.00023803537,0.00012355932,0.000091212685,0.00021337991,0.0007469268,0.00009409019,0.00002383347,0.00025680105,0.000021661415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006815537,0.00069911755,0.94199026,0.0003985766,0.00011129232,0.000014258323,0.0017044803,0.000031090876,0.0072609503,0.0007424149,0.0007539727,0.04561201],"study_design_scores_gemma":[0.012615936,0.0005168768,0.95637375,0.00095701526,0.000079427526,0.000014021395,0.00041481582,0.00144117,0.024414245,0.001522886,0.0014793026,0.00017057406],"about_ca_topic_score_codex":0.00008176767,"about_ca_topic_score_gemma":0.000014833992,"teacher_disagreement_score":0.045441438,"about_ca_system_score_codex":0.000095104464,"about_ca_system_score_gemma":0.00009591669,"threshold_uncertainty_score":0.5038603},"labels":[],"label_agreement":null},{"id":"W2094140885","doi":"10.1007/s40261-013-0071-3","title":"Pharmacokinetic and Pharmacodynamic Profile of Rosuvastatin in Patients with End-Stage Renal Disease on Chronic Haemodialysis","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"AstraZeneca","keywords":"Rosuvastatin; Medicine; Pharmacokinetics; Pharmacodynamics; Rosuvastatin Calcium; End stage renal disease; Urology; Dialysis; Population; Area under the curve; Internal medicine; Kidney disease; Pharmacology; Hemodialysis","score_opus":0.017598463046620848,"score_gpt":0.29924447481007505,"score_spread":0.2816460117634542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094140885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974766,0.00015032367,0.0000446955,0.00060194917,0.000057786558,0.0015143141,0.000035588066,0.000022543523,0.00009619274],"genre_scores_gemma":[0.9982352,0.00009753993,0.00050638494,0.00047520202,0.0001301419,0.00013126986,0.0002371732,0.000021682887,0.0001653538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981571,0.00026763603,0.0005943215,0.0003483558,0.00043536766,0.00019723774],"domain_scores_gemma":[0.99886984,0.00011406413,0.0001983159,0.00028577022,0.00012923178,0.0004027777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005815259,0.00014401195,0.00039634304,0.000112360874,0.000033369535,0.000010240298,0.000053270953,0.00004150309,0.00020807292],"category_scores_gemma":[0.0001977975,0.000108369335,0.00010675462,0.00023478351,0.00026888028,0.00011670783,0.000027452737,0.00028351913,0.000021926026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000677358,0.0005919596,0.8088542,0.00092844706,0.00017033111,0.000013725757,0.00016393515,0.0004386245,0.0006392575,0.000060021102,0.00032446906,0.18713765],"study_design_scores_gemma":[0.0065609044,0.00062191533,0.97834307,0.00036895342,0.000182793,3.6306733e-7,0.0000133554995,0.012638899,0.00095357344,0.00008079084,0.00011478223,0.000120601515],"about_ca_topic_score_codex":0.00022088662,"about_ca_topic_score_gemma":0.000017119432,"teacher_disagreement_score":0.18701705,"about_ca_system_score_codex":0.00008138236,"about_ca_system_score_gemma":0.000274257,"threshold_uncertainty_score":0.44191733},"labels":[],"label_agreement":null},{"id":"W2096365365","doi":"10.1007/s40261-015-0302-x","title":"Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System","year":2015,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); Santé Montérégie; Thornhill Medical (Canada)","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab emtansine; Capecitabine; Trastuzumab; Adverse effect; Oncology; Internal medicine; Breast cancer; Clinical trial; Metastatic breast cancer; Taxane; Cancer; Colorectal cancer","score_opus":0.08230834484887428,"score_gpt":0.41124979316270993,"score_spread":0.32894144831383565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096365365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96636826,0.0014734796,0.00007485132,0.01846394,0.00024542274,0.007149821,0.0061378265,0.000009356395,0.000077069366],"genre_scores_gemma":[0.99821967,0.00012028889,0.0009426129,0.0002302806,0.00004949294,0.00022636495,0.00013304812,0.00002228934,0.000055978475],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99721557,0.0006730088,0.0011052256,0.00029217787,0.00050174183,0.00021227483],"domain_scores_gemma":[0.99508095,0.0018503055,0.00061537477,0.00043224168,0.0016534836,0.00036764937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009043886,0.00016070408,0.0007370588,0.000050707742,0.0001139132,0.0000025137592,0.00018158571,0.000067235014,0.000016873157],"category_scores_gemma":[0.0011540302,0.0000808318,0.00013010464,0.00043137206,0.0006793708,0.000039723713,0.00003106932,0.00016963258,7.4911907e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06871605,0.0028356425,0.25477776,0.0044070063,0.007376547,0.00002510167,0.5005025,0.02076925,0.0014808845,0.0046037654,0.006764259,0.12774117],"study_design_scores_gemma":[0.022979928,0.0057442854,0.82884216,0.0077523193,0.0010128183,0.000012305422,0.11575898,0.013616842,0.003639916,0.00017344346,0.00023362582,0.00023336486],"about_ca_topic_score_codex":0.259359,"about_ca_topic_score_gemma":0.35511288,"teacher_disagreement_score":0.57406443,"about_ca_system_score_codex":0.0027365948,"about_ca_system_score_gemma":0.0064600785,"threshold_uncertainty_score":0.9991724},"labels":[],"label_agreement":null},{"id":"W2097671393","doi":"10.1007/s40261-013-0080-2","title":"Cross-Over, Open-Label Trial of the Effects of Gabapentin versus Pregabalin on Painful Peripheral Neuropathy and Health-Related Quality of Life in Haemodialysis Patients","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Dialysis and Renal Disease Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"McGill University","keywords":"Pregabalin; Gabapentin; Medicine; Neuropathic pain; Anesthesia; Peripheral neuropathy; Quality of life (healthcare); McGill Pain Questionnaire; Crossover study; Randomized controlled trial; Internal medicine; Visual analogue scale; Diabetes mellitus","score_opus":0.10081858985071827,"score_gpt":0.3959633070533829,"score_spread":0.2951447172026646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097671393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958248,0.000072679264,0.0000017149981,0.0009819724,0.00058646104,0.0023370693,0.000009967731,0.000006498804,0.0001788397],"genre_scores_gemma":[0.99892724,0.00006264205,0.00006156899,0.00070164853,0.000037091042,0.00004634704,0.000046418514,0.000011207339,0.0001058362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957293,0.0014394354,0.0019403148,0.00030851437,0.00044401386,0.00013840801],"domain_scores_gemma":[0.9969726,0.0010006435,0.0012317675,0.00041512793,0.00016766162,0.0002121733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022437216,0.00013259925,0.00081476936,0.000075098105,0.000038291015,0.00002242627,0.00018798474,0.00008808548,0.000028961713],"category_scores_gemma":[0.00766433,0.00009001319,0.00017858263,0.00034904762,0.00044771345,0.000109565655,0.00019962713,0.00019006632,0.000002520481],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019119337,0.005214609,0.9502025,0.0014060697,0.00029012316,7.3114364e-7,0.0006390237,0.00006949953,0.0003596873,0.0006229018,0.0009832676,0.021092197],"study_design_scores_gemma":[0.08778773,0.0015870935,0.9084076,0.00039035777,0.00010909327,9.725115e-9,0.000021021331,0.0011436754,0.00018016923,0.0002950229,0.000010112733,0.00006807317],"about_ca_topic_score_codex":0.0017570694,"about_ca_topic_score_gemma":0.000066025386,"teacher_disagreement_score":0.068668395,"about_ca_system_score_codex":0.000035962137,"about_ca_system_score_gemma":0.00015718098,"threshold_uncertainty_score":0.9175472},"labels":[],"label_agreement":null},{"id":"W2123457220","doi":"10.2165/00044011-200525120-00006","title":"Famciclovir for the Management of??Genital Herpes Simplex in Patients??with Inadequate Response to??Aciclovir or Valaciclovir","year":2005,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of British Columbia","funders":"","keywords":"Valaciclovir; Famciclovir; Aciclovir; Medicine; Genital herpes; Herpes Genitalis; Herpes simplex virus; Penciclovir; Dermatology; Pharmacotherapy; Virology; Herpesviridae; Internal medicine; Virus; Viral disease","score_opus":0.04670342193287763,"score_gpt":0.35732742689386937,"score_spread":0.31062400496099174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123457220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99237907,0.000023484263,0.0005222912,0.0044515897,0.000123002,0.002220438,0.000036168953,0.000045276636,0.00019868628],"genre_scores_gemma":[0.98788047,0.000020902135,0.008950308,0.0013144157,0.000106280015,0.00025974223,0.00004329914,0.00003233872,0.0013922175],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99802405,0.00020903371,0.0008192263,0.00036948733,0.0002987606,0.00027945108],"domain_scores_gemma":[0.9978815,0.0011228456,0.00017680672,0.00044251827,0.00015869412,0.00021763452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012267604,0.00019597284,0.00033947744,0.00014242377,0.00011453048,0.000019806117,0.00012269407,0.00009907109,0.00005187824],"category_scores_gemma":[0.0004034794,0.00011530164,0.00012748837,0.00054384203,0.00021928558,0.00014243908,0.00005709436,0.00016281832,0.000085110725],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0133089945,0.001426133,0.1473931,0.00011925204,0.0003984987,0.000011101838,0.0005592219,0.00043464897,0.000009987126,0.00036695722,0.0009938767,0.8349782],"study_design_scores_gemma":[0.009245259,0.0013404762,0.8808046,0.00022449496,0.00029539515,0.0000014120855,0.0002024838,0.0008745693,0.0005595345,0.00021120436,0.106055774,0.00018481605],"about_ca_topic_score_codex":0.000047666537,"about_ca_topic_score_gemma":0.000110357214,"teacher_disagreement_score":0.8347934,"about_ca_system_score_codex":0.00014661024,"about_ca_system_score_gemma":0.00013854462,"threshold_uncertainty_score":0.47018647},"labels":[],"label_agreement":null},{"id":"W2150339979","doi":"10.2165/11595370-000000000-00000","title":"Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus","year":2011,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo; McGill University","keywords":"Medicine; Type 2 Diabetes Mellitus; Pharmacotherapy; Diabetes mellitus; Secretion; Internal medicine; Type 2 diabetes; Gastroenterology; Pharmacology; Intensive care medicine; Endocrinology","score_opus":0.2086526985467771,"score_gpt":0.3294358003476996,"score_spread":0.1207831018009225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150339979","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07622526,0.9146059,0.00017818212,0.00038544682,0.0009907542,0.006200132,0.000012338475,0.00020549307,0.0011964638],"genre_scores_gemma":[0.005474056,0.9708376,0.01475011,0.0007083677,0.00096274714,0.00032314207,0.004946135,0.00019825897,0.0017995659],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99724036,0.0002579979,0.0010919916,0.0007261922,0.00031215622,0.00037130993],"domain_scores_gemma":[0.9983826,0.00015880991,0.0004334006,0.00044948873,0.00007338245,0.0005022886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006008581,0.0004473092,0.001424907,0.00032965792,0.00004105998,0.000043233493,0.00017732783,0.0002647122,0.000042730517],"category_scores_gemma":[0.0004187662,0.00032789077,0.00024261701,0.00059192604,0.00013570416,0.00014138829,0.00012859445,0.00050679,0.00024218785],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008339657,0.00036928937,0.036106456,0.003868436,0.00024916814,0.0000049811674,0.00009518626,0.000005812239,3.1020843e-8,0.0003418414,0.0009605674,0.9579148],"study_design_scores_gemma":[0.007969528,0.005568857,0.13805194,0.0779773,0.011025966,0.0000021296476,0.000041162006,0.0005397152,0.000006541132,0.0030787792,0.7537782,0.0019598608],"about_ca_topic_score_codex":0.000037268568,"about_ca_topic_score_gemma":0.000011674029,"teacher_disagreement_score":0.95595497,"about_ca_system_score_codex":0.00018578276,"about_ca_system_score_gemma":0.0003389219,"threshold_uncertainty_score":0.9999173},"labels":[],"label_agreement":null},{"id":"W2161313492","doi":"10.1007/s40261-014-0266-2","title":"Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks","year":2015,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"ViiV Healthcare; GlaxoSmithKline","keywords":"Darunavir; Dolutegravir; Raltegravir; Efavirenz; Medicine; Ritonavir; Integrase inhibitor; Pharmacology; Pharmacotherapy; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Internal medicine; Viral load","score_opus":0.15773271120190108,"score_gpt":0.42962761527089716,"score_spread":0.2718949040689961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161313492","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28632054,0.698056,0.000012400723,0.0011397165,0.00025602712,0.010775965,0.002191823,0.0003042349,0.00094334857],"genre_scores_gemma":[0.034226272,0.93953043,0.0025338875,0.0003810923,0.0003942994,0.0016876573,0.018716944,0.00026529972,0.002264092],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99400634,0.0013780496,0.0022693318,0.0012896481,0.00050371996,0.0005528939],"domain_scores_gemma":[0.9945658,0.0012664817,0.0017444766,0.0010032156,0.000529293,0.0008907688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068612804,0.0010201411,0.0046458053,0.000678651,0.00014631101,0.00003167001,0.00019539018,0.0009363844,0.000039404946],"category_scores_gemma":[0.00021170278,0.0007103451,0.00034702403,0.0013962107,0.00094877795,0.00013695481,0.00005316069,0.0010490719,0.00010713523],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004359283,0.008747147,0.1646861,0.020318175,0.0033880237,0.00027184444,0.0035765357,0.000017458144,0.00001617052,0.00038817408,0.008682732,0.7855484],"study_design_scores_gemma":[0.056957696,0.013364728,0.16112435,0.13411476,0.011749836,0.00014193275,0.00026778807,0.0022255273,0.00011439704,0.00021555978,0.6172447,0.0024786822],"about_ca_topic_score_codex":0.0012772825,"about_ca_topic_score_gemma":0.00055953074,"teacher_disagreement_score":0.7830697,"about_ca_system_score_codex":0.0007446793,"about_ca_system_score_gemma":0.001926049,"threshold_uncertainty_score":0.9995348},"labels":[],"label_agreement":null},{"id":"W2176476316","doi":"10.2165/00044011-200525120-00003","title":"Antihypertensive Effect of Irbesartan and Predictors of Response in Obesity-Associated Hypertension","year":2005,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton General Hospital; McMaster University","funders":"Sanofi","keywords":"Medicine; Irbesartan; Internal medicine; Blood pressure; Hydrochlorothiazide; Overweight; Tolerability; Body mass index; Diabetes mellitus; Obesity; Diastole; Nephropathy; Cardiology; Adverse effect; Endocrinology","score_opus":0.03470090359067777,"score_gpt":0.3112170291442123,"score_spread":0.2765161255535345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2176476316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99458706,0.001493276,7.144211e-7,0.0033131067,0.00012390318,0.00038025275,0.000008510738,0.000027276345,0.000065874614],"genre_scores_gemma":[0.9978202,0.00029876927,0.0002049852,0.0014543079,0.000087288005,0.0000053109866,0.000014140239,0.000013673677,0.000101298676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977406,0.00072307454,0.00085478585,0.00027631363,0.00025684494,0.00014835507],"domain_scores_gemma":[0.99643403,0.0026132104,0.00027133053,0.00022243203,0.00032186508,0.00013713591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021699886,0.00014462133,0.0010261306,0.00015565628,0.000037209637,0.000003008475,0.000046823632,0.00019256366,0.000004921231],"category_scores_gemma":[0.005855525,0.00010843577,0.00011508629,0.0002575569,0.0004868709,0.00008463753,0.00006116306,0.0002669653,0.0000044088342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020249803,0.0002501004,0.96802145,0.00010878588,0.00017550157,0.000018844063,0.00045405896,0.0000051222505,0.023903748,0.000012619476,0.0038822307,0.001142553],"study_design_scores_gemma":[0.00414731,0.0012466714,0.9662144,0.0005770733,0.00064258825,0.000013657654,0.00008683133,0.0009898329,0.025522744,0.000055167704,0.00040914555,0.000094569055],"about_ca_topic_score_codex":0.00006796261,"about_ca_topic_score_gemma":0.000033173732,"teacher_disagreement_score":0.003685536,"about_ca_system_score_codex":0.000010992326,"about_ca_system_score_gemma":0.000069253474,"threshold_uncertainty_score":0.7010033},"labels":[],"label_agreement":null},{"id":"W2179646396","doi":"10.1007/s40261-015-0336-0","title":"Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe","year":2015,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Guanfacine; Atomoxetine; Medicine; Stimulant; Methylphenidate; Dopamine; Context (archaeology); Attention deficit hyperactivity disorder; Monoaminergic; Pharmacology; Norepinephrine; Pharmacotherapy; Neuroscience; Psychiatry; Psychology; Clonidine; Receptor; Internal medicine","score_opus":0.39677855011462093,"score_gpt":0.5193796967377047,"score_spread":0.12260114662308375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179646396","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01095868,0.982786,0.000053755444,0.0018816023,0.00061982253,0.002793163,0.000022529413,0.00020211638,0.00068233674],"genre_scores_gemma":[0.00024187664,0.9877103,0.0008460813,0.0004744248,0.0008472989,0.0001640232,0.0013197074,0.000085182815,0.008311081],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99487305,0.0013675358,0.0019908596,0.00094935973,0.00046954423,0.00034967184],"domain_scores_gemma":[0.9970307,0.0006272718,0.00074883853,0.00051074417,0.00028498622,0.0007974851],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012049321,0.00056683994,0.0026163466,0.0002935066,0.000044800527,0.000033746834,0.00015673846,0.0006098022,0.00025924164],"category_scores_gemma":[0.0030321365,0.00042110225,0.0005629668,0.0010936677,0.00022827936,0.00017636042,0.00008291749,0.0011242926,0.0013929673],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086990054,0.00093883456,0.0005416139,0.0011315844,0.00017711172,0.0001467227,0.000051536073,0.000008255255,0.000003242794,0.00011625013,0.0062917527,0.9905061],"study_design_scores_gemma":[0.0037308345,0.0005946398,0.001380649,0.0042760465,0.0025386298,0.00009048189,0.000031626427,0.00030094513,8.6602734e-7,0.00021638455,0.98645455,0.00038433517],"about_ca_topic_score_codex":0.00006666887,"about_ca_topic_score_gemma":0.000019015048,"teacher_disagreement_score":0.9901218,"about_ca_system_score_codex":0.00058488577,"about_ca_system_score_gemma":0.0025020286,"threshold_uncertainty_score":0.9998241},"labels":[],"label_agreement":null},{"id":"W2287107829","doi":"10.1007/s40261-016-0381-3","title":"The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA","year":2016,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Eating Disorders and Behaviors","field":"Psychology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Binge-eating disorder; Binge eating; Pharmacotherapy; Medicine; Psychiatry; Bulimia nervosa; Stimulant; Eating disorders","score_opus":0.09954238075549586,"score_gpt":0.4170827267776626,"score_spread":0.31754034602216674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287107829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961882,0.00036194795,0.00035519231,0.001182781,0.00039232592,0.001350104,0.000014830336,0.000007471457,0.00014715124],"genre_scores_gemma":[0.9988192,0.0001779971,0.000045905177,0.000058530146,0.000064536056,0.0005111465,0.0000084660305,0.00001229819,0.00030192288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784964,0.0010334958,0.00061528414,0.00020757728,0.0001233764,0.00017061667],"domain_scores_gemma":[0.97916657,0.020009976,0.000327002,0.00040113574,0.00006981226,0.000025531872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002596226,0.00011245558,0.00022515941,0.000024856672,0.00014654167,0.000011107088,0.00024287187,0.000067304885,0.000013564612],"category_scores_gemma":[0.00090095785,0.00004087643,0.00015400797,0.00017821655,0.00068824826,0.0000365765,0.00001556341,0.0000800671,0.0000069321122],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012684212,0.00042434636,0.87007093,0.0000155688,0.000037644637,2.4534356e-7,0.0014812946,0.000012919121,0.00033040566,0.0030886577,0.00007484663,0.12433631],"study_design_scores_gemma":[0.0020697971,0.00067669014,0.9920162,0.00012565781,0.0000738731,3.4485308e-7,0.00066371023,0.00013780719,0.0003195815,0.0021182343,0.0017302006,0.00006789302],"about_ca_topic_score_codex":0.00058259815,"about_ca_topic_score_gemma":0.00085967296,"teacher_disagreement_score":0.12426841,"about_ca_system_score_codex":0.000019671701,"about_ca_system_score_gemma":0.000028562765,"threshold_uncertainty_score":0.25358793},"labels":[],"label_agreement":null},{"id":"W2327894690","doi":"10.1007/s40261-016-0397-8","title":"Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995","year":2016,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Simon Fraser University; Centre for Addiction and Mental Health","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Harm; Benzodiazepine; Narrative review; Psychiatry; Pharmacotherapy; Population; Intensive care medicine; Psychology; Environmental health; Internal medicine; Social psychology","score_opus":0.37809996263737117,"score_gpt":0.4652990289311206,"score_spread":0.0871990662937494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327894690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014480157,0.9797777,0.0000016215174,0.002970404,0.00007393658,0.002025312,0.00065989885,0.0000054251054,0.0000055579417],"genre_scores_gemma":[0.000297212,0.9934555,0.0015465406,0.0006552579,0.000056600806,0.00007408826,0.0037310482,0.000020849284,0.00016289389],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663943,0.00075811247,0.0013721037,0.00060030475,0.00042676838,0.00020330545],"domain_scores_gemma":[0.9957107,0.0025346074,0.0006552681,0.0006225249,0.00018447377,0.0002924721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084316585,0.0002847593,0.0014945869,0.000076574746,0.000082836596,0.000012727393,0.00018534838,0.00011953214,0.000016315375],"category_scores_gemma":[0.002923414,0.00015761086,0.00006862853,0.00026217249,0.00032891016,0.00016319886,0.00040125434,0.00037151214,0.0000045440515],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015742322,0.000045239616,0.030565754,0.037310522,0.00032979695,0.000032523185,0.00006854411,2.3140968e-8,3.5273055e-7,0.00006415079,0.007347596,0.92407805],"study_design_scores_gemma":[0.0024209917,0.00008822228,0.335456,0.26734945,0.00070753286,0.000059232447,0.000033583547,0.000025254796,0.0000025056152,0.0001317134,0.3934159,0.00030957427],"about_ca_topic_score_codex":0.080757655,"about_ca_topic_score_gemma":0.34607178,"teacher_disagreement_score":0.9237685,"about_ca_system_score_codex":0.00056061795,"about_ca_system_score_gemma":0.0038241185,"threshold_uncertainty_score":0.92536366},"labels":[],"label_agreement":null},{"id":"W2460337359","doi":"10.1007/s40261-016-0437-4","title":"Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers","year":2016,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Takeda Pharmaceuticals U.S.A.","keywords":"Vedolizumab; Medicine; Pharmacokinetics; Tolerability; Pharmacodynamics; Adverse effect; Placebo; Ulcerative colitis; Pharmacology; Area under the curve; Internal medicine; Gastroenterology; Cmax; Disease; Pathology","score_opus":0.023301745145831988,"score_gpt":0.32872720095539415,"score_spread":0.30542545580956215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460337359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954826,0.000063359854,0.0016343883,0.0015495457,0.0005688406,0.0005078926,0.00006690813,0.00002578499,0.00010063611],"genre_scores_gemma":[0.997517,0.00010905253,0.0009491808,0.0009085242,0.0002946583,0.000015999472,0.00007689436,0.000025447664,0.00010324124],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99780893,0.00033219164,0.00091235974,0.0005110762,0.00018819683,0.00024725217],"domain_scores_gemma":[0.99877757,0.00010115131,0.00023293361,0.00031240578,0.00013841165,0.00043753875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009591628,0.00018072421,0.00025130442,0.00005281137,0.000076369884,0.000017393622,0.00015741758,0.00013497427,0.000016202895],"category_scores_gemma":[0.0012476764,0.00016260553,0.00013600937,0.00008235212,0.00030629756,0.000017214476,0.00010396483,0.00009952225,0.000009546298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006879058,0.00063180545,0.17929016,0.00026862958,0.00020890584,0.000039990286,0.00037198397,0.00012789683,0.7600069,0.00046932936,0.0017162327,0.049989086],"study_design_scores_gemma":[0.008856723,0.002277012,0.84099257,0.00034207295,0.00026532286,0.000015439266,0.00010214738,0.0017138032,0.1345896,0.0011389278,0.008766754,0.00093965675],"about_ca_topic_score_codex":0.000012016352,"about_ca_topic_score_gemma":0.00006534055,"teacher_disagreement_score":0.6617024,"about_ca_system_score_codex":0.00006150078,"about_ca_system_score_gemma":0.00025612576,"threshold_uncertainty_score":0.6630861},"labels":[],"label_agreement":null},{"id":"W2492967488","doi":"10.1007/s40261-016-0443-6","title":"Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study","year":2016,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Bedaquiline; Medicine; Regimen; Tuberculosis; Cohort; Internal medicine; Mycobacterium tuberculosis; Pathology","score_opus":0.07280175794311688,"score_gpt":0.4181055599369192,"score_spread":0.34530380199380234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492967488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996151,0.00003518163,0.001633688,0.00048399076,0.00003166575,0.00156503,0.000035010715,0.000042772346,0.000021699481],"genre_scores_gemma":[0.99855894,0.000013301485,0.0010652066,0.000074119045,0.000076514974,0.000056743767,0.0001080776,0.000027145867,0.000019929881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99645716,0.0011829621,0.0011140575,0.0005331318,0.00043297102,0.00027971857],"domain_scores_gemma":[0.99424386,0.004200566,0.00034387747,0.0003684051,0.0004364406,0.0004068465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002274913,0.00020718548,0.0008950252,0.00013388113,0.00007862499,0.000008221301,0.00009110776,0.00016665882,0.000005125924],"category_scores_gemma":[0.0035680893,0.00012414453,0.00009083802,0.00018847152,0.0006684059,0.00020350271,0.00008800827,0.00027777045,0.0000051687657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013293527,0.00078865705,0.98831815,0.00014073122,0.00021399665,0.0000010537382,0.00020469035,0.00087511906,0.0004106184,0.0000116655765,0.00004147065,0.007664477],"study_design_scores_gemma":[0.0057602534,0.0017915086,0.9025529,0.00045636494,0.00026662493,9.672666e-8,0.00006982784,0.08842718,0.00034324598,0.00019398893,0.0000036222693,0.0001343878],"about_ca_topic_score_codex":0.00012099527,"about_ca_topic_score_gemma":0.0001119223,"teacher_disagreement_score":0.08755206,"about_ca_system_score_codex":0.000074946794,"about_ca_system_score_gemma":0.000084041065,"threshold_uncertainty_score":0.5062467},"labels":[],"label_agreement":null},{"id":"W2494421376","doi":"10.1007/s40261-016-0442-7","title":"A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence","year":2016,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"demographic modeling and climate adaptation","field":"Decision Sciences","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Centre for Addiction and Mental Health","funders":"H. Lundbeck A/S","keywords":"Alcohol consumption; Alcohol; Microsimulation; Markov chain; Alcohol dependence; Medicine; Reduction (mathematics); Heavy drinking; Markov model; Consumption (sociology); Econometrics; Pharmacotherapy; Alcohol use disorder; Psychiatry; Statistics; Economics; Mathematics; Engineering","score_opus":0.42368096994878446,"score_gpt":0.46640618105823356,"score_spread":0.0427252111094491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2494421376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805476,0.00039800946,0.017511576,0.0004942031,0.00018801472,0.0006218083,0.00016932686,0.000018468048,0.00005101453],"genre_scores_gemma":[0.9929914,0.00022752811,0.0065200315,0.000013578927,0.00005146671,0.00001980228,0.00007905863,0.000014513353,0.00008261148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941958,0.0010515966,0.0029116732,0.0006371251,0.0010070489,0.00019674617],"domain_scores_gemma":[0.9900581,0.0055745365,0.003033975,0.0006532481,0.0005895265,0.0000905696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035467732,0.00022503984,0.00087605306,0.00013114153,0.00013617487,0.000026434489,0.00031843476,0.00019752143,0.00003774272],"category_scores_gemma":[0.002904915,0.00013652108,0.0002516174,0.00047393967,0.0009768828,0.0006171175,0.000078339246,0.00011899036,0.000008656785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041748202,0.00039131974,0.8399866,0.000055667537,0.00012465254,1.12550396e-7,0.0037863287,0.017191233,0.11109092,0.00031619423,0.000062525025,0.026576923],"study_design_scores_gemma":[0.003869703,0.00048471283,0.41567507,0.0007686032,0.00033560858,0.0000014924834,0.001647449,0.37957233,0.14073303,0.056607764,0.000029275778,0.00027497497],"about_ca_topic_score_codex":0.00036808933,"about_ca_topic_score_gemma":0.000029444944,"teacher_disagreement_score":0.42431158,"about_ca_system_score_codex":0.00004315863,"about_ca_system_score_gemma":0.0000839908,"threshold_uncertainty_score":0.5567168},"labels":[],"label_agreement":null},{"id":"W2515349100","doi":"10.1007/s40261-016-0457-0","title":"Antiepileptic Drug Removal by Continuous Renal Replacement Therapy: A Review of the Literature","year":2016,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Pharmacological Effects and Toxicity Studies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Levetiracetam; Renal replacement therapy; Carbamazepine; Lacosamide; Phenytoin; Valproic Acid; Dosing; Intensive care medicine; Intensive care unit; Acute kidney injury; Gabapentin; Topiramate; Pharmacology; Epilepsy; Internal medicine","score_opus":0.06827889689270568,"score_gpt":0.40966517506328576,"score_spread":0.3413862781705801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515349100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00063451135,0.9886137,0.0000021059143,0.0059722075,0.00071504497,0.0033315555,0.00012886782,0.000052017698,0.0005499905],"genre_scores_gemma":[0.00003105422,0.98538256,0.000083599945,0.00914094,0.0006215743,0.000149513,0.00017158946,0.000038887414,0.0043802694],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943628,0.0020048344,0.0021354593,0.000660813,0.00054543,0.0002906951],"domain_scores_gemma":[0.99525446,0.0018849063,0.001601995,0.0007340865,0.00027848303,0.0002460901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031493504,0.00048319835,0.0030918005,0.00005341088,0.0001111365,0.000019185183,0.0003542847,0.00033348164,0.000108974156],"category_scores_gemma":[0.0041161133,0.0002077675,0.0014081432,0.0005052854,0.00078510615,0.00005908572,0.00019468342,0.0011176913,0.00004233293],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005794784,0.0001947426,0.0000625046,0.0623198,0.0004688459,0.000016234231,0.000043953492,4.3012465e-9,0.000023091876,0.000050300936,0.3486936,0.58806896],"study_design_scores_gemma":[0.0007728179,0.00019970216,0.00003517876,0.30133188,0.0008373023,0.00002727907,0.0000015614596,9.309346e-7,0.000036562422,0.000115160736,0.6964781,0.00016347306],"about_ca_topic_score_codex":0.000003428765,"about_ca_topic_score_gemma":3.3719837e-7,"teacher_disagreement_score":0.58790547,"about_ca_system_score_codex":0.00009184865,"about_ca_system_score_gemma":0.00036302462,"threshold_uncertainty_score":0.8472513},"labels":[],"label_agreement":null},{"id":"W2737067199","doi":"10.1007/s40261-017-0556-6","title":"Prescription Drug Price Paradox: Cost Analysis of Canadian Online Pharmacies versus US Medicare Beneficiaries for the Top 100 Drugs","year":2017,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Medical prescription; Medicine; Medicare Part D; Prescription drug; Beneficiary; Drug; Family medicine; Drug prices; Emergency medicine; Business; Pharmacology; Finance","score_opus":0.20812412305971914,"score_gpt":0.43406334927737134,"score_spread":0.2259392262176522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737067199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95341945,0.0003869971,0.00028602153,0.042702995,0.0010839746,0.001091564,0.00022506385,0.000033972832,0.00076994323],"genre_scores_gemma":[0.9932744,0.00059753563,0.0007877303,0.0025728566,0.0003822191,0.00012885059,0.00078719313,0.000013028125,0.0014561878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981045,0.000102936516,0.00077188946,0.00033963617,0.00043570378,0.00024533411],"domain_scores_gemma":[0.99627656,0.0012243608,0.0006595966,0.000883929,0.00048607631,0.000469475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012406105,0.00014717701,0.00045392927,0.0002646322,0.0005038251,0.000058384736,0.00046809213,0.000112790265,0.00028191268],"category_scores_gemma":[0.0048914636,0.00010926424,0.00024530521,0.0005224611,0.0007332442,0.00018447837,0.00004504576,0.00029798268,0.000031377785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001119329,0.00035869604,0.81440693,0.0002993047,0.0028841048,0.000004505903,0.0036088228,0.0004393587,0.00020078798,0.006706175,0.08991754,0.080054425],"study_design_scores_gemma":[0.0025481915,0.000077243996,0.87297153,0.00015617654,0.0026116942,3.9370448e-7,0.0010895596,0.034394708,0.00041318598,0.00043039315,0.085149504,0.0001573996],"about_ca_topic_score_codex":0.020881992,"about_ca_topic_score_gemma":0.04185461,"teacher_disagreement_score":0.079897024,"about_ca_system_score_codex":0.00007038008,"about_ca_system_score_gemma":0.00070390635,"threshold_uncertainty_score":0.985638},"labels":[],"label_agreement":null},{"id":"W2747687728","doi":"10.2165/11530800-000000000-00000","title":"Subjective Effects and Safety of Whole and Tampered Morphine Sulfate and Naltrexone Hydrochloride (ALO-01) Extended-Release Capsules versus Morphine Solution and Placebo in Experienced Non-Dependent Opioid Users","year":2009,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Johnson and Johnson","keywords":"Morphine; Placebo; Euphoriant; Medicine; Anesthesia; Visual analogue scale; Opioid; Oxycodone; Naltrexone; Crossover study; Heroin; Pharmacology; Internal medicine; Drug; Psychiatry","score_opus":0.017257573873969017,"score_gpt":0.29826670053137955,"score_spread":0.2810091266574105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747687728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99522626,0.0013385414,0.0000509043,0.0018962551,0.00013993242,0.001251978,0.000027641325,0.000036701025,0.00003180643],"genre_scores_gemma":[0.99647653,0.001994221,0.0010391065,0.0002093719,0.000064637985,0.000053490443,0.00010992148,0.000020863376,0.000031827643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786675,0.00017756394,0.0007379075,0.0006608165,0.0002801176,0.000276864],"domain_scores_gemma":[0.9983601,0.0006410379,0.00025299191,0.0002528212,0.00007913587,0.0004139361],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006136888,0.0003013383,0.0006503894,0.0001674679,0.00010707173,0.00002434122,0.000050095343,0.00017687828,0.0000031876766],"category_scores_gemma":[0.0011483239,0.0002736467,0.00004697414,0.00020797069,0.00064605253,0.0002788259,0.00007215545,0.00030196665,0.0000027429126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025910018,0.001938859,0.6419762,0.0013678622,0.00040060672,0.00022462412,0.024232294,0.00015010386,0.2688015,0.00045369266,0.00020010163,0.034344126],"study_design_scores_gemma":[0.021140985,0.0015545998,0.94641894,0.0004865662,0.00019317733,0.000018017296,0.0011405192,0.0065483493,0.020985635,0.0012620591,0.000007370168,0.0002437608],"about_ca_topic_score_codex":0.000469055,"about_ca_topic_score_gemma":0.00016883876,"teacher_disagreement_score":0.30444276,"about_ca_system_score_codex":0.00009545726,"about_ca_system_score_gemma":0.00011575419,"threshold_uncertainty_score":0.99997157},"labels":[],"label_agreement":null},{"id":"W2757607441","doi":"10.1007/s40261-017-0561-9","title":"In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations","year":2017,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Opioid; Pharmacology; Oxycodone; Immediate release; Medicine; Drug; Dosage form; Chromatography; Chemistry; Internal medicine","score_opus":0.08471633368849583,"score_gpt":0.40042209201315004,"score_spread":0.3157057583246542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757607441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923417,0.00033991845,0.00001768562,0.0053321477,0.00022780028,0.00094040117,0.000020751871,0.000020750647,0.00075882836],"genre_scores_gemma":[0.99580765,0.000038264283,0.0021340433,0.0012555205,0.00015034986,0.00014106226,0.000058278463,0.000025997655,0.00038882112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980513,0.00023457909,0.0007399472,0.00035535137,0.00045355622,0.00016527069],"domain_scores_gemma":[0.9983071,0.00024688957,0.00036856925,0.0006555985,0.00023442347,0.00018740151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016435585,0.00015343432,0.0003367805,0.00011215104,0.000108008215,0.000040028415,0.000092421265,0.00012415796,0.00010219876],"category_scores_gemma":[0.002496761,0.00013455158,0.00010208602,0.000075989075,0.00033822833,0.00036601388,0.00006368065,0.00022667336,0.000034736455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004737078,0.0005346145,0.9753204,0.00011627548,0.00007328342,0.0000051810757,0.005071442,0.000031574662,0.0013151201,0.00047628494,0.0010200926,0.015562023],"study_design_scores_gemma":[0.0044210968,0.000057175872,0.9638711,0.00024606794,0.0003129882,0.0000012261189,0.00012346989,0.011500236,0.0049179667,0.01351943,0.00089345477,0.00013578704],"about_ca_topic_score_codex":0.00045076455,"about_ca_topic_score_gemma":0.00016262301,"teacher_disagreement_score":0.015426236,"about_ca_system_score_codex":0.00008696694,"about_ca_system_score_gemma":0.00026754863,"threshold_uncertainty_score":0.54868543},"labels":[],"label_agreement":null},{"id":"W2765390494","doi":"10.1007/s40261-017-0581-5","title":"Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study","year":2017,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"GlaxoSmithKline","keywords":"Medicine; Quality of life (healthcare); Rash; Cohort; Observational study; Postherpetic neuralgia; Prospective cohort study; Neuralgia; Cohort study; Physical therapy; Brief Pain Inventory; McGill Pain Questionnaire; Pediatrics; Internal medicine; Neuropathic pain; Chronic pain; Anesthesia; Visual analogue scale","score_opus":0.12188452375459266,"score_gpt":0.4224204255638445,"score_spread":0.3005359018092518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765390494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968054,0.000025076713,1.737525e-7,0.0010276295,0.00011622159,0.0017771438,0.00016815294,0.000022336075,0.000057853096],"genre_scores_gemma":[0.99927694,0.000028778644,0.00010901691,0.0001891488,0.000038490543,0.000041515512,0.00018396825,0.000016499773,0.000115629155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967758,0.00061082206,0.0016933507,0.0004566144,0.0003148037,0.00014858626],"domain_scores_gemma":[0.99681413,0.0010652595,0.0010807854,0.00058048056,0.00021273832,0.0002466329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015553656,0.00016566567,0.00076473557,0.000089280606,0.00009908281,0.000020542127,0.00008706434,0.00013572382,0.000035073226],"category_scores_gemma":[0.0076229163,0.00012311571,0.00012714598,0.00014502148,0.00034607362,0.0001614531,0.000047133333,0.0002757487,0.000007937254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038201623,0.0018761588,0.98655456,0.00004429277,0.00024093704,0.000014064038,0.0032250287,0.000010391811,0.00002305221,0.000004819027,0.00006985127,0.0041166735],"study_design_scores_gemma":[0.013119857,0.0018828901,0.98371816,0.00050108414,0.000058771468,8.8366926e-7,0.00024068102,0.00020325856,0.000011739649,0.0001679521,0.0000013049639,0.00009340801],"about_ca_topic_score_codex":0.038138397,"about_ca_topic_score_gemma":0.0032185658,"teacher_disagreement_score":0.034919832,"about_ca_system_score_codex":0.0001028699,"about_ca_system_score_gemma":0.00038389623,"threshold_uncertainty_score":0.9682667},"labels":[],"label_agreement":null},{"id":"W2771385809","doi":"10.1007/s40261-017-0610-4","title":"Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects","year":2017,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; Mallinckrodt Pharmaceuticals","keywords":"Pharmacokinetics; Medicine; Acetaminophen; Morphine; Dosing; Pharmacology; Bioavailability; Oral administration; Opioid; Anesthesia; Analgesic; Internal medicine","score_opus":0.06099708031379279,"score_gpt":0.3626744945745505,"score_spread":0.30167741426075767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771385809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990752,0.00009550983,0.000094893214,0.0073466515,0.0001643643,0.00091213925,0.000009199892,0.00003597893,0.0005892748],"genre_scores_gemma":[0.99199045,0.00046431,0.0046240357,0.0023450023,0.00013899979,0.000024118623,0.00007077979,0.000028505909,0.00031378274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979292,0.00019107827,0.00085375,0.0004256987,0.00030410485,0.0002961744],"domain_scores_gemma":[0.99809897,0.00022708549,0.00059124845,0.00059211825,0.00015255768,0.00033804905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010740843,0.00021592785,0.0006354176,0.00012447125,0.00012444005,0.000050736136,0.00020929945,0.00012906436,0.000023454057],"category_scores_gemma":[0.0010869926,0.00018169534,0.000056204422,0.00008615504,0.00090926467,0.00016991232,0.00007574031,0.0004252347,0.000011926177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021411595,0.0005004382,0.97174,0.0006130314,0.000097435965,0.000119203854,0.0014064655,0.000008860086,0.0005510368,0.00052043045,0.000932444,0.021369513],"study_design_scores_gemma":[0.0087112505,0.001969464,0.98063445,0.00039957266,0.0001990738,0.000008008963,0.0001314552,0.0039519174,0.0016777905,0.0015588148,0.00054265244,0.00021556095],"about_ca_topic_score_codex":0.00038353793,"about_ca_topic_score_gemma":0.0002810706,"teacher_disagreement_score":0.021153951,"about_ca_system_score_codex":0.000038761278,"about_ca_system_score_gemma":0.00017187976,"threshold_uncertainty_score":0.7409321},"labels":[],"label_agreement":null},{"id":"W2771762421","doi":"10.1007/s40261-017-0598-9","title":"Lithium Toxicity in Older Adults: a Systematic Review of Case Reports","year":2017,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"China Scholarship Council","keywords":"Medicine; Polypharmacy; Lithium (medication); Toxicity; Internal medicine; Comorbidity","score_opus":0.11636072012543469,"score_gpt":0.4331381137862295,"score_spread":0.3167773936607948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771762421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001332383,0.99234676,0.0000022732522,0.00020925327,0.00028903421,0.00659092,0.000025751344,0.00003085874,0.00037193074],"genre_scores_gemma":[0.00020282231,0.99792176,0.00018447082,0.000265381,0.000103356666,0.000537246,0.0003649929,0.000041038,0.0003789096],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9934607,0.0009615467,0.0044273385,0.00061847403,0.0003374338,0.00019451216],"domain_scores_gemma":[0.99399185,0.0006457916,0.0032457365,0.0016386897,0.00020222868,0.0002756994],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033520847,0.00038866044,0.005206232,0.00014060405,0.000050072646,0.000014749997,0.000114588816,0.00044347145,0.000027830412],"category_scores_gemma":[0.008994935,0.00026450702,0.0010582532,0.00022260359,0.0002557874,0.00008024042,0.00007660636,0.00068612734,0.000036394635],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000030246945,0.0003066341,0.00058166083,0.9479422,0.00019386881,0.0017784577,0.000068209774,3.111959e-9,3.1287373e-9,0.00001240431,0.00032292667,0.048790634],"study_design_scores_gemma":[0.00045766795,0.000081872495,0.00025284197,0.9686702,0.0069805766,0.005444266,0.000013701032,0.000003457188,4.2499718e-7,0.00006383624,0.017839206,0.00019197146],"about_ca_topic_score_codex":0.00016567127,"about_ca_topic_score_gemma":0.00014527338,"teacher_disagreement_score":0.048598662,"about_ca_system_score_codex":0.00012547843,"about_ca_system_score_gemma":0.0007503435,"threshold_uncertainty_score":0.9999807},"labels":[],"label_agreement":null},{"id":"W2789269735","doi":"10.1007/s40261-018-0626-4","title":"Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Pharmacotherapy; Antipsychotic; Population; Psychiatry; Family medicine; Environmental health; Schizophrenia (object-oriented programming)","score_opus":0.07601212069905343,"score_gpt":0.376873753978564,"score_spread":0.30086163327951054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789269735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973391,0.00008166691,6.076663e-7,0.0016009962,0.00009451587,0.00085097604,0.0000047274657,0.000008987115,0.000018392797],"genre_scores_gemma":[0.9991461,0.000018658182,0.00050876924,0.00009993094,0.000133504,0.000013917203,0.000052472755,0.000009724295,0.000016933805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985188,0.00027653735,0.00045712807,0.00034581672,0.00023182889,0.000169856],"domain_scores_gemma":[0.99868727,0.0007190396,0.00015639608,0.00016994282,0.000045616885,0.00022171394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072160584,0.00010275589,0.00022074743,0.00009877339,0.000068645655,0.00002788071,0.000039345494,0.00004891981,0.0000035532585],"category_scores_gemma":[0.002718028,0.0000887344,0.000014145089,0.00020394856,0.00008239791,0.0001245587,0.000024742114,0.0002463767,0.000001295375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009264816,0.0001721347,0.9960549,0.000009650545,0.000025265395,0.000006297037,0.00046164813,0.000005061517,0.0000028824368,0.000018447081,0.0000060222665,0.002311197],"study_design_scores_gemma":[0.005206821,0.00025530334,0.9927219,0.00020069587,0.000044251614,0.0000022005936,0.00030304442,0.0009378486,0.00003531126,0.00021793097,7.387577e-7,0.00007395369],"about_ca_topic_score_codex":0.7586482,"about_ca_topic_score_gemma":0.8585592,"teacher_disagreement_score":0.09991098,"about_ca_system_score_codex":0.00010840695,"about_ca_system_score_gemma":0.0004278765,"threshold_uncertainty_score":0.36184838},"labels":[],"label_agreement":null},{"id":"W2795474249","doi":"10.1007/s40261-018-0648-y","title":"Translating Benzodiazepine Utilization Data into Meaningful Population Exposure: Integration of Two Metrics for Improved Reporting","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Sleep and related disorders","field":"Psychology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Manitoba Health; University of Manitoba","funders":"","keywords":"Defined daily dose; Zopiclone; Medicine; Zolpidem; Benzodiazepine; Metric (unit); Population; Consumption (sociology); Pharmacology; Drug; Statistics; Environmental health; Hypnotic; Internal medicine; Mathematics; Operations management; Insomnia; Engineering","score_opus":0.2832879371559091,"score_gpt":0.47366443236735567,"score_spread":0.19037649521144656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795474249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8173095,0.00040585632,0.1773437,0.00088087196,0.0022861029,0.0009184513,0.000022887038,0.00013932484,0.0006933108],"genre_scores_gemma":[0.96174437,0.000021093565,0.034476936,0.00026899748,0.00057867944,0.000031328458,0.002768972,0.000037171947,0.000072425486],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9957033,0.00036154065,0.0028740244,0.00065342203,0.00019247836,0.00021528194],"domain_scores_gemma":[0.99529153,0.00072585826,0.002635849,0.0007444558,0.0004891707,0.00011316167],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0038939638,0.00017628039,0.00037501834,0.00022566238,0.00019069656,0.00002918133,0.0002904947,0.0002981347,0.00004826432],"category_scores_gemma":[0.013088612,0.00016608583,0.00012420907,0.00082581554,0.00026443545,0.0003989217,0.000053263106,0.0002660031,0.000010982144],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025636438,0.00034924535,0.109711275,0.00008633491,0.00036338434,6.392146e-7,0.010799495,0.00008379583,0.009194926,0.0117614595,0.0018686305,0.8555244],"study_design_scores_gemma":[0.012349168,0.0017778489,0.12551963,0.000532455,0.001539177,0.0000067929636,0.0054443097,0.7199466,0.009167132,0.120601304,0.0020095224,0.001106007],"about_ca_topic_score_codex":0.0006099645,"about_ca_topic_score_gemma":0.0006483451,"teacher_disagreement_score":0.85441846,"about_ca_system_score_codex":0.000033770102,"about_ca_system_score_gemma":0.000068654015,"threshold_uncertainty_score":0.99522454},"labels":[],"label_agreement":null},{"id":"W2800927037","doi":"10.1007/s40261-018-0653-1","title":"Acetazolamide and Cardiac Failure","year":2018,"lang":"en","type":"letter","venue":"Clinical Drug Investigation","topic":"Eicosanoids and Hypertension Pharmacology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Acetazolamide; Medicine; Pharmacotherapy; Heart failure; Cardiology; Intensive care medicine; Internal medicine","score_opus":0.032390212415900024,"score_gpt":0.31501771566473136,"score_spread":0.28262750324883135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800927037","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47692665,0.0010693748,0.000015535745,0.51947755,0.001748809,0.00032498644,0.00008264501,0.000032381602,0.00032205886],"genre_scores_gemma":[0.011970954,0.0011108535,0.0011641318,0.9541847,0.021376178,0.000043226042,0.0029194425,0.00007848325,0.007152028],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978406,0.0004697864,0.00051808805,0.0007417923,0.00015474335,0.00027501181],"domain_scores_gemma":[0.9988846,0.00011769349,0.00023533484,0.00043268918,0.00018172109,0.00014793844],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005844025,0.00027073943,0.00043230059,0.000046193807,0.00010289469,0.00003878731,0.00020508045,0.0013837849,0.000040479514],"category_scores_gemma":[0.00041340568,0.0002448518,0.00019930587,0.000054471406,0.0008207275,0.0000044074495,0.00022011405,0.0009956452,0.00008282292],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010479205,0.0000073905317,0.0034191243,0.00003871462,0.00009510394,0.000011001781,0.00001082311,1.4507947e-7,0.01613406,0.000013970669,0.97981113,0.00044802844],"study_design_scores_gemma":[0.00032828047,0.00016030116,0.0020941915,0.00002827007,0.00013705474,0.0000066585335,0.00000710483,0.000019203078,0.0060992865,0.00063176703,0.99019045,0.000297443],"about_ca_topic_score_codex":0.000010350865,"about_ca_topic_score_gemma":0.000008791374,"teacher_disagreement_score":0.4649557,"about_ca_system_score_codex":0.000007512039,"about_ca_system_score_gemma":0.00014912775,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W2807503561","doi":"10.1007/s40261-018-0660-2","title":"Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Amino Acid Enzymes and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Pharmacokinetics; Tolerability; Medicine; Adverse effect; Placebo; Pharmacology; Morning; Evening; Dosing; Internal medicine","score_opus":0.055154740894502265,"score_gpt":0.380198570377732,"score_spread":0.32504382948322974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807503561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99706405,0.0008414512,0.00031258177,0.0002589608,0.00035174683,0.0010851912,0.000015949376,0.000016334168,0.000053760337],"genre_scores_gemma":[0.9960623,0.00048771422,0.0024191795,0.00036321074,0.0004968351,0.000031812822,0.00006937391,0.000027779008,0.0000418306],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973838,0.0004175907,0.0011554863,0.0005747785,0.00018861546,0.0002797537],"domain_scores_gemma":[0.9987511,0.0001577171,0.0003603843,0.0002608194,0.0001787168,0.00029127434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017997362,0.00023678876,0.0004786488,0.000100862824,0.00013381695,0.000039441176,0.000122025616,0.000187479,0.0000031930888],"category_scores_gemma":[0.0010668541,0.0002237492,0.00007049721,0.00022703611,0.0008839829,0.0000290695,0.00016774925,0.00026627252,0.0000012440339],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034640983,0.0010800197,0.6922126,0.0001877861,0.00018289819,0.00000489716,0.004967809,0.000050387807,0.23991096,0.00007568218,0.0005839019,0.026102094],"study_design_scores_gemma":[0.62286633,0.008762184,0.12922837,0.00044469768,0.00052304385,0.000033343447,0.004920708,0.017085295,0.2099736,0.00047730864,0.004318698,0.0013664243],"about_ca_topic_score_codex":0.0007959134,"about_ca_topic_score_gemma":0.0014317017,"teacher_disagreement_score":0.5882253,"about_ca_system_score_codex":0.00001229596,"about_ca_system_score_gemma":0.00014861945,"threshold_uncertainty_score":0.9124227},"labels":[],"label_agreement":null},{"id":"W2883630601","doi":"10.1007/s40261-018-0672-y","title":"The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol–Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Veterinary Pharmacology and Anesthesia","field":"Veterinary","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BioPhage Pharma (Canada); Innovaderm (Canada)","funders":"Esteve Pharmaceuticals","keywords":"Celecoxib; Medicine; Cmax; Tramadol; Bioavailability; Pharmacokinetics; Crossover study; Pharmacology; Oral administration; Bioequivalence; Analgesic; Placebo","score_opus":0.14055741941731265,"score_gpt":0.44165498609137444,"score_spread":0.3010975666740618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883630601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962118,0.00007255868,0.000008116506,0.00025642262,0.0002956099,0.0030149752,0.000024027888,0.00002300823,0.00009343694],"genre_scores_gemma":[0.99943805,0.0000088070165,0.00016981896,0.00014070337,0.00006596464,0.00011064612,0.000019677731,0.00002529136,0.000021065767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99387527,0.0031385683,0.0018327397,0.00055311696,0.00029710357,0.0003032309],"domain_scores_gemma":[0.99535996,0.0032438836,0.0007289736,0.0004109944,0.00010147809,0.00015473305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060430337,0.0002745904,0.0008957659,0.00009575494,0.0002075045,0.000042765878,0.00039425367,0.00021743934,0.000019388675],"category_scores_gemma":[0.0012731554,0.00021363812,0.00015469137,0.00029733765,0.0014921502,0.00029515155,0.00009112478,0.0004066393,0.0000049763667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42786565,0.0080416035,0.4341361,0.0007643233,0.0005405616,0.000074411095,0.0033787256,0.000010416335,0.11455275,0.00014407422,0.0004025201,0.010088865],"study_design_scores_gemma":[0.1709924,0.34424517,0.4267979,0.00048032872,0.00043650498,0.00006026109,0.0007442045,0.0027575863,0.051713753,0.0008570927,0.0002535495,0.0006612427],"about_ca_topic_score_codex":0.000116097275,"about_ca_topic_score_gemma":0.00026664214,"teacher_disagreement_score":0.33620358,"about_ca_system_score_codex":0.00005590514,"about_ca_system_score_gemma":0.00018646182,"threshold_uncertainty_score":0.87119097},"labels":[],"label_agreement":null},{"id":"W2891851132","doi":"10.1007/s40261-018-0694-5","title":"Regression and Genomic Analyses on the Association Between Dose-Normalized Mycophenolic Acid Exposure and Absolute Neutrophil Count in Steroid-Free, De Novo Kidney Transplant Recipients","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; University of Alberta","funders":"Vancouver Coastal Health Research Institute; University of British Columbia; F. Hoffmann-La Roche","keywords":"Medicine; Absolute neutrophil count; Mycophenolic acid; Neutropenia; Internal medicine; UGT2B7; Creatinine; Tacrolimus; Gastroenterology; Single-nucleotide polymorphism; Population; Immunology; Transplantation; Toxicity; Genotype; Biology","score_opus":0.0895704304835811,"score_gpt":0.373520759183502,"score_spread":0.28395032869992093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891851132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943877,0.00011310658,0.000019664925,0.0046250136,0.00014434847,0.00042141625,0.00008668664,0.000027462727,0.00017463996],"genre_scores_gemma":[0.9954735,0.0008622851,0.00038673644,0.00262498,0.00024200453,0.000022138413,0.00018338555,0.000017914625,0.00018703997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980948,0.00038180378,0.00065812236,0.00033731194,0.0002972533,0.00023068594],"domain_scores_gemma":[0.9984595,0.00062250614,0.00027701264,0.0002641306,0.00007555783,0.0003012955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009795482,0.00018514853,0.00038575396,0.000107292624,0.00015052926,0.000043246404,0.00009520259,0.00017859635,0.000014905992],"category_scores_gemma":[0.00043888408,0.00011771118,0.00007492751,0.0001800689,0.00019190139,0.000113692106,0.000022640477,0.0002964195,0.000015959491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004185337,0.00006268407,0.993998,0.000053224332,0.00015223122,0.000013185641,0.0009555021,0.000002057539,0.0033520036,0.00007404434,0.0001475519,0.0007709887],"study_design_scores_gemma":[0.0057171728,0.0004086772,0.9891279,0.0008374712,0.00033126134,0.000009052234,0.000029709228,0.00017269999,0.002345534,0.0007935722,0.0001173013,0.00010964455],"about_ca_topic_score_codex":0.00010942254,"about_ca_topic_score_gemma":0.000070604845,"teacher_disagreement_score":0.005298639,"about_ca_system_score_codex":0.0001444313,"about_ca_system_score_gemma":0.000099701276,"threshold_uncertainty_score":0.48001227},"labels":[],"label_agreement":null},{"id":"W2893335845","doi":"10.1007/s40261-018-0705-6","title":"Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier universitaire de Québec; University of Alberta; McGill University Health Centre; University of Ottawa; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; Sunnybrook Hospital; Queen Elizabeth II Health Sciences Centre; University of British Columbia; University of Toronto; Dalhousie University; McMaster University","funders":"Fonds de Recherche du Québec - Santé; Canadian Centre for Applied Research in Cancer Control","keywords":"Pazopanib; Sunitinib; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Cost effectiveness; Intensive care medicine","score_opus":0.3289610242284381,"score_gpt":0.4109753416940739,"score_spread":0.08201431746563581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2893335845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971764,0.00012214176,0.000008603237,0.00035980053,0.00033335408,0.0007912986,0.000013656041,0.000010605101,0.0011841488],"genre_scores_gemma":[0.9975866,0.000026464972,0.0018934164,0.0002171054,0.000118290205,0.000021069263,0.000041922944,0.000019432726,0.00007568094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656826,0.00074121193,0.0014191795,0.00046748333,0.0004729529,0.00033088704],"domain_scores_gemma":[0.99647826,0.0020616632,0.00039273486,0.000493187,0.0002481743,0.00032597003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016342325,0.00020061711,0.00062238483,0.00019623345,0.00003584046,0.000007857781,0.00013863736,0.00005957394,0.0001011177],"category_scores_gemma":[0.0017078167,0.00018660403,0.00009211927,0.00074606744,0.0004834304,0.00014457246,0.0000650583,0.00039537123,0.000008627946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010044444,0.0001088203,0.9954691,0.00017430025,0.00001537749,0.00013565962,0.00034760873,0.00007131818,0.0013185084,0.00002406916,0.00030445532,0.0010263603],"study_design_scores_gemma":[0.0031640164,0.00035828605,0.94053984,0.0005052699,0.00014253288,0.0000033243898,0.00027469508,0.015825637,0.03878532,0.00023360978,0.00002786585,0.00013963303],"about_ca_topic_score_codex":0.86484814,"about_ca_topic_score_gemma":0.9318499,"teacher_disagreement_score":0.06700176,"about_ca_system_score_codex":0.0013152469,"about_ca_system_score_gemma":0.0050926046,"threshold_uncertainty_score":0.90340614},"labels":[],"label_agreement":null},{"id":"W2898173867","doi":"10.1007/s40261-018-0719-0","title":"Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials","year":2018,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Neratinib; Medicine; Oncology; Internal medicine; Adverse effect; Diarrhea; Breast cancer; Clinical trial; Hazard ratio; Nausea; Cancer; Trastuzumab; Confidence interval","score_opus":0.5943309892068062,"score_gpt":0.6027997922926437,"score_spread":0.008468803085837528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898173867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048286307,0.9836679,0.0000256129,0.0005920761,0.000098554774,0.014961203,0.0004205334,0.000028236887,0.00015761507],"genre_scores_gemma":[0.00003663808,0.99588126,0.0013734769,0.00042321594,0.00022674013,0.0007383878,0.00035550425,0.00005876804,0.0009060015],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9679076,0.016542144,0.0132111525,0.0011667745,0.0009011268,0.00027120308],"domain_scores_gemma":[0.9581511,0.029987607,0.007973894,0.001788882,0.001359182,0.00073934766],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.064098865,0.00054274994,0.03039439,0.00041180354,0.00006210569,0.000028795605,0.00030192136,0.0006759672,0.00026768201],"category_scores_gemma":[0.13287017,0.0003212018,0.0050735855,0.0017316132,0.0020649007,0.000076655844,0.000224237,0.0011733471,0.000031439038],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005975957,0.00019725024,0.00019641439,0.8652211,0.12575871,0.0000027283947,0.000072356466,6.09068e-8,1.3036632e-7,0.00019810315,0.0018082141,0.0064851698],"study_design_scores_gemma":[0.00082702585,0.0005953925,0.000246961,0.11326942,0.8771928,0.000008109566,0.000010993115,0.00006706677,0.000002371525,0.00007526181,0.0074718106,0.00023281698],"about_ca_topic_score_codex":0.000024046209,"about_ca_topic_score_gemma":0.000012688859,"teacher_disagreement_score":0.7519517,"about_ca_system_score_codex":0.000083575054,"about_ca_system_score_gemma":0.0014254351,"threshold_uncertainty_score":0.999924},"labels":[],"label_agreement":null},{"id":"W2900661293","doi":"10.1007/s40261-018-0726-1","title":"Drugs that Can Kill a Toddler with One Tablet or Teaspoonful: A 2018 Updated List","year":2018,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Toddler; Drug; Accidental; Intensive care medicine; Pharmacotherapy; Pediatrics; Pharmacology; Psychiatry","score_opus":0.20738916300126933,"score_gpt":0.41880932038576707,"score_spread":0.21142015738449774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900661293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92392975,0.00014542612,0.00006973195,0.06412656,0.0004964039,0.0006643152,0.00002710349,0.0001787282,0.010362009],"genre_scores_gemma":[0.95517486,0.00027906682,0.0035106242,0.031982914,0.0014523041,0.0000388475,0.00012774026,0.000040377345,0.007393269],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978006,0.00026041266,0.0005762151,0.0005080606,0.0004637298,0.0003909816],"domain_scores_gemma":[0.99762696,0.00075147144,0.0002970126,0.00038828733,0.00029695698,0.0006392958],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011792472,0.00022330294,0.00048803433,0.0000499279,0.0002555004,0.000058777965,0.00014436767,0.0001492387,0.001311859],"category_scores_gemma":[0.0013842037,0.00014389078,0.000081209,0.0004249997,0.001294095,0.0002441915,0.000103604056,0.0005666153,0.00030056888],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01065764,0.0017119447,0.37925068,0.00036646027,0.0014326342,0.000118085816,0.004015655,0.0000020587809,0.0009635486,0.0014963987,0.55167276,0.048312142],"study_design_scores_gemma":[0.006531041,0.002387743,0.12241447,0.00060403644,0.001066451,0.000040138235,0.0007073849,0.0020458442,0.0048506227,0.0014431974,0.85735095,0.00055813586],"about_ca_topic_score_codex":0.0005767814,"about_ca_topic_score_gemma":0.00071144506,"teacher_disagreement_score":0.30567816,"about_ca_system_score_codex":0.000059342183,"about_ca_system_score_gemma":0.00028802172,"threshold_uncertainty_score":0.99960107},"labels":[],"label_agreement":null},{"id":"W2904095541","doi":"10.1007/s40261-018-0721-6","title":"A Literature Review of Psychotropic Medications and Alcohol as Risk Factors for Falls in Community Dwelling Older Adults","year":2018,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Balance, Gait, and Falls Prevention","field":"Health Professions","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Regional Municipality of Waterloo; University of Waterloo","funders":"University of Waterloo","keywords":"Medicine; Psychiatry; CINAHL; Psychotropic drug; Benzodiazepine; Poison control; Drug; Internal medicine; Psychological intervention; Emergency medicine","score_opus":0.12728007257417165,"score_gpt":0.49230984268360256,"score_spread":0.36502977010943094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904095541","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0161783,0.9767377,0.00006250235,0.00020866268,0.0008929784,0.0053552687,0.00037342982,0.000046596702,0.00014458911],"genre_scores_gemma":[0.0002733858,0.9932524,0.0008462082,0.00083486264,0.00047337663,0.0007948023,0.0032475716,0.000049195227,0.00022821578],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98847705,0.007053458,0.0033710536,0.0005232038,0.00024408246,0.00033117854],"domain_scores_gemma":[0.9885327,0.0069306768,0.0030112313,0.00081510167,0.00043789594,0.0002723536],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006179482,0.00037960784,0.0019579632,0.00019837602,0.00046499114,0.000012031539,0.00042271652,0.0010602508,0.000014730749],"category_scores_gemma":[0.006879703,0.00029515527,0.0004968561,0.0005989764,0.00041498936,0.00016189188,0.00010836479,0.0031071522,0.000044203003],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027880704,0.0006871767,0.011829398,0.7027577,0.0002359349,5.6564335e-7,0.007674543,1.6768904e-8,2.7063393e-7,0.00060530944,0.014531661,0.26164955],"study_design_scores_gemma":[0.0011467302,0.00011033217,0.02168636,0.74147844,0.0008041642,8.61405e-7,0.00030961772,0.000031724707,3.8325876e-8,0.0035117448,0.23064134,0.00027861496],"about_ca_topic_score_codex":0.0002152114,"about_ca_topic_score_gemma":0.00022462195,"teacher_disagreement_score":0.26137093,"about_ca_system_score_codex":0.000079832906,"about_ca_system_score_gemma":0.0005255275,"threshold_uncertainty_score":0.99995005},"labels":[],"label_agreement":null},{"id":"W2908559747","doi":"10.1007/s40261-018-00744-7","title":"Opioid Use and Pain Control in the Elderly After Elective or Urgent Orthopaedic Surgery: A Retrospective Cohort Study","year":2019,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Delirium; Retrospective cohort study; Opioid; Morphine; Cohort; Adverse effect; Orthopedic surgery; Anesthesia; Incidence (geometry); Confidence interval; Elective surgery; Surgery; Internal medicine; Intensive care medicine","score_opus":0.028575331215768246,"score_gpt":0.3071452122697988,"score_spread":0.2785698810540306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908559747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920419,0.00014628065,0.00002139507,0.0024044262,0.0002249755,0.005072665,0.000012161123,0.000045214332,0.000030994197],"genre_scores_gemma":[0.9943104,0.00010475397,0.00007044052,0.004390682,0.00010917525,0.00073008036,0.000047681657,0.000027632903,0.00020915152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960687,0.0017526004,0.00079220545,0.00062864285,0.0004816348,0.00027620204],"domain_scores_gemma":[0.9950439,0.0038533327,0.00020150216,0.0004924645,0.00017831083,0.00023053116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048566475,0.00023289854,0.0006869464,0.00012977507,0.000053508185,0.00005818536,0.00007085872,0.00012139352,0.00008933604],"category_scores_gemma":[0.0061619575,0.0001439234,0.00016190235,0.0004174421,0.00018776703,0.00018727094,0.000027168006,0.00048255315,0.000041225703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009010265,0.00092876336,0.99318314,0.000033901888,0.00018297975,0.00006466104,0.002656681,9.522947e-7,0.000006505231,0.000024490448,0.00087860995,0.001138274],"study_design_scores_gemma":[0.0038280154,0.002080052,0.9910257,0.0001497316,0.0002627652,0.000005400261,0.0014020265,0.00048335,0.0000055716405,0.00042151433,0.00018269474,0.00015317312],"about_ca_topic_score_codex":0.000443344,"about_ca_topic_score_gemma":0.0005047257,"teacher_disagreement_score":0.0043425844,"about_ca_system_score_codex":0.00016174772,"about_ca_system_score_gemma":0.00041948532,"threshold_uncertainty_score":0.7376884},"labels":[],"label_agreement":null},{"id":"W2909165413","doi":"10.1007/s40261-018-00743-8","title":"Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review","year":2019,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Hair Growth and Disorders","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre; Mediprobe Research (Canada)","funders":"","keywords":"Medicine; Hair loss; Hair growth; Dermatology; Latanoprost; Placebo; Hair follicle; Randomized controlled trial; Internal medicine; Surgery; Alternative medicine; Physiology; Pathology","score_opus":0.22350001816306975,"score_gpt":0.4640909259438874,"score_spread":0.24059090778081765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909165413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003326944,0.99240816,0.00003109556,0.00054749567,0.00024160024,0.005925098,0.000035257726,0.000012119612,0.00046649715],"genre_scores_gemma":[0.000019246565,0.9967658,0.0009870542,0.00055857474,0.00011347227,0.00026956009,0.00036674784,0.000029045877,0.0008905332],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972561,0.0002017592,0.0017258237,0.00037099404,0.00027506705,0.00017028347],"domain_scores_gemma":[0.9971134,0.0012613558,0.00069941225,0.00066998234,0.00010872842,0.00014713712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007100859,0.00025254802,0.00196731,0.000051722156,0.000028097156,0.0000036532501,0.00022023129,0.00020598198,0.000029420615],"category_scores_gemma":[0.0005408532,0.0001477156,0.0008556716,0.00027458527,0.00027074458,0.000019794745,0.00006409527,0.00020820816,0.00005112341],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029335917,0.000244485,0.0001582406,0.1025829,0.0008769196,0.0000013067469,0.000010559612,1.1486387e-7,2.9623775e-8,0.0003052179,0.0027087978,0.8930821],"study_design_scores_gemma":[0.0031867174,0.00040687594,0.0010279731,0.093520306,0.018332018,0.000003832163,0.000009931742,0.00003402448,0.0000011754663,0.00011187691,0.8832209,0.00014433987],"about_ca_topic_score_codex":0.000003547571,"about_ca_topic_score_gemma":0.000001159021,"teacher_disagreement_score":0.8929378,"about_ca_system_score_codex":0.0000339067,"about_ca_system_score_gemma":0.00031551518,"threshold_uncertainty_score":0.60236675},"labels":[],"label_agreement":null},{"id":"W2913271953","doi":"10.1007/s40261-019-00752-1","title":"Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects","year":2019,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"","keywords":"Abiraterone acetate; Pharmacokinetics; Cmax; Pharmacology; Abiraterone; Bioanalysis; Chemistry; Metabolite; Medicine; Chromatography; Oral administration; Internal medicine; Cancer; Prostate cancer","score_opus":0.1339849863886814,"score_gpt":0.4217515987455929,"score_spread":0.28776661235691153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913271953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932107,0.0005012196,0.000018227347,0.0034094737,0.0005253694,0.002160662,0.000021731401,0.000017577158,0.00013506423],"genre_scores_gemma":[0.9984807,0.00014243482,0.0005769403,0.00032224128,0.000077816876,0.000040542232,0.000058731326,0.00002801009,0.00027259724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962672,0.0007750698,0.0012562006,0.00039578715,0.0010508508,0.00025487074],"domain_scores_gemma":[0.9977341,0.00027800005,0.0005818677,0.00043021498,0.00073283125,0.00024297748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037639942,0.00019455937,0.0006261171,0.00013280404,0.00005228287,0.000015289186,0.00013515294,0.00012210551,0.000029446317],"category_scores_gemma":[0.0006905589,0.00014051964,0.00014711395,0.00043989706,0.0003735374,0.00017099833,0.00008941132,0.00023722618,0.000010919836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002545246,0.0005978395,0.17904213,0.00095340324,0.0003110638,0.000002777602,0.0019926368,0.00031964778,0.79568195,0.000039117025,0.0001941231,0.01832006],"study_design_scores_gemma":[0.010321119,0.0027956583,0.37109458,0.00071310246,0.00067104644,0.0000037282412,0.0002023793,0.0039148033,0.6094958,0.0005922155,0.0000464895,0.00014906596],"about_ca_topic_score_codex":0.000051296563,"about_ca_topic_score_gemma":0.000036830876,"teacher_disagreement_score":0.19205245,"about_ca_system_score_codex":0.00012649344,"about_ca_system_score_gemma":0.00069790176,"threshold_uncertainty_score":0.5730224},"labels":[],"label_agreement":null},{"id":"W3005447570","doi":"10.1007/s40261-020-00893-8","title":"Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Queen's University","funders":"Boehringer Ingelheim","keywords":"Pharmacotherapy; Randomized controlled trial; Schizophrenia (object-oriented programming); Medicine; Cognition; Physical therapy; Double blind; Psychiatry; Internal medicine; Placebo; Alternative medicine","score_opus":0.35070056278581757,"score_gpt":0.4565512925816959,"score_spread":0.10585072979587834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005447570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98317206,0.00007713773,0.0025120955,0.002622234,0.00020327505,0.011365453,0.000017155142,0.000018536106,0.000012078983],"genre_scores_gemma":[0.9748842,0.000022881266,0.02367149,0.00036717896,0.0002353795,0.00062870904,0.00016518637,0.000022397677,0.0000025786603],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99333185,0.0039984854,0.0012345134,0.00040000342,0.00083328004,0.00020188493],"domain_scores_gemma":[0.9905927,0.0075325463,0.0007242894,0.00018506916,0.00074907084,0.00021628717],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008323349,0.0001812951,0.0011261771,0.0001099583,0.000047836296,0.000009757,0.00013632764,0.000118773554,0.000024437431],"category_scores_gemma":[0.009911449,0.00011085251,0.0003413154,0.00044496587,0.0006229893,0.000078919606,0.00003435637,0.00031736935,0.0000013552791],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95391065,0.00064620853,0.0075049363,0.00005081359,0.0005989902,3.8620678e-7,0.0013522704,0.00010622033,0.00015965637,0.00020735971,0.000017456454,0.035445075],"study_design_scores_gemma":[0.9252137,0.0021767796,0.056435537,0.0002915575,0.0010408894,2.9931923e-7,0.00006955244,0.011840904,0.0012727282,0.0015629854,0.0000024426774,0.000092659204],"about_ca_topic_score_codex":0.000026894368,"about_ca_topic_score_gemma":0.000027765238,"teacher_disagreement_score":0.048930597,"about_ca_system_score_codex":0.00004946678,"about_ca_system_score_gemma":0.0008352956,"threshold_uncertainty_score":0.99842846},"labels":[],"label_agreement":null},{"id":"W3006624590","doi":"10.1007/s40261-020-00894-7","title":"Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases","year":2020,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Synthetic cannabinoids; Cannabis; Acne; Pharmacology; Cannabinoid; Bioinformatics; Dermatology; Psychiatry; Biology; Receptor; Internal medicine","score_opus":0.05416861842926524,"score_gpt":0.3990094038006741,"score_spread":0.3448407853714089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006624590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020528277,0.98060155,0.000504022,0.011776393,0.00034858973,0.0041580643,0.00037967652,0.000089278066,0.000089591],"genre_scores_gemma":[0.0009794262,0.9943093,0.0007997591,0.000948295,0.00062693754,0.00046442536,0.0004052942,0.0000826353,0.0013838987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99609303,0.0004883643,0.001582124,0.00091059954,0.00062159897,0.00030426704],"domain_scores_gemma":[0.9971549,0.00010672479,0.0003796755,0.000610437,0.0002610629,0.0014872117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009303049,0.00036970488,0.002370841,0.00016642906,0.0000658991,0.000034404322,0.00023262324,0.0003844167,0.00006784186],"category_scores_gemma":[0.002080306,0.0002939437,0.00075072923,0.0006004677,0.00060545554,0.000046565634,0.00032353043,0.00076068507,0.000047969967],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006458419,0.00015412387,0.00010024912,0.018896785,0.00011899063,0.00002132492,0.00004612748,4.4758147e-7,0.000013530791,0.0009833735,0.031646073,0.9479544],"study_design_scores_gemma":[0.0005303521,0.0005117519,0.0029867992,0.003211514,0.0014000516,0.00002088049,0.00003172503,0.00005606386,0.000032062453,0.0029978142,0.9879099,0.00031108205],"about_ca_topic_score_codex":0.00008885958,"about_ca_topic_score_gemma":0.0000072325256,"teacher_disagreement_score":0.95626384,"about_ca_system_score_codex":0.00011342676,"about_ca_system_score_gemma":0.0015167127,"threshold_uncertainty_score":0.99995124},"labels":[],"label_agreement":null},{"id":"W307221476","doi":"10.2165/00044011-200424030-00004","title":"Depression during Pregnancy","year":2004,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Maternal Mental Health During Pregnancy and Postpartum","field":"Medicine","cited_by":313,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Pregnancy; Depression (economics); Epidemiology; Observational study; Psychiatry; Dosing; Antidepressant; Pharmacotherapy; Intensive care medicine; Anxiety; Internal medicine","score_opus":0.05335177734112267,"score_gpt":0.36465486671468483,"score_spread":0.31130308937356216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W307221476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941307,0.00068555103,0.000036366335,0.0024710707,0.0005842173,0.000406469,0.000002312052,0.00013591597,0.0015474558],"genre_scores_gemma":[0.99594605,0.00025638717,0.0013479332,0.0007798421,0.00026513057,0.0000327571,0.000022453056,0.00001746123,0.0013320071],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868774,0.00006950066,0.0005524109,0.000280347,0.00020100924,0.00020901147],"domain_scores_gemma":[0.9991483,0.00006383252,0.00013396739,0.0002563647,0.00004148363,0.00035606115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017539546,0.00010963849,0.00020573543,0.000043331613,0.00011889293,0.000010971886,0.00006476387,0.000105865154,0.000051427327],"category_scores_gemma":[0.00021979852,0.00009262739,0.000087825756,0.00009358195,0.000118549586,0.00012643088,0.00004217487,0.00030173623,0.00022445808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003092907,0.00027163676,0.9905277,0.0030946948,0.000022068207,0.00014897577,0.0004772503,0.00003115347,0.0011547713,0.00095384376,0.000060264156,0.0029483403],"study_design_scores_gemma":[0.0026349088,0.00012395123,0.92062944,0.015892804,0.000027819768,0.00007920502,0.000013881986,0.000021862948,0.05497203,0.005354794,0.00013252885,0.000116775256],"about_ca_topic_score_codex":0.000033190696,"about_ca_topic_score_gemma":0.0000043361288,"teacher_disagreement_score":0.06989827,"about_ca_system_score_codex":0.00006292539,"about_ca_system_score_gemma":0.00009706862,"threshold_uncertainty_score":0.37772354},"labels":[],"label_agreement":null},{"id":"W3152873057","doi":"10.1007/s40261-021-01033-6","title":"Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma","year":2021,"lang":"en","type":"letter","venue":"Clinical Drug Investigation","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Manchester Biomedical Research Centre; Novartis Pharma; National Institute for Health and Care Research; Novartis","keywords":"Indacaterol; Mometasone furoate; Medicine; Lung function; Asthma; Anesthesia; Pharmacology; Lung; Internal medicine; Corticosteroid","score_opus":0.02132686585436193,"score_gpt":0.26729580283147597,"score_spread":0.24596893697711403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3152873057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9280916,0.00019110636,0.0001245437,0.069373325,0.000558427,0.0013640907,0.000054392323,0.00011419754,0.00012834225],"genre_scores_gemma":[0.5394527,0.000054622753,0.0007485295,0.43675986,0.0035376027,0.00024914357,0.017092615,0.00024770523,0.0018572498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99528605,0.0007839984,0.0013068108,0.0010650831,0.0010389065,0.0005191634],"domain_scores_gemma":[0.9972791,0.00026787142,0.00084561633,0.0006858026,0.0005740379,0.0003475561],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005940384,0.0005841927,0.0010508219,0.0003869759,0.00012217964,0.00009498686,0.00015632168,0.0009053384,0.00017229932],"category_scores_gemma":[0.00031534687,0.0004279775,0.00020977923,0.00068839715,0.0005599301,0.00045148705,0.0000652552,0.0025748715,0.00007734752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013597357,0.00028617802,0.8316687,0.00079741003,0.00023363651,0.0002664411,0.0001455596,0.00010083477,0.000013176522,0.0000034379323,0.16273516,0.0023897397],"study_design_scores_gemma":[0.0069237635,0.0013014234,0.91771674,0.0015380222,0.00060402637,0.000008801027,0.000048790975,0.00023825747,0.000088745335,0.00003113458,0.07095618,0.00054409663],"about_ca_topic_score_codex":0.000046506542,"about_ca_topic_score_gemma":0.000050985298,"teacher_disagreement_score":0.3886389,"about_ca_system_score_codex":0.00023970456,"about_ca_system_score_gemma":0.00086598063,"threshold_uncertainty_score":0.9998172},"labels":[],"label_agreement":null},{"id":"W3183348330","doi":"10.1007/s40261-021-01059-w","title":"Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada","year":2021,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Migraine and Headache Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Migraine; Discontinuation; Tolerability; Chronic Migraine; Concomitant; Internal medicine; Pediatrics; Adverse effect","score_opus":0.04766454268181435,"score_gpt":0.31495744755964744,"score_spread":0.2672929048778331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183348330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96973926,0.0004667224,0.0000016744846,0.029207887,0.000034635916,0.00037365308,0.000109505934,0.0000068277313,0.000059807146],"genre_scores_gemma":[0.9960964,0.00010533241,0.00023133519,0.0022415407,0.00006786105,0.000017650076,0.000045475317,0.000011059871,0.001183372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979752,0.0005136086,0.00087103376,0.00023450975,0.00027811935,0.00012757616],"domain_scores_gemma":[0.99743176,0.0014879155,0.00022494787,0.00036372247,0.000332795,0.00015883826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064728817,0.00011278571,0.0004198226,0.000028876995,0.000045353914,0.0000041764,0.00007303211,0.00005166338,0.000023967996],"category_scores_gemma":[0.0071467934,0.00007868024,0.000081041966,0.00022928437,0.00021351098,0.00003639798,0.00006299717,0.00017180065,0.0000013412987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004145916,0.00022504844,0.95243895,0.00008619321,0.00009808883,0.00028471273,0.0054592025,0.000004764445,0.0017600993,0.000041879295,0.03473179,0.0007233594],"study_design_scores_gemma":[0.0021013878,0.00040838923,0.9849956,0.00036750958,0.00004636777,0.000005834378,0.002795071,0.000048984803,0.002518714,0.00009434326,0.006522211,0.00009558093],"about_ca_topic_score_codex":0.7813417,"about_ca_topic_score_gemma":0.986036,"teacher_disagreement_score":0.2046943,"about_ca_system_score_codex":0.00007547398,"about_ca_system_score_gemma":0.003863313,"threshold_uncertainty_score":0.85558957},"labels":[],"label_agreement":null},{"id":"W4212935414","doi":"10.1007/s40261-022-01121-1","title":"Significant Correlations between p-Cresol Sulfate and Mycophenolic Acid Plasma Concentrations in Adult Kidney Transplant Recipients","year":2022,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta Hospital; Alberta Hospital Edmonton; University of Alberta","funders":"","keywords":"Thymoglobulin; Medicine; Basiliximab; Mycophenolic acid; Tacrolimus; Internal medicine; Renal function; Kidney transplantation; Transplantation; Urology; Gastroenterology","score_opus":0.05223121414555955,"score_gpt":0.3257007181582811,"score_spread":0.2734695040127216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212935414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939188,0.000027174992,0.00013691474,0.0038745627,0.00030256851,0.0007451102,0.00047930967,0.00005484709,0.0004607306],"genre_scores_gemma":[0.99496126,0.00019500063,0.0008007488,0.0012116592,0.000083647465,0.00013239964,0.0021850418,0.000020327529,0.0004098974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778485,0.00033125648,0.00090086996,0.00040262323,0.00034596003,0.00023444212],"domain_scores_gemma":[0.9985968,0.00048588787,0.00018534105,0.00019347102,0.0000665151,0.0004719681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040418384,0.00016951884,0.00036592112,0.00014056223,0.00026577307,0.00002256252,0.0000804747,0.00008167908,0.000091041635],"category_scores_gemma":[0.0002588276,0.00015911079,0.000100286714,0.00035719943,0.0002010689,0.00012732008,0.000021919062,0.00049287564,0.000029749617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016048612,0.00015997404,0.9955356,0.000041383642,0.00007569213,0.00003811334,0.0012012589,0.000097777396,0.0003529759,0.0012587492,0.00018709485,0.00089090614],"study_design_scores_gemma":[0.005943038,0.00026787844,0.98839104,0.00026862384,0.000257604,0.000020306423,0.00016118948,0.002722804,0.0007600342,0.000637925,0.00040281363,0.00016676565],"about_ca_topic_score_codex":0.00014642366,"about_ca_topic_score_gemma":0.000032681455,"teacher_disagreement_score":0.0071445713,"about_ca_system_score_codex":0.00009878981,"about_ca_system_score_gemma":0.00024005795,"threshold_uncertainty_score":0.64883494},"labels":[],"label_agreement":null},{"id":"W4220663751","doi":"10.1007/s40261-022-01129-7","title":"Multiple Sclerosis Relapses Following Cessation of Fingolimod","year":2022,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"National Health and Medical Research Council; Grifols; Multiple Sclerosis Society; Multiple Sclerosis International Federation; Acorda Therapeutics; Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques; Teva Pharmaceutical Industries; Biogen; Celgene; Fondazione Italiana Sclerosi Multipla; Sanofi Genzyme; University of Melbourne; Sanofi","keywords":"Fingolimod; Medicine; Smoking cessation; Multiple sclerosis; Internal medicine; Pharmacotherapy; Disease; Physical therapy; Psychiatry; Pathology","score_opus":0.19720931043894974,"score_gpt":0.3747379330857507,"score_spread":0.17752862264680097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220663751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949943,0.0001868787,0.00007114612,0.0031167772,0.00042740736,0.00055317534,0.000025838955,0.000083414714,0.00054110057],"genre_scores_gemma":[0.9961937,0.00014484361,0.002316217,0.0005698701,0.0001578031,0.00015697531,0.00012639987,0.000023960376,0.00031024124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971947,0.000505005,0.00088118995,0.00037009333,0.00081438123,0.0002346437],"domain_scores_gemma":[0.997415,0.0015609819,0.0002995412,0.0003684134,0.0001586773,0.0001973836],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002140638,0.00012693017,0.00042833007,0.00015340735,0.00033529184,0.000012077235,0.00015581792,0.000059235797,0.00010596113],"category_scores_gemma":[0.00869269,0.00012310562,0.00030607736,0.00049862347,0.0002914659,0.00013806295,0.0002877398,0.0004999117,0.000015181741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017746308,0.00032681227,0.953728,0.00011539379,0.00015974537,0.000003796801,0.0011549314,0.0003353763,0.023782145,0.00015227294,0.0083667245,0.011697347],"study_design_scores_gemma":[0.0031411005,0.00034363728,0.977371,0.0001831071,0.00009950206,0.000001222958,0.0008369092,0.007851139,0.0076571833,0.0005349904,0.0018368637,0.0001433578],"about_ca_topic_score_codex":0.00020126371,"about_ca_topic_score_gemma":0.000023708299,"teacher_disagreement_score":0.023642994,"about_ca_system_score_codex":0.00012329475,"about_ca_system_score_gemma":0.00018464813,"threshold_uncertainty_score":0.9996575},"labels":[],"label_agreement":null},{"id":"W4246989892","doi":"10.1007/s40261-013-0114-9","title":"Italian Perspective on Psoriasis, Spondyloarthritis, Rheumatoid Arthritis and Juvenile Idiopathic Arthritis: Immunopathology and Role of Etanercept","year":2013,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital","funders":"Pfizer","keywords":"Etanercept; Medicine; Rheumatoid arthritis; Psoriasis; Arthritis; Dermatology; Juvenile rheumatoid arthritis; Antirheumatic Agents; Psoriatic arthritis; Immunopathology; Pharmacotherapy; Immunology; Internal medicine","score_opus":0.017533638634001536,"score_gpt":0.29929788868104024,"score_spread":0.2817642500470387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246989892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9520854,0.042254113,0.0000039411643,0.003343682,0.00012723361,0.0007206082,0.000012826379,0.000059118596,0.0013930913],"genre_scores_gemma":[0.9663111,0.0325151,0.0002705454,0.00049481663,0.0000894291,0.000091259455,0.000034737343,0.00003235799,0.00016066508],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99719673,0.0004689137,0.001177579,0.00051998347,0.00031945258,0.00031735873],"domain_scores_gemma":[0.99841267,0.00026686455,0.00030155524,0.00038231697,0.00033994942,0.00029666696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012409122,0.00022131404,0.00085820444,0.00017228696,0.00014899198,0.000044933004,0.00009526411,0.00027614424,0.00018848793],"category_scores_gemma":[0.0019837231,0.00021636204,0.00011900176,0.00018492537,0.0013331523,0.00029860128,0.00009647564,0.00066004,0.00013703844],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005359408,0.0005675686,0.11422875,0.00021683596,0.00014499332,0.000091435824,0.0074642077,0.0000020945365,0.027093034,0.023141284,0.0023539956,0.82415986],"study_design_scores_gemma":[0.010168723,0.003969713,0.89378613,0.003975151,0.000039507366,0.00046773796,0.017013079,0.0006854287,0.007024096,0.05883366,0.0034238873,0.0006128994],"about_ca_topic_score_codex":0.00040576942,"about_ca_topic_score_gemma":0.00006608698,"teacher_disagreement_score":0.82354695,"about_ca_system_score_codex":0.000048438767,"about_ca_system_score_gemma":0.0002472981,"threshold_uncertainty_score":0.8822988},"labels":[],"label_agreement":null},{"id":"W4289918702","doi":"10.1007/s40261-022-01182-2","title":"Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective","year":2022,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Regione Autonoma della Sardegna; Università degli Studi di Cagliari","keywords":"Major depressive disorder; Cost-effectiveness analysis; CYP2C19; Medicine; Psychiatry; Quality-adjusted life year; Cost effectiveness; Cost–utility analysis; Clinical psychology; Risk analysis (engineering); Internal medicine","score_opus":0.3473253564150627,"score_gpt":0.532487651890823,"score_spread":0.18516229547576035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289918702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947245,0.00028202432,0.0005003179,0.0006617019,0.00074439927,0.0016120067,0.00129183,0.000033756056,0.0001494576],"genre_scores_gemma":[0.99751985,0.000037831458,0.00021781265,0.0014747977,0.0001025036,0.00035692216,0.00024683052,0.000031458196,0.000011971598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9888098,0.008286045,0.0011809329,0.0007832158,0.0005378176,0.00040217448],"domain_scores_gemma":[0.9886764,0.009341309,0.0009255625,0.0004242176,0.00032992018,0.0003025674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034985489,0.00035010866,0.00089313753,0.000299146,0.0004962265,0.000027557215,0.00063175184,0.00018954194,0.00067779],"category_scores_gemma":[0.0013471183,0.00028029052,0.00041687244,0.0015424713,0.0010017932,0.00014402076,0.00025093614,0.0014035043,0.0000019143713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007440804,0.0018943253,0.7937901,0.000041526953,0.0010872637,0.000013659239,0.002825738,0.15604657,0.024022553,0.000081556034,0.000046254794,0.019406373],"study_design_scores_gemma":[0.003528949,0.0001533101,0.54006666,0.000022426397,0.0020502945,3.7102714e-7,0.0016050689,0.42356598,0.027690433,0.0009803766,0.0001246388,0.00021150024],"about_ca_topic_score_codex":0.00034514815,"about_ca_topic_score_gemma":0.00014755393,"teacher_disagreement_score":0.2675194,"about_ca_system_score_codex":0.00022412608,"about_ca_system_score_gemma":0.0004557056,"threshold_uncertainty_score":0.99996495},"labels":[],"label_agreement":null},{"id":"W4303649374","doi":"10.1007/s40261-022-01209-8","title":"The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Hartstichting; Medical Research Council; ZonMw; Teva Pharmaceutical Industries","keywords":"Medicine; Colchicine; Renal function; Internal medicine; Creatinine; Creatine kinase; Blood urea nitrogen; Placebo; Liver function; Liver function tests; Bilirubin; Gastroenterology; Coronary artery disease; Endocrinology; Pathology","score_opus":0.0128010725083666,"score_gpt":0.2588416079498216,"score_spread":0.246040535441455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303649374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965113,0.0012625578,0.000014926768,0.0007071738,0.0003402815,0.0010637708,0.000041963543,0.000009077426,0.000048959406],"genre_scores_gemma":[0.9977923,0.00023332903,0.000019089262,0.000972302,0.000383926,0.00009233863,0.0003041109,0.000018819339,0.0001837766],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976684,0.0010071241,0.00057182135,0.00038515346,0.0002193451,0.00014818413],"domain_scores_gemma":[0.99839264,0.0008282373,0.00023374737,0.00039125507,0.00006116239,0.00009293183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011211907,0.00017553817,0.00026088313,0.000029596818,0.0003875477,0.00002888654,0.00016257983,0.00010925203,0.000016849772],"category_scores_gemma":[0.0012312436,0.00011520934,0.00009356212,0.00014596844,0.0003196224,0.000009292694,0.00021571352,0.00031838828,0.0000027977878],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18642025,0.0007611705,0.052536413,0.00014129336,0.0009845163,0.000027651258,0.0024360253,0.0012394916,0.69653034,0.0006725281,0.0062674345,0.051982917],"study_design_scores_gemma":[0.064019434,0.022555709,0.79841155,0.00019624551,0.0004793921,0.0000049167757,0.00041273967,0.00036259432,0.104869895,0.0005500783,0.0076931734,0.0004442869],"about_ca_topic_score_codex":0.00008864702,"about_ca_topic_score_gemma":0.00015459869,"teacher_disagreement_score":0.7458751,"about_ca_system_score_codex":0.000011079141,"about_ca_system_score_gemma":0.00006928435,"threshold_uncertainty_score":0.46981004},"labels":[],"label_agreement":null},{"id":"W4319302860","doi":"10.1007/s40261-022-01241-8","title":"A Single- and Multiple-Dose Pharmacokinetic Study of Oral Perampanel in Healthy Chinese Subjects","year":2023,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai","keywords":"Perampanel; Pharmacokinetics; Tolerability; Cmax; Medicine; Area under the curve; Pharmacology; Epilepsy; Anesthesia; Gastroenterology; Adverse effect","score_opus":0.14763831980539976,"score_gpt":0.4407086908938581,"score_spread":0.29307037108845835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319302860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962508,0.00009762089,5.0766346e-7,0.0022626023,0.000102925835,0.0011796299,0.00000458399,0.000060817787,0.000040474737],"genre_scores_gemma":[0.9991274,0.00013795364,0.00015058788,0.00030365188,0.000069957336,0.00004377207,0.0000606643,0.000016677135,0.000089356734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811524,0.0003829991,0.0006324229,0.00032829048,0.00030019687,0.00024083076],"domain_scores_gemma":[0.99834543,0.0008997168,0.00009922744,0.00020281975,0.00007991542,0.00037291052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010112264,0.00012502311,0.00039518648,0.00021115257,0.00003933523,0.000009803786,0.000053078176,0.000057611007,0.000010566245],"category_scores_gemma":[0.0022460506,0.000095867,0.000050546616,0.00066606526,0.00020336494,0.00006451166,0.00006215064,0.00029175065,0.00002614278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091188354,0.001767379,0.9880294,0.000116770265,0.000040651976,0.00008577862,0.0015188797,0.000030562547,0.0010899985,0.0000027309736,0.00013831694,0.006267639],"study_design_scores_gemma":[0.012609447,0.0032301645,0.97381854,0.00007958168,0.000036627225,0.0000041617836,0.00049467257,0.009208904,0.00016662874,0.00026328347,0.000019507044,0.00006850251],"about_ca_topic_score_codex":0.00042053108,"about_ca_topic_score_gemma":0.00063097826,"teacher_disagreement_score":0.014210889,"about_ca_system_score_codex":0.00004084043,"about_ca_system_score_gemma":0.00011887199,"threshold_uncertainty_score":0.3909343},"labels":[],"label_agreement":null},{"id":"W4381598306","doi":"10.1007/s40261-023-01278-3","title":"Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The IN2COVID Phase I Randomized Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Tolerability; Medicine; Placebo; Adverse effect; Vital signs; Internal medicine; Bioavailability; Cohort; Randomized controlled trial; Pharmacology; Anesthesia; Pathology","score_opus":0.07083239280995628,"score_gpt":0.37751660517047075,"score_spread":0.30668421236051446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381598306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99031776,0.0004129948,0.00002922494,0.0058221067,0.0011983585,0.0020106887,0.000042625317,0.00008917717,0.00007704132],"genre_scores_gemma":[0.9983265,0.00072408916,0.000017085235,0.00049046637,0.00006134423,0.00013430542,0.00011188683,0.000011334943,0.00012297889],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98907775,0.008214123,0.0017688265,0.0005364993,0.00006665697,0.00033616362],"domain_scores_gemma":[0.987948,0.010983885,0.00045276727,0.00045216878,0.00010707411,0.000056129946],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.009996895,0.00022750226,0.0011215006,0.00017337242,0.00013532855,0.00001659017,0.00030906853,0.00041729794,0.00014672162],"category_scores_gemma":[0.012454131,0.00014322007,0.00027657166,0.00041868823,0.0038682246,0.00011882953,0.00034461645,0.00079386926,0.00012216053],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9766863,0.00066385034,0.0026772046,0.00005318842,0.00008157663,0.000001974485,0.0011829225,0.0000011943158,0.0045424458,0.0004219202,0.0004992961,0.013188144],"study_design_scores_gemma":[0.9632085,0.0061278925,0.0142311575,0.0002178213,0.000052945245,0.0000131749275,0.0006182347,0.00047454768,0.009850496,0.0037719184,0.001144623,0.0002886881],"about_ca_topic_score_codex":0.00034989047,"about_ca_topic_score_gemma":0.0001328446,"teacher_disagreement_score":0.013477783,"about_ca_system_score_codex":0.00005269076,"about_ca_system_score_gemma":0.0001970807,"threshold_uncertainty_score":0.99884266},"labels":[],"label_agreement":null},{"id":"W4384820193","doi":"10.1007/s40261-023-01287-2","title":"Elevations in Creatine Kinase are Not Related to the Choice or Dose of Statins in Patients Taking Colchicine 0.5 mg Daily: Insights from the LoDoCo2 Trial","year":2023,"lang":"en","type":"letter","venue":"Clinical Drug Investigation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Medical Research Council; ZonMw; Teva Pharmaceutical Industries","keywords":"Medicine; Colchicine; Creatine kinase; Pharmacotherapy; Pharmacology; Simvastatin; Internal medicine; Intensive care medicine","score_opus":0.09666996585426156,"score_gpt":0.36331875718599727,"score_spread":0.2666487913317357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384820193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7309256,0.000059538568,0.0000058264204,0.2634858,0.0008035216,0.004455324,0.00017717417,0.000042619227,0.000044609642],"genre_scores_gemma":[0.54993874,0.00017310613,0.00037156368,0.43513542,0.0063120048,0.00091053965,0.005828911,0.0001738352,0.0011558919],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9930363,0.0020532683,0.0026282226,0.0007452736,0.0011735529,0.00036334],"domain_scores_gemma":[0.99143183,0.0053215274,0.0013741187,0.0013293697,0.00037274076,0.00017042273],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026202695,0.00036101573,0.001257969,0.00027230443,0.00014380887,0.000035824443,0.0003852364,0.0007156039,0.000045763813],"category_scores_gemma":[0.023360822,0.00020462155,0.0003361856,0.0016969346,0.0002660925,0.000094366216,0.00015153915,0.0031856855,0.000056340054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018746186,0.0014205072,0.3046698,0.0011238133,0.0010509552,0.00039486313,0.010317724,0.0006659016,0.000051433704,0.00014853265,0.64410365,0.017306656],"study_design_scores_gemma":[0.037005633,0.00073796563,0.91120267,0.0028281726,0.00032581342,5.8590217e-7,0.00022352865,0.0004632729,0.000027556724,0.0004616631,0.0464634,0.0002597337],"about_ca_topic_score_codex":0.008002385,"about_ca_topic_score_gemma":0.008453857,"teacher_disagreement_score":0.6065329,"about_ca_system_score_codex":0.00025323586,"about_ca_system_score_gemma":0.000761438,"threshold_uncertainty_score":0.999114},"labels":[],"label_agreement":null},{"id":"W4386501607","doi":"10.1007/s40261-023-01282-7","title":"Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis","year":2023,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"Merck Sharp and Dohme","keywords":"Posaconazole; Voriconazole; Medicine; Aspergillosis; Pharmacokinetics; Population; Clinical endpoint; Internal medicine; Adverse effect; Quartile; Randomized controlled trial; Confidence interval; Antifungal; Immunology","score_opus":0.11925961162710076,"score_gpt":0.41330703928924056,"score_spread":0.2940474276621398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386501607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967377,0.00024833388,0.000005950035,0.0007916583,0.00005651107,0.0020994954,0.00003754011,0.000009396428,0.000013421174],"genre_scores_gemma":[0.9991313,0.00038455825,0.000063555046,0.000051349107,0.000021226359,0.00008713103,0.000026952872,0.000007416449,0.00022648962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788153,0.00057606644,0.0009667779,0.00026430175,0.00021797618,0.00009334878],"domain_scores_gemma":[0.9945414,0.004416497,0.00041563917,0.0002816778,0.00025139964,0.00009335094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020414041,0.00011148796,0.0010248325,0.00017042346,0.00004699254,0.0000037991485,0.0000540267,0.000068365516,0.000008010389],"category_scores_gemma":[0.0018797757,0.00006900152,0.0003097923,0.00071378285,0.00060423324,0.000036817706,0.00003388223,0.000050130297,2.6949172e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19396906,0.0005820246,0.78598136,0.00013792733,0.0015784246,8.671614e-7,0.0031532957,0.000056900833,0.013634865,0.000050474842,0.00003209626,0.00082273077],"study_design_scores_gemma":[0.16706339,0.0009759413,0.80796283,0.00005001377,0.0048037483,1.7586267e-7,0.0014055631,0.0015383569,0.0159482,0.00019510994,0.0000056102645,0.00005104693],"about_ca_topic_score_codex":0.00010060671,"about_ca_topic_score_gemma":0.00014089985,"teacher_disagreement_score":0.026905678,"about_ca_system_score_codex":0.00001756436,"about_ca_system_score_gemma":0.00012425517,"threshold_uncertainty_score":0.28138006},"labels":[],"label_agreement":null},{"id":"W4387326964","doi":"10.1007/s40261-023-01303-5","title":"Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence","year":2023,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Polymyositis; Dermatomyositis; Mallinckrodt; Rheumatoid arthritis; Etanercept; Rituximab; Immunology; Dermatology; Lymphoma","score_opus":0.22788604157527756,"score_gpt":0.4625133993624705,"score_spread":0.23462735778719293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387326964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49191117,0.4997325,0.000024662695,0.00024076623,0.0005224058,0.0072383895,0.00019734733,0.000125808,0.000006956177],"genre_scores_gemma":[0.0015114648,0.99530715,0.00028019032,0.00002981336,0.0005693431,0.00064107415,0.00092898007,0.00011183491,0.0006201314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947187,0.0010506647,0.0024971538,0.000960382,0.000517438,0.0002556826],"domain_scores_gemma":[0.99222827,0.004337352,0.0014761103,0.0006241745,0.00071030896,0.0006237768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017578157,0.0004047639,0.0028562127,0.00023628733,0.00009119458,0.0000326459,0.00014445253,0.0004744594,0.000003893483],"category_scores_gemma":[0.007022263,0.00027456688,0.0003757137,0.00029116683,0.0006207424,0.00027670967,0.000096306736,0.000404549,0.0000080335485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010031482,0.0010551349,0.59016067,0.05207227,0.00096980715,0.000014510243,0.001183797,5.914794e-8,0.0000032939781,0.0002861827,0.00015864435,0.35309252],"study_design_scores_gemma":[0.013764653,0.012140898,0.68399507,0.17150168,0.010295921,0.00012915443,0.0004316866,0.00076598645,0.0000019728782,0.0005239649,0.10514841,0.0013006122],"about_ca_topic_score_codex":0.000047277994,"about_ca_topic_score_gemma":0.000007713783,"teacher_disagreement_score":0.49557468,"about_ca_system_score_codex":0.0008019216,"about_ca_system_score_gemma":0.0016682902,"threshold_uncertainty_score":0.9999707},"labels":[],"label_agreement":null},{"id":"W4390618444","doi":"10.1007/s40261-023-01329-9","title":"Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches","year":2024,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Imatinib; Health care; Tyrosine kinase; Tyrosine-kinase inhibitor; Life expectancy; Intensive care medicine; Tolerability; Pharmacology; Cancer research; Internal medicine; Cancer; Environmental health; Population; Adverse effect","score_opus":0.15196433801219633,"score_gpt":0.3743277414487546,"score_spread":0.22236340343655825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390618444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10696957,0.8878788,0.00015227323,0.0004990223,0.00011872223,0.004305242,0.000028565717,0.0000201097,0.000027699845],"genre_scores_gemma":[0.099409334,0.89693224,0.0030138607,0.00007349889,0.00015006348,0.00008606993,0.00025456568,0.000054684977,0.00002570284],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99630666,0.0009852182,0.0014558495,0.0005873209,0.00044864957,0.00021632802],"domain_scores_gemma":[0.99807847,0.00036715926,0.0009642061,0.0004200576,0.00007380047,0.00009631704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016347559,0.0003613638,0.0010825435,0.00021490286,0.000114607996,0.000044936784,0.0001591612,0.00026594993,0.0000014638155],"category_scores_gemma":[0.0001971601,0.00019385139,0.00012589418,0.0006626612,0.0014720251,0.000098620774,0.00012801852,0.0005311622,5.0902935e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015105514,0.00015367141,0.004734286,0.06490123,0.00037626538,0.00010414162,0.00091169303,0.00210678,0.000007843468,0.00097226613,0.00004061074,0.92554015],"study_design_scores_gemma":[0.014650562,0.003950984,0.010070345,0.49319744,0.032388702,0.0018360857,0.005109219,0.42150927,0.0007512737,0.0007270194,0.013765173,0.002043929],"about_ca_topic_score_codex":0.0005104918,"about_ca_topic_score_gemma":0.00014971835,"teacher_disagreement_score":0.92349625,"about_ca_system_score_codex":0.0009775814,"about_ca_system_score_gemma":0.0015530473,"threshold_uncertainty_score":0.790503},"labels":[],"label_agreement":null},{"id":"W4391391181","doi":"10.1007/s40261-024-01341-7","title":"Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance","year":2024,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Etanercept; Medicine; Adalimumab; Biosimilar; Rheumatoid arthritis; Internal medicine; Infliximab; Observational study; Disease; Arthritis","score_opus":0.041359489177806366,"score_gpt":0.3287282879898965,"score_spread":0.28736879881209015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391391181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997123,0.00084791123,0.00018591156,0.0002821193,0.00051234616,0.0007523573,0.00020512604,0.00008310995,0.000008111073],"genre_scores_gemma":[0.99775285,0.0008930468,0.00095903967,0.00004648019,0.00007770866,0.000049144386,0.00012684969,0.000023356226,0.00007155758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975594,0.00045334545,0.0009950501,0.00061269867,0.000083937186,0.00029555534],"domain_scores_gemma":[0.99813634,0.0011448135,0.0002512758,0.00021405242,0.00012335824,0.0001301804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016190347,0.00024977117,0.0006202898,0.00014184244,0.000117207404,0.000031836116,0.00009867221,0.00036362268,0.000012428174],"category_scores_gemma":[0.0005294888,0.00016315696,0.0001212359,0.00030769056,0.0009028821,0.00030304457,0.000047818437,0.0005035202,0.000004722146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002335531,0.00023028906,0.98534954,0.00015346172,0.00012410269,0.0000020666994,0.00002291186,0.0000025704144,0.00015868909,0.00002639456,0.00014825283,0.011446216],"study_design_scores_gemma":[0.0031253605,0.002434237,0.98722583,0.0012620976,0.00010314809,0.0000011120742,0.00001104088,0.0007268694,0.004445861,0.000117060205,0.00032753957,0.0002198422],"about_ca_topic_score_codex":0.000009050748,"about_ca_topic_score_gemma":0.0000056157232,"teacher_disagreement_score":0.011226374,"about_ca_system_score_codex":0.00005943228,"about_ca_system_score_gemma":0.00009666967,"threshold_uncertainty_score":0.66533476},"labels":[],"label_agreement":null},{"id":"W4401794058","doi":"10.1007/s40261-024-01368-w","title":"Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2024,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Universidad Autónoma de Madrid","keywords":"Roflumilast; Medicine; Psoriasis; Randomized controlled trial; Adverse effect; Food and drug administration; Dermatology; Meta-analysis; Safety profile; Intensive care medicine; Pharmacology; Internal medicine; Pulmonary disease","score_opus":0.19724499704418705,"score_gpt":0.41843696655347923,"score_spread":0.22119196950929218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401794058","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011768086,0.98227865,0.000036622685,0.00022052706,0.00025028732,0.016418597,0.0006591525,0.000010877189,0.0000076238475],"genre_scores_gemma":[0.00020065556,0.99475193,0.00007556626,0.000031213793,0.000031844367,0.0037660757,0.00036866489,0.000017533996,0.0007565194],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98067474,0.011088092,0.0075814696,0.00044599653,0.000077987424,0.00013171433],"domain_scores_gemma":[0.9290509,0.06570489,0.0045230254,0.00051813805,0.00016486028,0.000038184295],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.01334039,0.00047555895,0.043419216,0.00023372192,0.0000563098,0.000009715873,0.00016823008,0.00042876974,0.000045006913],"category_scores_gemma":[0.013111982,0.0001838446,0.012996809,0.00036482472,0.0008038736,0.000021200965,0.00003386052,0.00011849384,0.0000032445284],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054862034,0.00019549234,0.0000012314214,0.22719872,0.7547982,2.5895918e-7,0.00019425648,2.8158806e-7,0.0000016113249,0.00082166237,0.00007143819,0.011230679],"study_design_scores_gemma":[0.050163005,0.00022796693,0.0000033344897,0.013249136,0.9338495,0.0000020012794,0.00001878688,0.000006421818,0.000013363727,0.00009923445,0.0022499969,0.000117261065],"about_ca_topic_score_codex":0.000020649957,"about_ca_topic_score_gemma":0.000009617428,"teacher_disagreement_score":0.21394958,"about_ca_system_score_codex":0.000022885984,"about_ca_system_score_gemma":0.00014434542,"threshold_uncertainty_score":0.9968878},"labels":[],"label_agreement":null},{"id":"W4407859078","doi":"10.1007/s40261-025-01426-x","title":"Economic Model of Uridine Triacetate Versus Supportive Care for the Treatment of Patients with Life-Threatening Early-Onset Severe Toxicity","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Toxicity; Pharmacotherapy; Intensive care medicine; Pediatrics; Internal medicine","score_opus":0.05931122926178046,"score_gpt":0.34798245632751945,"score_spread":0.288671227065739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407859078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969581,0.00037578575,0.000055813947,0.0006932651,0.00019471407,0.0012525218,0.00030125998,0.000012109497,0.00015643651],"genre_scores_gemma":[0.9986932,0.00025643207,0.00044496552,0.00006858,0.000035587273,0.00014210642,0.0001337259,0.00000865787,0.00021672464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904954,0.000039635426,0.0004957548,0.00021621399,0.000088566725,0.00011029465],"domain_scores_gemma":[0.9985375,0.00074458035,0.00025444647,0.0001827939,0.00021088029,0.00006984386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011054672,0.00012952446,0.00047504657,0.000037400783,0.00008501161,0.0000044384383,0.000044347194,0.000049687907,0.0000050395197],"category_scores_gemma":[0.00018888612,0.00007482306,0.0001690715,0.00006896228,0.00025998297,0.000040521376,0.00001695248,0.000049725113,6.8470666e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014375619,0.00033864053,0.97018355,0.0001156195,0.0011574482,2.9349258e-7,0.0029163503,0.0015093326,0.0000049491873,0.0000986114,0.00025128055,0.009048308],"study_design_scores_gemma":[0.025428208,0.0073466967,0.95351696,0.00016035189,0.0018484187,7.04846e-8,0.0009244572,0.0067960313,0.003264104,0.0004237181,0.00017024911,0.000120746656],"about_ca_topic_score_codex":0.00013335544,"about_ca_topic_score_gemma":0.00027173597,"teacher_disagreement_score":0.0166666,"about_ca_system_score_codex":0.00017989558,"about_ca_system_score_gemma":0.00038213763,"threshold_uncertainty_score":0.30511957},"labels":[],"label_agreement":null},{"id":"W4414016326","doi":"10.1007/s40261-025-01476-1","title":"Off-Label Prescription of Benzodiazepines: A Retrospective Cohort Study of Prescribing Prevalence in Primary Care","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Sleep and related disorders","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Medical prescription; Benzodiazepine; Off-label use; Pharmacy; Pharmacoepidemiology; Pharmacotherapy; Psychiatry; Pediatrics; Family medicine; Internal medicine; Pharmacology","score_opus":0.03358103271673089,"score_gpt":0.34480058428255417,"score_spread":0.31121955156582326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414016326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866423,0.0018709234,0.00002657233,0.00008005985,0.0009423602,0.0017021073,0.000012881856,0.00004040386,0.0086824],"genre_scores_gemma":[0.99888116,0.00018911409,0.00011309383,0.00012365231,0.000030397108,0.000120798424,0.000041996835,0.000012556684,0.00048722376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704665,0.00071560533,0.0012772563,0.0005249877,0.00026163083,0.00017388102],"domain_scores_gemma":[0.9984041,0.00035425782,0.0004295381,0.00048137107,0.00027612242,0.000054643468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009816602,0.00014584929,0.0004697512,0.00023439257,0.000039667204,0.0000066307753,0.00023039452,0.00025500564,0.00003220787],"category_scores_gemma":[0.00081743416,0.00014280972,0.000081585466,0.00065477676,0.00033896952,0.00012991115,0.000078610276,0.00043716462,0.0000071985864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016191314,0.0013823326,0.9820921,0.00025818645,0.00023268718,0.000001492565,0.009645197,0.0000708286,0.00014321243,0.00071187183,0.0005665436,0.0047336617],"study_design_scores_gemma":[0.0036769519,0.000358185,0.98849195,0.0005117689,0.0002613624,1.6617203e-7,0.0050835735,0.0002362531,0.000091425594,0.0011649367,0.000014876932,0.00010856153],"about_ca_topic_score_codex":0.00062963634,"about_ca_topic_score_gemma":0.00017740564,"teacher_disagreement_score":0.012238875,"about_ca_system_score_codex":0.000111064095,"about_ca_system_score_gemma":0.00012368441,"threshold_uncertainty_score":0.58236116},"labels":[],"label_agreement":null},{"id":"W4414443146","doi":"10.1007/s40261-025-01478-z","title":"Mucous Membrane Pemphigoid Outcome Measurement in Clinical Research: A Scoping Review","year":2025,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Outcome (game theory); Critical appraisal; Patient-reported outcome; MEDLINE; Pharmacotherapy; Perspective (graphical); Pemphigoid","score_opus":0.6380473468550989,"score_gpt":0.6038945010449779,"score_spread":0.03415284581012101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414443146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000041161184,0.98347986,0.0000070319215,0.0029516963,0.0012057538,0.01081776,0.000021873864,0.00020335233,0.0012715016],"genre_scores_gemma":[0.000026610182,0.9918796,0.00044689412,0.004062996,0.00074077246,0.0011216302,0.00046765397,0.000121047065,0.0011328063],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9736469,0.010235063,0.010865663,0.0018930652,0.0024465641,0.0009127584],"domain_scores_gemma":[0.9804503,0.011724551,0.0022407377,0.003034277,0.0014624551,0.0010877321],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.04876473,0.00079977734,0.0077651287,0.0008259446,0.00017370058,0.000059981736,0.0008702345,0.0010526297,0.00021603289],"category_scores_gemma":[0.13617857,0.00066424033,0.0024701613,0.0022249366,0.0013170184,0.00012657553,0.00061839394,0.004547327,0.00073287357],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003407153,0.00057680375,0.0025275194,0.53108954,0.0001900788,0.00014849534,0.000016582157,2.2326138e-7,5.1088044e-8,0.00007447749,0.017312199,0.44802997],"study_design_scores_gemma":[0.001035828,0.0001385692,0.0011986523,0.73031,0.0020019598,0.000017487282,0.00000782308,0.0000067438405,2.7814656e-7,0.00016249396,0.2647235,0.0003966331],"about_ca_topic_score_codex":0.000078108234,"about_ca_topic_score_gemma":0.00010752059,"teacher_disagreement_score":0.44763333,"about_ca_system_score_codex":0.0008507987,"about_ca_system_score_gemma":0.012536713,"threshold_uncertainty_score":0.99958086},"labels":[],"label_agreement":null},{"id":"W4414755693","doi":"10.1007/s40261-025-01487-y","title":"Intra-arterial Injection of OTR4132, a Novel Neuroprotector in Acute Ischemic Stroke: The MaTRISS Trial","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Horizon 2020 Framework Programme; European Commission","keywords":"Clinical trial; Pharmacotherapy; Randomized controlled trial; Adverse effect; Drug","score_opus":0.034105945531067786,"score_gpt":0.3325746821015559,"score_spread":0.2984687365704881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414755693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846573,0.000027037258,0.0012643498,0.00818634,0.0015966762,0.0018983723,0.00001662158,0.000057555364,0.0022957793],"genre_scores_gemma":[0.99372774,0.000031535958,0.0014821221,0.0019589677,0.0006345495,0.00014796133,0.000046280893,0.000019321647,0.0019515376],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976639,0.00018702644,0.001231877,0.0004048308,0.00030698918,0.00020534993],"domain_scores_gemma":[0.9985261,0.00042405483,0.00035745988,0.0005031878,0.00010531152,0.000083904735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012346093,0.00017317136,0.00045555027,0.00018408854,0.00004652786,0.000020860985,0.0002160111,0.0001810916,0.00002841657],"category_scores_gemma":[0.001963518,0.00013208992,0.00018788638,0.00055801723,0.00037172134,0.00009671483,0.00014000382,0.00063633313,0.000014153433],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058586333,0.0015573322,0.031495567,0.0005600141,0.0010613459,0.00002535621,0.0011090633,0.00010255678,0.5945809,0.0014212704,0.2907313,0.018768992],"study_design_scores_gemma":[0.33215174,0.004020614,0.26596242,0.0018790554,0.0035486124,0.00005953676,0.0014124501,0.02162215,0.29553875,0.0014224298,0.071306325,0.0010758888],"about_ca_topic_score_codex":0.000100058576,"about_ca_topic_score_gemma":0.000012906018,"teacher_disagreement_score":0.2990421,"about_ca_system_score_codex":0.00009083234,"about_ca_system_score_gemma":0.00024571668,"threshold_uncertainty_score":0.53864706},"labels":[],"label_agreement":null},{"id":"W4415229655","doi":"10.1007/s40261-025-01474-3","title":"Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Attention Deficit Hyperactivity Disorder","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada)","funders":"Neuraxpharm","keywords":"Bioequivalence; Methylphenidate; Crossover study; Bioavailability; Suspension (topology); Drug; Dosage form","score_opus":0.18074646386597096,"score_gpt":0.46231584406963544,"score_spread":0.2815693802036645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415229655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98138815,0.0042102304,0.0002567413,0.0047492557,0.0010537875,0.007862681,0.00024838556,0.00015447069,0.000076280405],"genre_scores_gemma":[0.9922678,0.000615833,0.0035326688,0.001443726,0.000142392,0.00089208403,0.0006798776,0.000079909536,0.00034569937],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9910139,0.0020176824,0.0033540425,0.0018749668,0.00073919987,0.0010002145],"domain_scores_gemma":[0.9879004,0.00688367,0.0015574418,0.0010530076,0.0018559105,0.0007496086],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0053820475,0.00085029885,0.0030783901,0.0005776501,0.0003641533,0.00008320068,0.00029575123,0.0005431422,0.00006736079],"category_scores_gemma":[0.016450506,0.00076814875,0.00051450625,0.0014983685,0.0024411946,0.0009786946,0.000317621,0.0011630179,0.00002767452],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81494606,0.016064165,0.03973515,0.008311565,0.0037072247,0.00008891642,0.009084543,0.0017265311,0.08402928,0.0005386738,0.006218393,0.0155495275],"study_design_scores_gemma":[0.76294583,0.012694735,0.026764527,0.003964588,0.0057691545,0.000020229765,0.016767282,0.050014243,0.11114881,0.004427587,0.0027872934,0.0026956953],"about_ca_topic_score_codex":0.00057779235,"about_ca_topic_score_gemma":0.0008721923,"teacher_disagreement_score":0.05200018,"about_ca_system_score_codex":0.00038393238,"about_ca_system_score_gemma":0.0011054734,"threshold_uncertainty_score":0.99947697},"labels":[],"label_agreement":null},{"id":"W4415567623","doi":"10.1007/s40261-025-01489-w","title":"Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Pharmacogenetics and Drug Metabolism","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Melbourne; International Society of Oncology Pharmacy Practitioners","keywords":"Reimbursement; DPYD; Genotyping; Standard of care; Pharmacotherapy; Health care; Pharmacogenetics; Health economics","score_opus":0.21893161215604237,"score_gpt":0.5177472132587021,"score_spread":0.2988156011026597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415567623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531883,0.00033732416,0.00018822626,0.00011308988,0.0012678811,0.0022472607,0.00036731284,0.000023528806,0.00013652252],"genre_scores_gemma":[0.99857694,0.00016153314,0.0004421109,0.0002594065,0.00005624778,0.00029254664,0.00013696341,0.000016782073,0.00005744775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961181,0.0018935867,0.0010688201,0.00043784874,0.00018447186,0.0002971438],"domain_scores_gemma":[0.99733615,0.0013331131,0.00038672826,0.00021279654,0.00050048047,0.00023074272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001327079,0.00024442983,0.00078078755,0.00024629303,0.00008183526,0.000009179675,0.00022181435,0.00024316167,0.00006082364],"category_scores_gemma":[0.00044137053,0.00023873324,0.00016595131,0.0005194915,0.0004019751,0.000077545934,0.00007491834,0.00037530888,0.0000036968438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002145558,0.00043612797,0.9195383,0.0004248743,0.00016356702,0.0000011317684,0.0017461092,0.040452745,0.021191537,0.00008640958,0.00013618357,0.013677457],"study_design_scores_gemma":[0.0039112396,0.00015064335,0.5788607,0.000312348,0.00017190026,1.1916142e-8,0.000069087924,0.0021640982,0.41341102,0.00013917965,0.0006822936,0.00012747168],"about_ca_topic_score_codex":0.00040343264,"about_ca_topic_score_gemma":0.0002498683,"teacher_disagreement_score":0.39221948,"about_ca_system_score_codex":0.00028321068,"about_ca_system_score_gemma":0.0003623159,"threshold_uncertainty_score":0.9735259},"labels":[],"label_agreement":null},{"id":"W4416626155","doi":"10.1007/s40261-025-01504-0","title":"Treatment of Non-severe COVID-19 with Molnupiravir: A Systematic Review with Meta-analysis and Trial Sequential Analysis of the Evidence from Randomized Controlled Trials","year":2025,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Randomized controlled trial; Pharmacotherapy; Coronavirus disease 2019 (COVID-19); MEDLINE; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Severe acute respiratory syndrome; Meta-analysis; Coronavirus; Systematic review","score_opus":0.2447877601629181,"score_gpt":0.48226276946680274,"score_spread":0.23747500930388465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416626155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9191467,0.04283129,0.0056773126,0.007253136,0.00007289671,0.024833784,0.000093184804,0.000028371203,0.00006329304],"genre_scores_gemma":[0.9788175,0.0013696564,0.00066087086,0.01614434,0.000055008953,0.00272063,0.000038070706,0.000014418159,0.00017945978],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9835333,0.010433065,0.0043295044,0.0005749854,0.0009726845,0.00015645858],"domain_scores_gemma":[0.94444275,0.04986499,0.003531354,0.0013421485,0.0006673129,0.00015146774],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.017802294,0.0003098069,0.018120198,0.0005291407,0.0000765149,0.00003562713,0.0002239561,0.00013639749,0.00003734094],"category_scores_gemma":[0.059598915,0.00011953662,0.0062280744,0.0029855836,0.0009691213,0.00007891148,0.00004508036,0.00017310832,0.0000010457817],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38916537,0.0002643206,0.011465017,0.012823668,0.5855846,0.000006786836,0.00030981915,0.000054657932,0.00023031415,0.000048059308,0.000025892807,0.000021508069],"study_design_scores_gemma":[0.2991137,0.00038448474,0.00029656914,0.0031531435,0.6917425,6.1926835e-7,0.000042349446,0.004274183,0.00078037276,0.00013021249,0.000004047786,0.000077862926],"about_ca_topic_score_codex":0.0022707365,"about_ca_topic_score_gemma":0.00060826325,"teacher_disagreement_score":0.10615789,"about_ca_system_score_codex":0.0001191063,"about_ca_system_score_gemma":0.0016976066,"threshold_uncertainty_score":0.99645686},"labels":[],"label_agreement":null},{"id":"W44331634","doi":"10.2165/11588810-000000000-00000","title":"Identifying Amnestic Mild Cognitive Impairment in Primary Care","year":2011,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Dementia and Cognitive Impairment Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; Eisai; Pfizer","keywords":"Clinical Dementia Rating; Dementia; Medicine; Cognition; Montreal Cognitive Assessment; Cognitive impairment; Rating scale; Disease; Recall; Clinical psychology; Audiology; Psychiatry; Psychology; Internal medicine; Cognitive psychology; Developmental psychology","score_opus":0.12943722046456144,"score_gpt":0.3926775700269315,"score_spread":0.2632403495623701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W44331634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866551,0.00025126367,0.0001309595,0.00022177945,0.00021961908,0.0011020171,0.0000068580703,0.00006728743,0.011345118],"genre_scores_gemma":[0.9959441,0.00009978095,0.0011721862,0.0017124995,0.00013754416,0.00012693477,0.00025091082,0.000023559889,0.0005325224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764895,0.00033408974,0.00073842955,0.00046478907,0.00045524098,0.00035850832],"domain_scores_gemma":[0.9987042,0.0003061012,0.00013102964,0.00019259892,0.00030625964,0.00035981913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010505447,0.00016720471,0.00033563172,0.00021365052,0.00007263263,0.000023534129,0.00010011202,0.00011639555,0.00022187762],"category_scores_gemma":[0.0005368167,0.00015340252,0.00014773561,0.00035946292,0.000407336,0.00019928129,0.00010457387,0.0004993042,0.00029954806],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034114602,0.00039188698,0.98633265,0.00034761947,0.00004068938,0.000097845215,0.002822016,9.2991655e-8,0.00012359764,0.000064657404,0.00020133558,0.009236462],"study_design_scores_gemma":[0.003717859,0.0005371613,0.9873981,0.0010844127,0.0001302188,0.0000074736627,0.0023494144,0.000055261327,0.0029737304,0.0015646749,0.000027770286,0.00015393789],"about_ca_topic_score_codex":0.00011760532,"about_ca_topic_score_gemma":0.00003955729,"teacher_disagreement_score":0.010812596,"about_ca_system_score_codex":0.00016282572,"about_ca_system_score_gemma":0.00035634683,"threshold_uncertainty_score":0.62555736},"labels":[],"label_agreement":null},{"id":"W47119266","doi":"10.2165/00044011-200222100-00005","title":"Antidepressant Selection, Healthcare Resource Consumption and Costs in a Large Workplace Environment","year":2002,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Mental Health Treatment and Access","field":"Psychology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Medical prescription; Antidepressant; Psychiatry; Depression (economics); Health care; Major depressive disorder; Psychotropic drug; Emergency medicine; Drug; Anxiety; Pharmacology; Mood","score_opus":0.08901846562884352,"score_gpt":0.38935892432678504,"score_spread":0.3003404586979415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W47119266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904847,0.0018011701,0.000038736674,0.0060934103,0.00022796415,0.0006635333,0.000011511841,0.00005263311,0.0006263205],"genre_scores_gemma":[0.99441254,0.00058878266,0.00018659883,0.0032662828,0.000120598976,0.00010272295,0.00005794303,0.000015487341,0.0012490513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769175,0.00075375254,0.0006388222,0.0004632733,0.00014696563,0.00030541833],"domain_scores_gemma":[0.9989745,0.00040822776,0.00018871158,0.00018431002,0.000011999294,0.00023226406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008673902,0.00013422716,0.00021495754,0.000082944694,0.00017631582,0.00002267107,0.000070989954,0.00016360199,0.00067583186],"category_scores_gemma":[0.000064230124,0.00013118383,0.000033108645,0.00013450345,0.00016346162,0.00011673312,0.00003910424,0.00033812175,0.00035414912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053308788,0.00025648338,0.9680782,0.000034637458,0.000009973595,0.000007057466,0.00077286235,0.0000024690162,0.0000038123987,0.0011657639,0.009799356,0.019816091],"study_design_scores_gemma":[0.0022521338,0.00012522127,0.9857664,0.00015173614,0.000015010262,0.000007984085,0.00020767114,0.0014644946,0.00003184615,0.00044351342,0.009383502,0.00015045793],"about_ca_topic_score_codex":0.0002642358,"about_ca_topic_score_gemma":0.00033152718,"teacher_disagreement_score":0.019665632,"about_ca_system_score_codex":0.00012168996,"about_ca_system_score_gemma":0.000005441127,"threshold_uncertainty_score":0.7399885},"labels":[],"label_agreement":null},{"id":"W4765708","doi":"10.2165/00044011-200929050-00003","title":"Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment","year":2009,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bayer Canada; Astellas Pharma; GlaxoSmithKline; Pfizer","keywords":"Tolterodine; Overactive bladder; Solifenacin; Medicine; Tolerability; Urology; Adverse effect; Nocturia; Urinary urgency; Internal medicine; Urinary system","score_opus":0.03128411834866037,"score_gpt":0.3371129593835576,"score_spread":0.30582884103489727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4765708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931221,0.000049853446,0.00003057798,0.0051305755,0.00008009715,0.0012985802,0.000036743037,0.000047794394,0.00020368762],"genre_scores_gemma":[0.9957789,0.0000440045,0.0009366435,0.0026730443,0.00006968401,0.000036612088,0.00029040137,0.000021993523,0.00014870826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751866,0.0003795943,0.0007499419,0.000602639,0.00043680196,0.000312367],"domain_scores_gemma":[0.99801356,0.0007213528,0.00017900749,0.00034624245,0.00014361259,0.00059620367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003762235,0.0002524931,0.00053381594,0.00015153975,0.00008146766,0.00003562965,0.00005170804,0.00010887776,0.00003399595],"category_scores_gemma":[0.0010735145,0.00017789885,0.000072176736,0.00022233879,0.000076043456,0.00027420468,0.0000427505,0.00037077765,0.000018274963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018554307,0.00118606,0.9176801,0.000007972606,0.00014248703,0.00010238737,0.0022386718,0.000015414163,0.00019537461,0.000006585274,0.0002917317,0.07627782],"study_design_scores_gemma":[0.0068298182,0.0034782428,0.9870467,0.00015932809,0.00010088092,0.0000036914848,0.00016294274,0.00034789112,0.0005089863,0.0010508569,0.00010235857,0.00020828044],"about_ca_topic_score_codex":0.00041379055,"about_ca_topic_score_gemma":0.00007319658,"teacher_disagreement_score":0.07606954,"about_ca_system_score_codex":0.00014581106,"about_ca_system_score_gemma":0.00018479455,"threshold_uncertainty_score":0.7254505},"labels":[],"label_agreement":null},{"id":"W645710337","doi":"10.1007/s40261-015-0300-z","title":"Recombinant Human C1 Esterase Inhibitor in the Management of Hereditary Angioedema","year":2015,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Valeant Pharmaceuticals International; CSL Behring; BioCryst; Viropharma","keywords":"Hereditary angioedema; Medicine; Danazol; Pharmacology; C1-inhibitor; Population; Angioedema; Pharmacokinetics; Gastroenterology; Internal medicine; Immunology","score_opus":0.19398339833349348,"score_gpt":0.441416956826433,"score_spread":0.24743355849293952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W645710337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013913312,0.980304,0.000004196583,0.00079349545,0.0013897896,0.0024322027,0.000022533543,0.00006231511,0.0010781261],"genre_scores_gemma":[0.0022411505,0.99160504,0.00075979135,0.00056849193,0.0013276892,0.00020475055,0.0015057605,0.00008385098,0.001703459],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950388,0.00078031025,0.0026515634,0.000607763,0.00061629666,0.00030523073],"domain_scores_gemma":[0.9972012,0.0005654823,0.0009626775,0.0008528231,0.00014637821,0.00027145096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036568057,0.00043020965,0.00193181,0.0002288171,0.00007958569,0.00002980442,0.00036725958,0.00041896,0.000030056086],"category_scores_gemma":[0.00021553985,0.00029075064,0.0007544816,0.0006530868,0.00041311927,0.0001331717,0.0001276661,0.00061885465,0.000055482393],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000325598,0.0006873172,0.0039777523,0.021451531,0.00036114952,0.0002289386,0.00068970025,0.0000015439454,2.1549307e-7,0.002610371,0.039207894,0.930751],"study_design_scores_gemma":[0.0024970423,0.00049998995,0.009801217,0.054400407,0.002973136,0.00007557708,0.000368766,0.00006191991,0.0000037474983,0.005465945,0.9232843,0.00056795386],"about_ca_topic_score_codex":0.000094930314,"about_ca_topic_score_gemma":0.000028161374,"teacher_disagreement_score":0.93018305,"about_ca_system_score_codex":0.0001275097,"about_ca_system_score_gemma":0.00041710646,"threshold_uncertainty_score":0.99995446},"labels":[],"label_agreement":null},{"id":"W777891328","doi":"10.2165/11588190-000000000-00000","title":"Intranasal versus Oral Administration of Lisdexamfetamine Dimesylate","year":2011,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Forensic Toxicology and Drug Analysis","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Medicine; Stimulant; Cmax; Pharmacokinetics; Crossover study; Adverse effect; Oral administration; Nasal administration; Dosing; Pharmacology; Anesthesia; Placebo","score_opus":0.33068591961739974,"score_gpt":0.481907058468223,"score_spread":0.15122113885082328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W777891328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882582,0.000099163924,0.00023639706,0.00091752486,0.0024508226,0.00021766682,0.00002416181,0.00009418224,0.0077019203],"genre_scores_gemma":[0.99588025,0.000113467264,0.0020403764,0.0009163835,0.00024358349,0.000016427688,0.00010965932,0.000016409853,0.00066344003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970983,0.0010224518,0.0010708453,0.00037080984,0.00015185749,0.00028573108],"domain_scores_gemma":[0.99782395,0.00096096087,0.00044599126,0.0002756602,0.00016817666,0.00032523012],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020282902,0.00019841049,0.00043801646,0.00011664774,0.00013250342,0.000005966117,0.0002464372,0.00052567665,0.0013783168],"category_scores_gemma":[0.00089122757,0.00018790746,0.00022708054,0.0003417768,0.001531326,0.0001851929,0.00005427932,0.00077600265,0.00017162548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0281938,0.0049195867,0.57852185,0.00030095997,0.004096012,0.00023011022,0.010056898,0.000526013,0.009508991,0.13861722,0.0514333,0.17359525],"study_design_scores_gemma":[0.022068506,0.005376029,0.46887928,0.000094490984,0.004500395,0.000031188156,0.0012646999,0.029378373,0.37992707,0.04976535,0.036986038,0.0017285976],"about_ca_topic_score_codex":0.000047742597,"about_ca_topic_score_gemma":0.00021066322,"teacher_disagreement_score":0.37041807,"about_ca_system_score_codex":0.000025209452,"about_ca_system_score_gemma":0.00018935729,"threshold_uncertainty_score":0.99953455},"labels":[],"label_agreement":null},{"id":"W87703995","doi":"10.2165/00044011-200828100-00003","title":"Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins","year":2008,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Abbott (Canada)","funders":"","keywords":"Medicine; Atorvastatin; Combination therapy; Rosuvastatin; Fenofibrate; Rosuvastatin Calcium; Simvastatin; Statin; Pharmacotherapy; Internal medicine; Pharmacology; Clinical endpoint; Clinical trial; Fibrate; Randomized controlled trial; Gastroenterology","score_opus":0.2015735245686092,"score_gpt":0.40608301158157345,"score_spread":0.20450948701296426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W87703995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532974,0.00025785126,0.0017247912,0.00056929485,0.00007411443,0.0011063658,0.000009248368,0.000028461214,0.0009001189],"genre_scores_gemma":[0.9920637,0.00007913547,0.0070435954,0.00023963711,0.00022672328,0.000020510934,0.00016415594,0.000019827045,0.00014274279],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967354,0.0004049711,0.0009876419,0.0002655415,0.0014608796,0.0001455554],"domain_scores_gemma":[0.99774486,0.00011953103,0.0005563613,0.00047226262,0.0008418835,0.00026510053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003559136,0.00012456834,0.0005163919,0.00009841576,0.0000580282,0.000003866913,0.000059338327,0.00015972201,0.00004190073],"category_scores_gemma":[0.0011937721,0.00009916547,0.00019619694,0.00032258977,0.00022377801,0.0001500003,0.000013574828,0.00020939078,0.000010383914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020344283,0.000979573,0.5965438,0.0014660847,0.0012748396,0.000018329052,0.009023709,0.0007457176,0.01028042,0.0014545802,0.005659563,0.37051895],"study_design_scores_gemma":[0.008434727,0.0016504949,0.9401158,0.00040753555,0.00088292756,0.000051794104,0.00019978391,0.0069927266,0.038699765,0.0018912146,0.0005060986,0.0001671131],"about_ca_topic_score_codex":0.00025889426,"about_ca_topic_score_gemma":0.000043973283,"teacher_disagreement_score":0.37035182,"about_ca_system_score_codex":0.00007977495,"about_ca_system_score_gemma":0.002047275,"threshold_uncertainty_score":0.40438503},"labels":[],"label_agreement":null},{"id":"W89469982","doi":"10.2165/11539360-000000000-00000","title":"Effects of Adalimumab versus Placebo on Risk of Symptom Worsening in Psoriasis and Subsequent Impacts on Health-Related Quality-of-Life","year":2010,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Abbott Laboratories","keywords":"Medicine; Adalimumab; Psoriasis; Quality of life (healthcare); Pharmacotherapy; Placebo; Intensive care medicine; Internal medicine; Physical therapy; Alternative medicine; Dermatology; Disease","score_opus":0.050805862688002475,"score_gpt":0.3349130731399031,"score_spread":0.2841072104519006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W89469982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707586,0.0006700379,0.0000016580044,0.00029037727,0.0013906076,0.00045580196,0.000039226958,0.0000219097,0.000054510478],"genre_scores_gemma":[0.9992701,0.0003751786,0.0001228642,0.000067606656,0.000028160637,0.00001596823,0.00008256309,0.000013235448,0.000024327917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616045,0.0018921682,0.0013453441,0.0003102083,0.00007802518,0.00021378073],"domain_scores_gemma":[0.99078965,0.007651804,0.0011374151,0.00027163315,0.000058042,0.0000914372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022741554,0.00018037228,0.0007241764,0.00017426962,0.0000615877,0.000002940691,0.00010659723,0.00039130516,0.000015902897],"category_scores_gemma":[0.0056575104,0.00015519967,0.00014203733,0.00021115418,0.0004606158,0.00005164837,0.000031257707,0.0004933684,0.000016833912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028584788,0.0016881563,0.7600203,0.0007690403,0.0014515258,0.0000042047604,0.0059940554,0.00014771099,0.13494815,0.008842175,0.00035035558,0.057199504],"study_design_scores_gemma":[0.019213125,0.0017058294,0.8329498,0.0004432156,0.00015018659,6.819697e-7,0.00013303226,0.000022423703,0.14412963,0.0010492093,0.00003154788,0.00017128458],"about_ca_topic_score_codex":0.0011766966,"about_ca_topic_score_gemma":0.0004890598,"teacher_disagreement_score":0.072929494,"about_ca_system_score_codex":0.000035413013,"about_ca_system_score_gemma":0.00018343473,"threshold_uncertainty_score":0.67729765},"labels":[],"label_agreement":null}]}